<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="review-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Front Neurol</journal-id><journal-id journal-id-type="publisher-id">Front. Neur.</journal-id><journal-title-group><journal-title>Frontiers in Neurology</journal-title></journal-title-group><issn pub-type="epub">1664-2295</issn><publisher><publisher-name>Frontiers Research Foundation</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">22125548</article-id><article-id pub-id-type="pmc">3221408</article-id><article-id pub-id-type="doi">10.3389/fneur.2011.00068</article-id><article-categories><subj-group subj-group-type="heading"><subject>Neuroscience</subject><subj-group><subject>Review Article</subject></subj-group></subj-group></article-categories><title-group><article-title>The Promise of Neuroprotective Agents in Parkinson&#x02019;s Disease</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Seidl</surname><given-names>Stacey E.</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author"><name><surname>Potashkin</surname><given-names>Judith A.</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="author-notes" rid="fn001">*</xref></contrib></contrib-group><aff id="aff1"><sup>1</sup><institution>Department of Biological Sciences, DePaul University</institution><country>Chicago, IL, USA</country></aff><aff id="aff2"><sup>2</sup><institution>Department of Cellular and Molecular Pharmacology, The Chicago Medical School, Rosalind Franklin University of Medicine and Science</institution><country>North Chicago, IL, USA</country></aff><author-notes><fn fn-type="edited-by"><p>Edited by: Steven L. Roberds, Tuberous Sclerosis Alliance, USA</p></fn><fn fn-type="edited-by"><p>Reviewed by: P. Hemachandra Reddy, Oregon Health and Science University, USA; Jason B. Wu, Cedars-Sinai Medical Center, USA</p></fn><corresp id="fn001">*Correspondence: Judith A. Potashkin, Department of Cellular and Molecular Pharmacology, The Chicago Medical School, Rosalind Franklin University of Medicine and Science, 3333 Green Bay Road, North Chicago, IL 60064-3037, USA. e-mail: <email>judy.potashkin@rosalindfranklin.edu</email></corresp><fn fn-type="other" id="fn002"><p>This article was submitted to Frontiers in Neuropharmacology, a specialty of Frontiers in Neurology.</p></fn></author-notes><pub-date pub-type="epreprint"><day>10</day><month>10</month><year>2011</year></pub-date><pub-date pub-type="epub"><day>21</day><month>11</month><year>2011</year></pub-date><pub-date pub-type="collection"><year>2011</year></pub-date><volume>2</volume><elocation-id>68</elocation-id><history><date date-type="received"><day>12</day><month>9</month><year>2011</year></date><date date-type="accepted"><day>21</day><month>10</month><year>2011</year></date></history><permissions><copyright-statement>Copyright &#x000a9; 2011 Seidl and Potashkin.</copyright-statement><copyright-year>2011</copyright-year><license license-type="open-access" xlink:href="http://www.frontiersin.org/licenseagreement"><license-p>This is an open-access article subject to a non-exclusive license between the authors and Frontiers Media SA, which permits use, distribution and reproduction in other forums, provided the original authors and source are credited and other Frontiers conditions are complied with.</license-p></license></permissions><abstract><p>Parkinson&#x02019;s disease (PD) is characterized by loss of dopamine neurons in the substantia nigra of the brain. Since there are limited treatment options for PD, neuroprotective agents are currently being tested as a means to slow disease progression. Agents targeting oxidative stress, mitochondrial dysfunction, and inflammation are prime candidates for neuroprotection. This review identifies Rasagiline, Minocycline, and creatine, as the most promising neuroprotective agents for PD, and they are all currently in phase III trials. Other agents possessing protective characteristics in delaying PD include stimulants, vitamins, supplements, and other drugs. Additionally, combination therapies also show benefits in slowing PD progression. The identification of neuroprotective agents for PD provides us with therapeutic opportunities for modifying the course of disease progression and, perhaps, reducing the risk of onset when preclinical biomarkers become available.</p></abstract><kwd-group><kwd>neuroprotection</kwd><kwd>neurodegeneration</kwd><kwd>Parkinson&#x02019;s disease</kwd></kwd-group><counts><fig-count count="1"/><table-count count="1"/><equation-count count="0"/><ref-count count="298"/><page-count count="19"/><word-count count="18355"/></counts></article-meta></front><body><sec><title>Introduction</title><p>Parkinson&#x02019;s disease (PD) is a neurodegenerative disorder that results from the death of neuronal cells containing dopamine (DA) in the midbrain. Usually at the time of clinical diagnosis the patient has already lost 60% or more of the neurons in the substantia nigra pars compacta (SNpc). PD affects approximately 3% of the population over the age of 65. Most cases of PD are idiopathic and current evidence suggests that environmental factors along with a genetic susceptibility are the major causes (Lang and Lozano, <xref ref-type="bibr" rid="B151">1998</xref>). Genetic forms of PD exist, but they represent less than 5% of the cases (Langston, <xref ref-type="bibr" rid="B152">1998</xref>). Oxidative stress, mitochondrial dysfunction, and inflammation play key roles in the development of PD (Michel et al., <xref ref-type="bibr" rid="B177">2002</xref>; Jenner, <xref ref-type="bibr" rid="B130">2003</xref>). Because a large proportion of the baby boomers are reaching the typical age of onset for PD, there have been increased efforts to search for neuroprotective agents that will prevent the irreversible loss of neurons. In this review we summarize the current evidence that neuroprotective agents may be useful for preventing or slowing the development of PD.</p></sec><sec><title>Caffeine and Nicotine are Promising Neuroprotective Stimulants for Parkinson&#x02019;s Disease</title><p>Most epidemiological studies support a protective benefit of drinking caffeinated beverages (Ross et al., <xref ref-type="bibr" rid="B221">2000</xref>; Ascherio et al., <xref ref-type="bibr" rid="B18">2001</xref>; Saaksjarvi et al., <xref ref-type="bibr" rid="B224">2008</xref>), although one study showed no benefit (Xu et al., <xref ref-type="bibr" rid="B279">2006</xref>). Animal studies in general also indicate that caffeine is neuroprotective. Chronic caffeine administration in mice provided protection against dopaminergic neuron toxicity from exposure to a combination of paraquat and maneb (van den Pol, <xref ref-type="bibr" rid="B269">1986</xref>; Kachroo et al., <xref ref-type="bibr" rid="B136">2010</xref>). In addition, acute and chronic treatment of mice with caffeine reduced the effect of acute 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) (Chen et al., <xref ref-type="bibr" rid="B50">2001</xref>) and 6-hydroxydopamine (6-OHDA) treatment on striatal DA loss (Joghataie et al., <xref ref-type="bibr" rid="B133">2004</xref>). Motor dysfunctions were attenuated and DA levels increased after caffeine treatment in MPTP- and 6-OHDA-treated animals (Joghataie et al., <xref ref-type="bibr" rid="B133">2004</xref>; Aguiar et al., <xref ref-type="bibr" rid="B4">2006</xref>). In addition, caffeine treatment partially restored noradrenaline, DA, 3,4 dihydroxyphenylacetic acid, homovanillic acid, and their metabolites in 6-OHDA-lesioned rats (Aguiar et al., <xref ref-type="bibr" rid="B4">2006</xref>). Although serotonin levels decreased, levels of its metabolite, 5-hydroxyindoleacetic acid, were unchanged. In treatment, the time frame of caffeine&#x02019;s beneficial effects is extended by its metabolites theophylline and paraxanthine, which also exert protective effects (Xu et al., <xref ref-type="bibr" rid="B281">2010</xref>). An additional benefit of caffeine is that tolerance does not develop with long-term exposure (Xu et al., <xref ref-type="bibr" rid="B280">2002</xref>).</p><p>The effect of estrogen on caffeine&#x02019;s neuroprotective capabilities is significant. Results from epidemiological studies showed improvement in male Parkinson&#x02019;s patients only (Ascherio et al., <xref ref-type="bibr" rid="B18">2001</xref>; Costa et al., <xref ref-type="bibr" rid="B61">2010</xref>). Interestingly, in post-menopausal women, caffeine consumption is also linked to a reduced risk of PD, but only among those who were not taking hormone-replacement therapy (Ascherio et al., <xref ref-type="bibr" rid="B16">2003</xref>). In a follow up case-controlled study the relationships between gender, caffeine intake, estrogen, and the risk of PD were examined by investigating single nucleotide polymorphisms (SNPs) in the caffeine metabolizing genes [the cytochrome P450 (CYP) gene CYP1A2 and <italic>N</italic>-acetyltransferase 2 (NAT2)] and estrogen receptors (ESR1 and ESR2). A significant increased risk of PD was observed in women who had the CYP1A2 polymorphism, whereas NAT2, ESR1, and ESR2 had marginal effects on PD risk (Palacios et al., <xref ref-type="bibr" rid="B192">2010</xref>). In another study, estrogen and caffeine were administered to both male and female MPTP-treated mice, which prevented neuroprotection in all of the animals (Xu et al., <xref ref-type="bibr" rid="B279">2006</xref>). Thus, the beneficial effects of caffeine may be limited to men and post-menopausal women who are not receiving hormone-replacement therapy.</p><p>Complimentary genetic and pharmacological data from rodent studies indicate that one mechanism by which caffeine reduces dopaminergic toxicity is through antagonism of adenosine A<sub>2A</sub> receptors (see review Prediger, <xref ref-type="bibr" rid="B207">2010</xref>). In contrast, the indirect pathway of the basal ganglia contributes to the progression of PD via glutamatergic neuron overstimulation through adenosine A<sub>2A</sub> receptors (Bove et al., <xref ref-type="bibr" rid="B34">2005b</xref>). Caffeine also activates PI3K/Akt signaling and thus reduces apoptosis (Nakaso et al., <xref ref-type="bibr" rid="B184">2008</xref>).</p><p>Nicotine is comparable to caffeine with regards to lowering the risk of developing PD (Simon et al., <xref ref-type="bibr" rid="B249">2009</xref>). In a Chinese epidemiological study, there was a significant reduced rate of PD in individuals who drank coffee and smoked cigarettes, which was dose-dependent (Tan et al., <xref ref-type="bibr" rid="B258">2003</xref>). Toxicant responsive enzymes, including CYP1A1, CYP2E1, and glutathione <italic>S</italic>-transferase (GST) enzymes GST-ya, GST-yc, GSTA4-4, and vesicular monoamine transporter-2 play critical roles in modulating the protective effects of nicotine and caffeine in MPTP-treated animals (Singh et al., <xref ref-type="bibr" rid="B251">2008</xref>). Interestingly, decaffeinated coffee and nicotine-free tobacco were neuroprotective in a <italic>Drosophila</italic> model of PD, but, the neuroprotection depended on the cytoprotective transcription factor nuclear factor-erythroid 2 p45-related factor 2 (Nrf2) and cafestol (an activator) (Trinh et al., <xref ref-type="bibr" rid="B268">2010</xref>). This suggests that coffee and tobacco containing Nrf2-activating compounds account for the decreased risk of PD.</p><p>Nicotine without caffeine, has also shown beneficial effects in reducing the risk of PD in epidemiological studies and animal studies (reviewed in Quick, <xref ref-type="bibr" rid="B208">2004</xref>). Animals receiving nicotine at low doses (0.1&#x02009;mg/kg s.c) <italic>in vitro</italic> showed reduce DA depletion resulting from MPTP and 6-OHDA treatments (Ferger et al., <xref ref-type="bibr" rid="B86">1998</xref>; Costa et al., <xref ref-type="bibr" rid="B60">2001</xref>). A large dosage of nicotine (0.4&#x02009;mg/kg s.c), however, enhanced dopamine loss <italic>in vivo</italic> (Ferger et al., <xref ref-type="bibr" rid="B86">1998</xref>). Additionally, nicotine attenuated motor deficits and nigrostriatal neurodegeneration produced by chronic administration of rotenone in mice. In 6-OHDA-lesioned rats, subchronic nicotine (0.4&#x02009;mg/kg) and apomorphine treatment reduced parkinsonian contralateral rotations (Meshul et al., <xref ref-type="bibr" rid="B176">2002</xref>). Chronic nicotine treatment in MPTP-treated primates restored and maintained dopaminergic function and prevented cell loss in the SNpc (Quik et al., <xref ref-type="bibr" rid="B210">2006</xref>). In addition, simple exposure to tobacco smoke prior to MPTP treatment reduced the loss of striatal DA in mice (Carr and Rowell, <xref ref-type="bibr" rid="B41">1990</xref>). Additionally, in humans, acute nicotine treatment can improve impaired controlled semantic processing in PD patients (Holmes et al., <xref ref-type="bibr" rid="B117">2011</xref>). To date, nicotine is still in Phase II trials focusing on optimizing dosage and increasing sample size.</p><p>Nicotine is an alkaloid that is the predominant ingredient found in cigarettes. It has a high rate of absorption and diffuses quickly through the bloodstream and across the blood&#x02013;brain barrier (BBB). Nicotine reduces the oxidative stress that is associated with the progression of PD by scavenging free radicals produced by monoamine oxidase-B (MAO-B), which metabolizes DA (Fowler et al., <xref ref-type="bibr" rid="B91">1996</xref>; Iida et al., <xref ref-type="bibr" rid="B123">1999</xref>). In addition, nicotine is capable of augmenting neurotrophic factors and cholinergic receptor expression (Ferrea and Winterer, <xref ref-type="bibr" rid="B89">2009</xref>). Nicotine pretreatment attenuated the loss of dopaminergic cells in MPTP-induced mesencephalic neurons (Quik and Jeyarasasingam, <xref ref-type="bibr" rid="B209">2000</xref>). Neuroprotection was blocked by a nicotine receptor antagonist suggesting the effect was mediated by nicotinic acetylcholine receptors (nAChR; Quik and Jeyarasasingam, <xref ref-type="bibr" rid="B209">2000</xref>). These results suggest that the neuroprotective mechanism of nicotine may be directly or indirectly connected to the nAChR up-regulation in cerebral cortical blood flow (Linville et al., <xref ref-type="bibr" rid="B159">1993</xref>). Moreover, it indicates that nAChR agonists could be beneficial in slowing the progression of PD (Maggio et al., <xref ref-type="bibr" rid="B161">1997</xref>). Recently it has been suggested that stimulating nAChRs or PI3KAkt/PKB signaling could suppress dopaminergic cell death induced by rotenone (Takeuchi et al., <xref ref-type="bibr" rid="B257">2009</xref>). In similar studies, nicotine induced fibroblast growth factor (FGF-2) and the brain-derived neurotrophic factor (BDNF) in the striatum (Maggio et al., <xref ref-type="bibr" rid="B161">1997</xref>). Neuroprotection of DA neurons by nicotine is primarily gated by cytoplasmic Ca<sup>2+</sup> through a mechanism involving &#x003b1;-bungarotoxin-sensitive (&#x003b1;7) nAChRs and secondarily through T-type voltage-gated calcium channels (Toulorge et al., <xref ref-type="bibr" rid="B266">2011</xref>).</p></sec><sec><title>Urate and Uric Acid have Moderate Neuroprotective Properties</title><p>Uric acid (UA) is a natural antioxidant that can reduce oxidative stress by acting as a scavenger of free radicals and an iron chealator (Ames et al., <xref ref-type="bibr" rid="B10">1981</xref>; Davies et al., <xref ref-type="bibr" rid="B63">1986</xref>; Yu et al., <xref ref-type="bibr" rid="B295">1998</xref>; Hink et al., <xref ref-type="bibr" rid="B114">2002</xref>). Urate suppresses oxyradical accumulation (Yu et al., <xref ref-type="bibr" rid="B295">1998</xref>), inhibits cytotoxic activity of lactoperoxidase (Everse and Coates, <xref ref-type="bibr" rid="B80">2004</xref>), and protects against DA-induced apoptosis (Jones et al., <xref ref-type="bibr" rid="B134">2000</xref>). UA has been found to suppress oxidative stress and prevent dopaminergic cell death in animals (Duan et al., <xref ref-type="bibr" rid="B74">2002</xref>). In addition, slower rates of clinical progression were observed in untreated early stage PD patients who have higher plasma, serum, and cerebrospinal fluid (CSF) concentrations of UA (Schwarzschild et al., <xref ref-type="bibr" rid="B239">2008</xref>; Ascherio et al., <xref ref-type="bibr" rid="B17">2009</xref>). In contrast, lower levels of urate were present in CSF (Tohgi et al., <xref ref-type="bibr" rid="B264">1993</xref>) and post-mortem in the SNpc of patients with PD (Church and Ward, <xref ref-type="bibr" rid="B57">1994</xref>). In a population-based cohort study of 4,695 participants aged 55&#x02009;years and older, higher serum levels of UA were associated with a significantly decreased risk of PD (de Lau et al., <xref ref-type="bibr" rid="B64">2005</xref>). Urate therapy reduced the risk of PD in a dose-dependent manner (de Lau et al., <xref ref-type="bibr" rid="B64">2005</xref>; Schwarzschild et al., <xref ref-type="bibr" rid="B239">2008</xref>). Additionally in a prospective study of subjects with early stage PD there was a 49% reduction in the progression of the disease with high urate intake (Schwarzschild et al., <xref ref-type="bibr" rid="B239">2008</xref>).</p><p>Like caffeine, urate (Alonso et al., <xref ref-type="bibr" rid="B9">2007</xref>) and UA (Alonso et al., <xref ref-type="bibr" rid="B9">2007</xref>; Schwarzschild et al., <xref ref-type="bibr" rid="B239">2008</xref>; Andreadou et al., <xref ref-type="bibr" rid="B12">2009</xref>) show a gender-specific bias with a greater benefit observed in male PD patients. Epidemiological studies however contradict these results and show no gender specificity (de Lau et al., <xref ref-type="bibr" rid="B64">2005</xref>; Annanmaki et al., <xref ref-type="bibr" rid="B13">2007</xref>; Chen et al., <xref ref-type="bibr" rid="B48">2009</xref>).</p><p>Life style choices play an important role in PD progression. Exercise, for example, decreases PD, possibly by increasing serum UA levels and decreasing excretion of UA (Schlesinger and Schlesinger, <xref ref-type="bibr" rid="B237">2008</xref>). Additionally, individuals who eat diets that increase plasma urate levels have a reduced risk of PD. Dietary changes expected to increase plasma urate levels like dairy protein (but not milk) (Choi et al., <xref ref-type="bibr" rid="B55">2005</xref>) and vitamin C contribute to reducing the risk of PD in men (Gao et al., <xref ref-type="bibr" rid="B93">2008</xref>). These studies also suggest that a PD patient&#x02019;s diet should include adequate sources of purines, such as meat and seafood, which results in higher concentrations of UA (Annanmaki et al., <xref ref-type="bibr" rid="B13">2007</xref>). Diets that result in lower UA levels could accelerate disease progression (Annanmaki et al., <xref ref-type="bibr" rid="B13">2007</xref>). One must keep in mind however that a high concentration of UA in the blood serum increases the risk of gout and high alcohol and fructose consumption compounds this risk (Choi et al., <xref ref-type="bibr" rid="B54">2004</xref>). Therefore, even if PD patients choose to modify their diet for potential neuroprotective effects, the physician must carefully monitor them for other at risk chronic diseases (Gao et al., <xref ref-type="bibr" rid="B93">2008</xref>).</p></sec><sec><title>Vitamin D, Beta-Carotene and Riboflavin are Candidates for Neuroprotective Agents</title><p>Vitamin E (&#x003b1;-tocopherol) is a lipid-soluble antioxidant that can inhibit iron accumulation, suppress microglial activation, scavenge oxygen radicals, and prohibits the peroxidation of membrane lipids (Tappel, <xref ref-type="bibr" rid="B260">1962</xref>; Burton et al., <xref ref-type="bibr" rid="B36">1983</xref>; Cheeseman et al., <xref ref-type="bibr" rid="B46">1988</xref>; Chow, <xref ref-type="bibr" rid="B56">1991</xref>; Lan and Jiang, <xref ref-type="bibr" rid="B150">1997</xref>; Li et al., <xref ref-type="bibr" rid="B156">2001</xref>). Vitamin E also induces interleukin-1&#x003b1; and tumor necrosis factor (TNF)-&#x003b1; and suppresses p38 MAPK and NF&#x003ba;B activation (Li et al., <xref ref-type="bibr" rid="B156">2001</xref>). Vitamin E is regulated by &#x003b1;-tocopherol transfer protein (TTP) in the liver and brain (Kaempf-Rotzoll et al., <xref ref-type="bibr" rid="B137">2003</xref>). Studies have demonstrated that lack of TTP causes a systemic deficiency of vitamin E in humans and mice (Traber and Sies, <xref ref-type="bibr" rid="B267">1996</xref>; Yokota et al., <xref ref-type="bibr" rid="B288">2001</xref>), which can lead to enhanced oxidative stress in the brain (Yokota et al., <xref ref-type="bibr" rid="B288">2001</xref>). However, vitamin E is also believed to reduce oxidative stress caused by iron accumulation in the brain (Lan and Jiang, <xref ref-type="bibr" rid="B150">1997</xref>). Vitamin E deficiency increases MPTP toxicity in mice (Odunze et al., <xref ref-type="bibr" rid="B188">1990</xref>). Vitamin E supplementation, however, had a protective effect on DA neurons in the SNpc (Roghani and Behzadi, <xref ref-type="bibr" rid="B220">2001</xref>) and reduced DA loss (Lan and Jiang, <xref ref-type="bibr" rid="B150">1997</xref>). Pretreatment with vitamin E was shown to reduce lipid peroxidation levels (Lan and Jiang, <xref ref-type="bibr" rid="B150">1997</xref>), but depletion of striatal DA was not attenuated by pretreatment (Gong et al., <xref ref-type="bibr" rid="B101">1991</xref>; Chi et al., <xref ref-type="bibr" rid="B51">1992</xref>). Other studies have shown that vitamin E has no protective effects against DA-induced toxicity in PC12 cells (Offen et al., <xref ref-type="bibr" rid="B189">1996</xref>) and only partial protection in MPTP-treated rodents (Perry et al., <xref ref-type="bibr" rid="B201">1987</xref>). In addition, a genetic vitamin E deficiency did not affect MPTP susceptibility in mice (Ren et al., <xref ref-type="bibr" rid="B216">2006</xref>). So either the protective effects of vitamin E is dependent on the mechanism by which PD is induced or high acute dose of vitamin E have different neuroprotective effects than chronic low doses (Fariss and Zhang, <xref ref-type="bibr" rid="B84">2003</xref>; Ricciarelli et al., <xref ref-type="bibr" rid="B217">2007</xref>).</p><p>There are no differences in the amount of vitamin E in the cerebellum (Dexter et al., <xref ref-type="bibr" rid="B67">1992</xref>) or CSF (Molina et al., <xref ref-type="bibr" rid="B179">1997</xref>) between PD patients and healthy individuals. Clinical trials also show no neuroprotective benefit of taking vitamin E (Fernandez-Calle et al., <xref ref-type="bibr" rid="B88">1992</xref>; LeWitt, <xref ref-type="bibr" rid="B155">1994</xref>; Morens et al., <xref ref-type="bibr" rid="B180">1996</xref>). A meta-analysis however showed a protective effect of both moderate intake (0.67&#x02013;0.98) and high intake (0.78, 0.57&#x02013;1.06) of vitamin E (Etminan et al., <xref ref-type="bibr" rid="B78">2005</xref>). Thus, choosing foods that are vitamin E-rich may be neuroprotective (Perlmutter, <xref ref-type="bibr" rid="B195">1988</xref>; Zhang et al., <xref ref-type="bibr" rid="B296">2002</xref>). The risk of PD was significantly lower in men than in women with high intake of vitamin E from food (Zhang et al., <xref ref-type="bibr" rid="B296">2002</xref>).</p><p>Vitamin C or ascorbate, is highly concentrated in the CNS, and is associated primarily with the activity of glutamatergic neurons, which makes it a good candidate for a neuroprotector or a neuromodulator (Grunewald, <xref ref-type="bibr" rid="B104">1993</xref>). Vitamin C is decreased in vascular parkinsonisms (Paraskevas et al., <xref ref-type="bibr" rid="B193">2003</xref>). Results from a pilot study in which high doses of vitamin E and C were given to participants showed a decrease in PD progression in early stage patients (Fahn, <xref ref-type="bibr" rid="B83">1992</xref>). Yet, other studies have shown few beneficial effects of vitamin C alone and some have shown an increase risk of PD (Scheider et al., <xref ref-type="bibr" rid="B235">1997</xref>; Zhang et al., <xref ref-type="bibr" rid="B296">2002</xref>; Etminan et al., <xref ref-type="bibr" rid="B78">2005</xref>). In a case-controlled study of people who consumed diets rich in vitamin C, there was a 40% risk reduction of PD than those consuming small amounts (Perlmutter, <xref ref-type="bibr" rid="B195">1988</xref>). Because of the conflicting data, there is currently not enough data to support vitamin C as neuroprotective for PD.</p><p>Calcitriols are a group of fat-soluble secosteroids that include vitamin D and its derivatives D<sub>2</sub>, D<sub>3</sub>, D<sub>4</sub>, and D<sub>5</sub> (Garcion et al., <xref ref-type="bibr" rid="B95">2002</xref>). D<sub>3</sub> is obtained through the skin during sun exposure and can be ingested (Eyles et al., <xref ref-type="bibr" rid="B81">2003</xref>). Vitamin D deficiency is prevalent in PD patients (Sato et al., <xref ref-type="bibr" rid="B233">1997</xref>). Vitamin D receptors (DVR) in the brain are found primarily in dopaminergic neurons in the SNpc (Eyles et al., <xref ref-type="bibr" rid="B82">2005</xref>) and VDR mRNA expression in the blood is a useful risk marker for identifying PD patients (Scherzer et al., <xref ref-type="bibr" rid="B236">2007</xref>). Vitamin D has anti-inflammatory properties, it can regulate expression of glial cell line-derived neurotrophic factor (GDNF), and regulates calcium (Ca<sup>2+</sup>) homeostasis (Evans, <xref ref-type="bibr" rid="B79">1988</xref>; Naveilhan et al., <xref ref-type="bibr" rid="B185">1996</xref>; Garcion et al., <xref ref-type="bibr" rid="B95">2002</xref>; Smith et al., <xref ref-type="bibr" rid="B253">2006</xref>; Chan et al., <xref ref-type="bibr" rid="B44">2009</xref>; Butler et al., <xref ref-type="bibr" rid="B37">2011</xref>). A disruption of Ca<sup>2+</sup> homeostasis accelerates SNpc dopaminergic neuron loss (Butler et al., <xref ref-type="bibr" rid="B37">2011</xref>). In contrast, GDNF stimulation can alleviate PD symptoms in both primate and PD patients (Gash et al., <xref ref-type="bibr" rid="B98">1996</xref>; Kordower et al., <xref ref-type="bibr" rid="B145">2000</xref>; Gill et al., <xref ref-type="bibr" rid="B99">2003</xref>). Vitamin D was also shown to be beneficial in 6-OHDA-treated animals and in cell cultures (Wang et al., <xref ref-type="bibr" rid="B271">2001</xref>; Smith et al., <xref ref-type="bibr" rid="B253">2006</xref>). In addition, vitamin D increased neuromuscular function in parkinsonian rodents (Holick, <xref ref-type="bibr" rid="B116">2007</xref>). In contrast to these findings, one case-controlled human study found an increased risk of PD with high consumption of vitamin D (Anderson et al., <xref ref-type="bibr" rid="B11">1999</xref>). Together these findings suggest that dietary intake of vitamin D in moderate amounts may be effective in protecting individuals from PD progression although further studies are needed (Holick, <xref ref-type="bibr" rid="B116">2007</xref>).</p><p>Serum levels of vitamin A are similar between, PD patients and controls suggesting that levels of vitamin A are unrelated to the risk of PD (Fernandez-Calle et al., <xref ref-type="bibr" rid="B88">1992</xref>, <xref ref-type="bibr" rid="B87">1993</xref>; Jimenez-Jimenez et al., <xref ref-type="bibr" rid="B132">1993</xref>; Etminan et al., <xref ref-type="bibr" rid="B78">2005</xref>). An epidemiological study, however, found that there was a decrease in the risk of PD in individuals who consumed foods containing carotenoids and beta-carotene (Perlmutter, <xref ref-type="bibr" rid="B195">1988</xref>). Vitamin A&#x02019;s precursor beta-carotene, may offer neuroprotective effects by preventing lipid peroxidation (Glover, <xref ref-type="bibr" rid="B100">1960</xref>; Kartha and Krishnamurthy, <xref ref-type="bibr" rid="B138">1977</xref>). A recent study showed that pretreatment with beta-carotene partially protected against MPTP-induced neurotoxicity in mice (Perry et al., <xref ref-type="bibr" rid="B200">1985</xref>; Yong et al., <xref ref-type="bibr" rid="B289">1986</xref>), although the same was not true of primates (Perry et al., <xref ref-type="bibr" rid="B201">1987</xref>).</p><p>Riboflavin, vitamin B-2, is a water-soluble vitamin present predominately in dairy products (Powers, <xref ref-type="bibr" rid="B205">2003</xref>). Its biologically active forms are flavin adenine dinucleotide and flavin mononucleotide, which are electron carriers that participate in a wide range of redox reactions (Huennekens, <xref ref-type="bibr" rid="B121">1956</xref>; Merrill et al., <xref ref-type="bibr" rid="B175">1981</xref>). Riboflavin plays an active role in energy production and affects iron accumulation (Sirivech et al., <xref ref-type="bibr" rid="B252">1977</xref>; Powers et al., <xref ref-type="bibr" rid="B206">1983</xref>; Powers, <xref ref-type="bibr" rid="B204">1987</xref>). The mechanism of action of riboflavin in the brain remains unknown, but may involve glutathione depletion, cumulative mitochondrial DNA mutations, disturbed mitochondrial protein complexes, and abnormal iron metabolism (Di Monte, <xref ref-type="bibr" rid="B69">1991</xref>; Jenner et al., <xref ref-type="bibr" rid="B131">1992</xref>; Logroscino et al., <xref ref-type="bibr" rid="B160">1997</xref>). Riboflavin may also effect glutathione production (Perlmutter, <xref ref-type="bibr" rid="B195">1988</xref>). The amount of riboflavin is lower in PD patients compared to healthy and disease controls, suggesting that taking riboflavin supplements may be beneficial (Coimbra and Junqueira, <xref ref-type="bibr" rid="B59">2003</xref>). Intake of riboflavin, compared to other B-vitamins was shown to reduce the risk of PD (Murakami et al., <xref ref-type="bibr" rid="B182">2010</xref>). In fact, the risk of PD was reduced 51% by users obtaining a high consumption (Perlmutter, <xref ref-type="bibr" rid="B195">1988</xref>) and daily doses of riboflavin for 6&#x02009;months showed improved motor capacity of PD patients in 3&#x02009;months (Coimbra and Junqueira, <xref ref-type="bibr" rid="B59">2003</xref>). These promising results indicate that additional longitudinal studies are needed to determine the long-term effects of chronic administration of riboflavin supplements.</p></sec><sec><title>Among the Supplements Creatine Shows the Most Promise as a Neuroprotective Agent</title><p>Coenzyme Q10 (CoQ10), also known as ubiquinone, is a promising agent for neuroprotection in PD and other neurodegenerative diseases because of its role in the mitochondrial electron transport chain (METC) and as an antioxidant (Beal and Shults, <xref ref-type="bibr" rid="B24">2003</xref>). CoQ10 serves as an electron acceptor in complex I and II of the METC. CoQ10 is protective by inhibiting SIN-1-induced apoptosis (Sharma et al., <xref ref-type="bibr" rid="B242">2004</xref>), suppressing intra-mitochondrial and intra-nuclear biosynthesis of 8-OH-2dG, inhibiting translocation of caspase-3, attenuating &#x003b1;-synuclein expression, and blocking intra-mitochondrial accumulation of metal ions (Ebadi et al., <xref ref-type="bibr" rid="B76">2004</xref>).</p><p>Animal studies have shown that rotenone-induced parkinsonism reduced CoQ10 concentrations in plasma and the striatum with a corresponding decrease in striatal levels of DA, mitochondrial complex I activity and ATP levels, as well as significant increase in B-cell lymphoma 2 (Bcl-2) expression (Abdin and Hamouda, <xref ref-type="bibr" rid="B1">2008</xref>). Administration of CoQ10 protected the nigrostriatal dopaminergic neurons in MPTP-treated mice (Shults et al., <xref ref-type="bibr" rid="B245">1999</xref>). In addition, a diet containing CoQ10 (1,600&#x02009;mg/kg/day, 2&#x02009;months) or CoQ10 supplementation diminished neural tissue damage (Cleren et al., <xref ref-type="bibr" rid="B58">2008</xref>). CoQ10 was also effective in preventing DA depletion, loss of tyrosine hydroxylase neurons and formation of &#x003b1;-synuclein inclusions in the SNpc in mice (Cleren et al., <xref ref-type="bibr" rid="B58">2008</xref>).</p><p>Reduced levels of CoQ10 are present in PD patients&#x02019; plasma and platelets (Matsubara et al., <xref ref-type="bibr" rid="B168">1991</xref>; Gotz et al., <xref ref-type="bibr" rid="B102">2000</xref>) and in cortex (Hargreaves et al., <xref ref-type="bibr" rid="B105">2008</xref>), which correlated with reduced activity of complex I and II/III (Shults et al., <xref ref-type="bibr" rid="B246">1997</xref>, <xref ref-type="bibr" rid="B245">1999</xref>). In addition, the percent of CoQ10 in its oxidized form is elevated in PD patients (Sohmiya et al., <xref ref-type="bibr" rid="B254">2004</xref>). Chronic administration of CoQ10 in PD patients delays the progression of PD (Shults et al., <xref ref-type="bibr" rid="B247">2002</xref>; Shults, <xref ref-type="bibr" rid="B243">2003</xref>) with no adverse effects (Galpern and Cudkowicz, <xref ref-type="bibr" rid="B92">2007</xref>). Additionally, CoQ10 supplements showed promising results in a small group of <italic>de novo</italic> PD patients during phase II clinical trials although no follow up study has been published (Shults et al., <xref ref-type="bibr" rid="B247">2002</xref>). More recently, another human trial found inconclusive results from CoQ10 supplements in PD patients (Investigators, <xref ref-type="bibr" rid="B127">2007</xref>). CoQ10 (2,400&#x02009;mg/day) and vitamin E (1,200&#x02009;IU/day) together initially was thought to be beneficial for PD patients (Shults et al., <xref ref-type="bibr" rid="B244">2004</xref>), however, in Phase III trials it was deemed futile (NINDS<xref ref-type="fn" rid="fn1"><sup>1</sup></xref>).</p><p>Creatine is a guanidino compound found primarily in meat products and is produced endogenously by the liver, kidney, and pancreas (Tarnopolsky and Beal, <xref ref-type="bibr" rid="B261">2001</xref>; Adhihetty and Beal, <xref ref-type="bibr" rid="B3">2008</xref>). Creatine possesses antioxidant properties and can regulate intracellular calcium, suppress extracellular glutamate levels, and inhibit the opening of the mitochondrial permeability transition pore (MPT; Figure <xref ref-type="fig" rid="F1">1</xref>) (Xu et al., <xref ref-type="bibr" rid="B278">1996</xref>; Lawler et al., <xref ref-type="bibr" rid="B153">2002</xref>; Dedeoglu et al., <xref ref-type="bibr" rid="B66">2003</xref>).</p><fig id="F1" position="float"><label>Figure 1</label><caption><p><bold>The mechanisms of action of neuroprotective agents that are in clinical trials</bold>. Rasagiline shows neuroprotective properties by suppressing mitochondrial apoptosis stopping the mitochondrial permeability transition pore (MPT) opening by inhibiting caspase-3, nuclear poly [ADP-ribose] polymerase 1 (PARP-1) activation, stopping the translocation of glyceraldehyde-3-phosphate dehydrogenase (GAPDH), and halting nucleosomal DNA fragmentation. Rasagiline increases the expression of the anti-apoptotic proteins B-cell lymphoma 2 (Bcl-2) and B-cell lymphoma-extra large (Bcl-xL) through the protein kinase C (PKC) pathway, in addition to down-regulating the pro-apoptotic Bcl-2-associated death promoter (Bad) and Bcl-2-associated X protein (Bax). Minocycline inhibits the inflammatory response to prevent cell death and it chealates metals. Creatine inhibits activation of the MPT and represses iron (Fe<sup>2+</sup>) accumulation.</p></caption><graphic xlink:href="fneur-02-00068-g001"/></fig><p>A combination of CoQ10 and creatine shows an additive neuroprotective effect in chronic MPTP-treated mice (Yang et al., <xref ref-type="bibr" rid="B284">2009</xref>). Additionally, creatine has shown promising neuroprotective effects in combination with CoQ10 in PD patients (Yang et al., <xref ref-type="bibr" rid="B284">2009</xref>). Alone, creatine protects against MPTP-induced DA depletion in the SNpc (Matthews et al., <xref ref-type="bibr" rid="B169">1999</xref>). Interestingly, in a stage II clinical trial creatine showed a delay in the progression of PD by 50% compared to controls that received a placebo (Investigators, <xref ref-type="bibr" rid="B126">2006</xref>). In a follow up study 18&#x02009;months later, creatine continued to show efficacy as a neuroprotective agent (Investigators, <xref ref-type="bibr" rid="B128">2008</xref>) and it is currently in Phase III trials (NET-PDLS<xref ref-type="fn" rid="fn2"><sup>2</sup></xref>).</p><p>Omega-3 polyunsaturated fatty acids appear to be neuroprotective for several diseases (Bousquet et al., <xref ref-type="bibr" rid="B31">2011</xref>) including a small study with PD patients (da Silva et al., <xref ref-type="bibr" rid="B62">2008</xref>). Animal studies have shown that the omega-3 fatty acid docosahexaenoic acid (DHA) can replace the omega-6 fatty acids already present in the brains of mice that had been given supplements after MPTP treatment (Bousquet et al., <xref ref-type="bibr" rid="B32">2008</xref>). DHA is an essential factor in growth and development in the brain (Horrocks and Yeo, <xref ref-type="bibr" rid="B119">1999</xref>) and has anti-inflammatory capabilities due to its ability to inhibit cyclo-oxygenase-2 (COX-2) (Massaro et al., <xref ref-type="bibr" rid="B167">2006</xref>). DHA (5&#x02013;50&#x02009;&#x003bc;g/ml) protected neurons against cytotoxicity, inhibited both nitrogen oxide (NO) production and Ca<sup>2+</sup> influx, and increased the activities of antioxidant enzymes of glutathione peroxidase and glutathione reductase (Wang et al., <xref ref-type="bibr" rid="B272">2003</xref>) in cell cultures. DHA does not alter the levels of glutathione (GSH) (Wang et al., <xref ref-type="bibr" rid="B272">2003</xref>). Animal studies showed that DHA decreased apoptosis of dopaminergic cells after MPTP treatment (Ozsoy et al., <xref ref-type="bibr" rid="B191">2011</xref>). Short-term administration of DHA (100&#x02009;mg/kg) reduced 40% of the levodopa-induced dyskinesias in Parkinsonian primates (Samadi et al., <xref ref-type="bibr" rid="B230">2006</xref>). DHA also preserved DA levels, tyrosine hydroxylase (TH)-positive neurons and nuclear receptor related-1 protein expression from MPTP-induced neurotoxicity in mice (Bousquet et al., <xref ref-type="bibr" rid="B32">2008</xref>). Chronic administration of uridine and DHA increased the levels of neural phosphatides and proteins in synaptic membranes (Wurtman et al., <xref ref-type="bibr" rid="B277">2006</xref>) and dendritic spines in rodents (Sakamoto et al., <xref ref-type="bibr" rid="B228">2007</xref>). DHA and uridine administration also reduced parkinsonian related behaviors and elevated DA levels in 6-OHDA rats (Cansev et al., <xref ref-type="bibr" rid="B40">2008</xref>). Human studies on the effects of DHA are now needed before recommendations may be made to PD patients.</p><p>DHA&#x02019;s proposed mechanisms of neuroprotection are linked to its anti-oxidative activity <italic>in vivo</italic> (Hashimoto et al., <xref ref-type="bibr" rid="B108">2002</xref>; Yavin et al., <xref ref-type="bibr" rid="B286">2002</xref>; Calon et al., <xref ref-type="bibr" rid="B39">2004</xref>; Wu et al., <xref ref-type="bibr" rid="B274">2004</xref>; Bazan, <xref ref-type="bibr" rid="B23">2005</xref>), its ability to increase glutathione reductase activity (Hashimoto et al., <xref ref-type="bibr" rid="B108">2002</xref>) and decrease the accumulation of oxidized proteins (Calon et al., <xref ref-type="bibr" rid="B39">2004</xref>; Wu et al., <xref ref-type="bibr" rid="B274">2004</xref>) and levels of lipid peroxide and reactive oxygen species (ROS) (Hashimoto et al., <xref ref-type="bibr" rid="B108">2002</xref>, <xref ref-type="bibr" rid="B109">2005</xref>). DHA also triggered inactivation of cell-signaling pathways leading to caspase activation (Calon et al., <xref ref-type="bibr" rid="B39">2004</xref>, <xref ref-type="bibr" rid="B38">2005</xref>) and hyperphosphorylation of tau (Green et al., <xref ref-type="bibr" rid="B103">2007</xref>). In addition, DHA regulates the PI3K/Akt cascade (Akbar and Kim, <xref ref-type="bibr" rid="B8">2002</xref>; Akbar et al., <xref ref-type="bibr" rid="B7">2005</xref>; Kim, <xref ref-type="bibr" rid="B141">2007</xref>). DHA has no association with beta-secretase or gamma-secretase complex, but it can down-regulate presenilin-1 <italic>in vitro</italic> and <italic>in vivo</italic> (Lim et al., <xref ref-type="bibr" rid="B158">2005</xref>; Green et al., <xref ref-type="bibr" rid="B103">2007</xref>). Other potential mechanisms of action of DHA include regulation of inflammation, gene transcription, and cell membrane properties (de Urquiza et al., <xref ref-type="bibr" rid="B65">2000</xref>; Salem et al., <xref ref-type="bibr" rid="B229">2001</xref>; Jump, <xref ref-type="bibr" rid="B135">2002</xref>).</p><p>Melatonin has been associated with nigrostriatal protection, reduced auto-oxidation of <sc>l</sc>-3,4-dihydroxyphenylalanine, and has antioxidant properties (Fertl et al., <xref ref-type="bibr" rid="B90">1993</xref>; Miller et al., <xref ref-type="bibr" rid="B178">1996</xref>; Reiter et al., <xref ref-type="bibr" rid="B215">1997</xref>; Khaldy et al., <xref ref-type="bibr" rid="B140">2000</xref>; Rocchitta et al., <xref ref-type="bibr" rid="B219">2006</xref>). Decreased levels of melatonin are present in PD patients compared to controls (Sandyk, <xref ref-type="bibr" rid="B232">1990</xref>). Melatonin&#x02019;s free radical scavenging properties and its ability to easily pass the BBB suggest that it may be neuroprotective (Antolin et al., <xref ref-type="bibr" rid="B14">2002</xref>; see review Mayo et al., <xref ref-type="bibr" rid="B171">2005</xref>).</p><p>Animal studies have shown that melatonin can prevent cell death and damage induced by MPTP (Acuna-Castroviejo et al., <xref ref-type="bibr" rid="B2">1997</xref>), 6-OHDA (Kim et al., <xref ref-type="bibr" rid="B143">1998</xref>), and iron (Maharaj et al., <xref ref-type="bibr" rid="B162">2006a</xref>) in neurons and astrocytes (Martin et al., <xref ref-type="bibr" rid="B165">2002</xref>). Melatonin blocked apoptosis and necrosis in 6-OHDA-treated undifferentiated and nerve growth factor (NGF)-differentiated PC12 cells (Mayo et al., <xref ref-type="bibr" rid="B172">1998</xref>, <xref ref-type="bibr" rid="B170">1999</xref>). Contrary to these results, striatal DA depletion and DA neuron loss increased after melatonin treatment of rotenone-induced Parkinsonism (Tapias et al., <xref ref-type="bibr" rid="B259">2010</xref>). Melatonin given to PD patients improved the duration of sleep and reduced sleep disturbances (Dowling et al., <xref ref-type="bibr" rid="B71">2005</xref>). There are no clinical studies to date that have investigated whether melatonin is neuroprotective for PD patients.</p><p>The antioxidant GSH, which is involved in iron metabolism and plays an ancillary role in thiol&#x02013;redox control, is depleted in the SNpc of PD patients (Perry et al., <xref ref-type="bibr" rid="B199">1982</xref>; Riederer et al., <xref ref-type="bibr" rid="B218">1989</xref>; Pearce et al., <xref ref-type="bibr" rid="B194">1997</xref>). When GSH was depleted <italic>in vitro</italic> and <italic>in vivo</italic>, there was oxidative damage of complex I proteins (Chinta and Andersen, <xref ref-type="bibr" rid="B52">2006</xref>; Chinta et al., <xref ref-type="bibr" rid="B53">2007</xref>; Kumar et al., <xref ref-type="bibr" rid="B146">2011</xref>), defects in basal ganglia formed (Sian et al., <xref ref-type="bibr" rid="B248">1994</xref>), and the ubiquitin&#x02013;proteasome system functioned poorly (Martin and Teismann, <xref ref-type="bibr" rid="B164">2009</xref>), but the electron transport chain complex was unaffected (Heales et al., <xref ref-type="bibr" rid="B111">2011</xref>). Collectively these studies suggest that GSH may facilitate cascading events leading to oxidative stress (Bharath et al., <xref ref-type="bibr" rid="B27">2002</xref>; Garrido et al., <xref ref-type="bibr" rid="B97">2011</xref>).</p><p>Animal studies have also shown that excessive or reduced GSH levels can initiate degeneration of DA neurons (Garrido et al., <xref ref-type="bibr" rid="B97">2011</xref>). However, chronically decreased GSH concentrations in the brain did not directly correlate to a reduction in the viability of DA neurons in the SNpc, nor decrease the number of striatal DA terminals, but does make neurons more susceptible to neurotoxins (Schulz et al., <xref ref-type="bibr" rid="B238">2000</xref>). Treatment with MPTP in GSH peroxidase-deficient mice resulted in depletion of DA (Klivenyi et al., <xref ref-type="bibr" rid="B144">2000</xref>). In nigral TH immune responsive cells similar results were seen with a greater reduction of DA neurons when lower levels of GSH were present prior to toxin administration (Pileblad et al., <xref ref-type="bibr" rid="B202">1989</xref>; Seaton et al., <xref ref-type="bibr" rid="B240">1996</xref>; Wullner et al., <xref ref-type="bibr" rid="B276">1996</xref>). These studies suggest that the concentration of GSH is key to its neuroprotective capabilities. It has been hypothesized that enhancement of GSH synthesis or inhibition of its degradation may result in a decrease in disease progression (Schulz et al., <xref ref-type="bibr" rid="B238">2000</xref>).</p><p>Phytic acid (IP6) is a naturally occurring iron chelator in food that acts by altering cell-signaling pathways and the activity or expression of antioxidant enzymes (Shamsuddin et al., <xref ref-type="bibr" rid="B241">1997</xref>; Xu et al., <xref ref-type="bibr" rid="B283">2011</xref>). IP6 is capable of inhibiting MPTP, 6-OHDA, and iron toxicity in cell culture (Xu et al., <xref ref-type="bibr" rid="B282">2008</xref>, <xref ref-type="bibr" rid="B283">2011</xref>). IP6 increases cell survival in MPTP-treated cells and repressed caspase-3 activity and DNA fragmentation (Xu et al., <xref ref-type="bibr" rid="B282">2008</xref>). IP6 also suppressed hydroxyl radical formation after 1-methyl-4-phenylpyridinium (MPP+) treatment in rats (Obata, <xref ref-type="bibr" rid="B187">2003</xref>). Further animal and human studies are needed to test IP6&#x02019;s antioxidant&#x02019;s properties.</p></sec><sec><title>Several Commonly Prescribed Drugs are Emerging as Therapeutic Agents for PD</title><p>Common household drugs such as aspirin and Ibuprofen protect against neuro-inflammation, which can lead to neurodegeneration in the brain (Hirsch and Hunot, <xref ref-type="bibr" rid="B115">2009</xref>). The use of non-steroidal anti-inflammatory drugs (NSAIDS) has been shown to lower the risk of PD in epidemiological studies (Chen et al., <xref ref-type="bibr" rid="B49">2003</xref>; Ton et al., <xref ref-type="bibr" rid="B265">2006</xref>; Wahner et al., <xref ref-type="bibr" rid="B270">2007</xref>; Gao et al., <xref ref-type="bibr" rid="B94">2011</xref>) and protect against neuronal death, ROS/peroxidation, and dopaminergic neurotoxicity by inhibiting cyclo-oxygenase enzymes in animals (Bilodeau et al., <xref ref-type="bibr" rid="B28">1995</xref>; Kaufmann et al., <xref ref-type="bibr" rid="B139">1997</xref>; Aubin et al., <xref ref-type="bibr" rid="B19">1998</xref>; Saini et al., <xref ref-type="bibr" rid="B226">1998</xref>; Casper et al., <xref ref-type="bibr" rid="B43">2000</xref>; Sairam et al., <xref ref-type="bibr" rid="B227">2003</xref>). Pretreatment with NSAIDS is neuroprotective in MPTP and 6-OHDA-treated animals and <italic>in vitro</italic> (Esposito et al., <xref ref-type="bibr" rid="B77">2007</xref>). In humans there was a reduction in PD risk observed in individuals who use Ibuprofen, but no reduction was found in individuals who use NSAIDS or Acetaminophen (Chen et al., <xref ref-type="bibr" rid="B47">2005</xref>; Ton et al., <xref ref-type="bibr" rid="B265">2006</xref>; Driver et al., <xref ref-type="bibr" rid="B72">2011</xref>; Gao et al., <xref ref-type="bibr" rid="B94">2011</xref>). A case-controlled study also concluded that NSAID&#x02019;s and aspirin show no association with altering the risk of PD (Becker et al., <xref ref-type="bibr" rid="B25">2011</xref>). In some studies there was a reported increased risk of PD observed in individual who use aspirin (Bower et al., <xref ref-type="bibr" rid="B35">2006</xref>; Hernan et al., <xref ref-type="bibr" rid="B113">2006</xref>). In contrast, other studies showed that aspirin was protective and functioned by ROS scavenging <italic>in vivo</italic> (Di Matteo et al., <xref ref-type="bibr" rid="B68">2006</xref>; Maharaj et al., <xref ref-type="bibr" rid="B163">2006b</xref>). Ibuprofen protects DA neurons against glutamate toxicity and decreases MPTP toxicity <italic>in vitro</italic> (Casper et al., <xref ref-type="bibr" rid="B43">2000</xref>; Morioka et al., <xref ref-type="bibr" rid="B181">2004</xref>; Carrasco et al., <xref ref-type="bibr" rid="B42">2005</xref>). A meta-analysis determined that regular use of Ibuprofen also reduced the risk of developing PD in humans by 40% (Samii et al., <xref ref-type="bibr" rid="B231">2009</xref>; Gao et al., <xref ref-type="bibr" rid="B94">2011</xref>). The results from these studies together suggest that Ibuprofen and aspirin may be neuroprotective.</p><p>The dihydropyridine L-type calcium channel blocker Isradipine has been reported to reduce hypoxia-induced activation of Ca<sup>2+</sup>-dependent xanthine oxidases, monoamine oxidases, cytosolic phospholipase A<sub>2</sub>, and cyclo-oxygenases (COX-2) along with a decrease in free radical generation and cytochrome-<italic>c</italic> release (Barhwal et al., <xref ref-type="bibr" rid="B22">2009</xref>). Increased expression of calpain, caspase-3, (Barhwal et al., <xref ref-type="bibr" rid="B22">2009</xref>), and glutamate-induced neurotoxicity (Pizzi et al., <xref ref-type="bibr" rid="B203">1991</xref>) was also inhibited by Isradipine.</p><p>The use of L-type Ca<sup>2+</sup> channel antagonists protects SNpc DA neurons in MPTP-treated animals (Kupsch et al., <xref ref-type="bibr" rid="B147">1995</xref>, <xref ref-type="bibr" rid="B149">1996</xref>; Chan et al., <xref ref-type="bibr" rid="B45">2007</xref>), but the same was not true of 6-OHDA-treated animals (Sautter et al., <xref ref-type="bibr" rid="B234">1997</xref>). This discrepancy may be the result of the different mechanisms by which the two toxins act on mitochondria (Bove et al., <xref ref-type="bibr" rid="B33">2005a</xref>). Currently very few studies specifically address Isradipine&#x02019;s neuroprotective capabilities, however a dose-dependent effect was observed in 6-OHDA-treated animals (Ilijic et al., <xref ref-type="bibr" rid="B124">2011</xref>). In a pilot study in which PD patients were treated with Isradipine no negative side effects were noted thus paving the way for further clinical testing (Simuni et al., <xref ref-type="bibr" rid="B250">2010</xref>).</p><p>Because a mutation in the DJ-1 protein causes early onset of autosomal PD (Bonifati et al., <xref ref-type="bibr" rid="B30">2003</xref>; Ibanez et al., <xref ref-type="bibr" rid="B122">2003</xref>) and lower levels of DJ-1 are associated with PD, it is thought that drugs that up-regulate DJ-1 may slow disease progression by moderating oxidative stress and protein aggregation (Zhou et al., <xref ref-type="bibr" rid="B298">2011</xref>). DJ-1 acts through multiple pathways, and works in parallel with PINK1/parkin (Zhou et al., <xref ref-type="bibr" rid="B298">2011</xref>). Phenylbutyrate, a chaperone molecule and histone deacetylase inhibitor, increased DJ-1 expression in DA cell cultures, rescued cells from oxidative stress, and reduced &#x003b1;-synuclein aggregation (Zhou et al., <xref ref-type="bibr" rid="B298">2011</xref>). In MPTP-treated animals, phenylbutyrate protected DA neurons in the SNpc and increase DJ-1 expression (Gardian et al., <xref ref-type="bibr" rid="B96">2004</xref>; Zhou et al., <xref ref-type="bibr" rid="B298">2011</xref>). Long-term administration of phenylbutyrate reduced deterioration in motor and cognitive functions in mice (Zhou et al., <xref ref-type="bibr" rid="B298">2011</xref>). Similar results were seen with 4-phenylbutyrate in rotenone-treated mice (Inden et al., <xref ref-type="bibr" rid="B125">2007</xref>).</p><p>Type 2 diabetes has been correlated with an increase risk of PD and a high prevalence of insulin resistance has been found in PD patients, suggesting that the two chronic diseases may share similar dysregulated pathways that play a role in cell death and dysfunction (Arvanitakis et al., <xref ref-type="bibr" rid="B15">2004</xref>; Jeerakathil et al., <xref ref-type="bibr" rid="B129">2007</xref>). Possible shared pathways may be related to insulin regulation, suggesting that diabetes drugs may possess neuroprotective effects (Holst et al., <xref ref-type="bibr" rid="B118">2011</xref>). Glucagon-like peptide-1 (GLP-1) is commonly used to treat type 2 diabetes. GLP-1 also acts as a growth factor in the brain, and can induce neurite outgrowth and protect against oxidative injury in cultured neuronal cells (Perry et al., <xref ref-type="bibr" rid="B197">2007</xref>). The anti-apoptotic actions of GLP-1 is thought to be related to the activation of the transcription factor cAMP response element-binding protein by phosphorylation (Perry et al., <xref ref-type="bibr" rid="B198">2002</xref>; Li et al., <xref ref-type="bibr" rid="B157">2009</xref>). Previous studies have also claimed that PDA, PI3K, and MAPK may be involved in the mechanism of action of GLP-1, in addition to MAPK-independent signaling and growth factor-dependent Ser/Thr kinase AktPKB (Lazaroff et al., <xref ref-type="bibr" rid="B154">1995</xref>; During et al., <xref ref-type="bibr" rid="B75">2003</xref>; Perry and Greig, <xref ref-type="bibr" rid="B196">2005</xref>).</p><p>Exendin-4 (Ex-4), an analog of GLP-1, protected DA neurons from degeneration, preserved DA levels, and improved motor function in rodents (Li et al., <xref ref-type="bibr" rid="B157">2009</xref>) by inhibiting microglial activation and matrix metalloproteinase-3 expression (Kim et al., <xref ref-type="bibr" rid="B142">2009</xref>). Ex-4 has also been shown to protect ventral mesencephalic dopaminergic cells in culture, reverse nigral lesions, and protect against 6-OHDA toxicity (Harkavyi et al., <xref ref-type="bibr" rid="B106">2008</xref>; Li et al., <xref ref-type="bibr" rid="B157">2009</xref>). Ex-4 receptors also show neuroprotection by mediating and increasing neurogenesis in the subventricular zone in rodents (Bertilsson et al., <xref ref-type="bibr" rid="B26">2008</xref>). In addition to Ex-4, other analogs of GLP-1 offer promising neurprotective effects (see review Harkavyi and Whitton, <xref ref-type="bibr" rid="B107">2010</xref>). One of these, Liraglutide, has been shown to be neuroprotective in an Alzheimer&#x02019;s disease model (McClean et al., <xref ref-type="bibr" rid="B173">2010</xref>, <xref ref-type="bibr" rid="B174">2011</xref>).</p></sec><sec><title>Rasagiline and Minocycline are Currently in Clinical Trials as Neuroprotective Agents for PD</title><p>Rasagiline is a selective and potent propargylamine MAO-B inhibitor (Tatton et al., <xref ref-type="bibr" rid="B262">2003</xref>), that reduces MPTP and 6-OHDA toxicity in PC12 and SH-SY5Y cells, (Maruyama et al., <xref ref-type="bibr" rid="B166">2000</xref>) and is neuroprotective <italic>in vivo</italic> (Heikkila et al., <xref ref-type="bibr" rid="B112">1985</xref>; Huang et al., <xref ref-type="bibr" rid="B120">1999</xref>; Speiser et al., <xref ref-type="bibr" rid="B255">1999</xref>; Sagi et al., <xref ref-type="bibr" rid="B225">2001</xref>; Youdim et al., <xref ref-type="bibr" rid="B291">2001a</xref>). Pretreatment with Rasagiline prevents nigrostriatal damage induced by MPTP in primates (Kupsch et al., <xref ref-type="bibr" rid="B148">2001</xref>; Sagi et al., <xref ref-type="bibr" rid="B225">2001</xref>). Chronic administration of Rasagiline increased DA neuron survival in lesioned SNpc and improved motor impairments (Blandini et al., <xref ref-type="bibr" rid="B29">2004</xref>). Rasagiline also increased the expression of the neurotrophins BDNF, GDNF, and NGF (Murer et al., <xref ref-type="bibr" rid="B183">2001</xref>). In humans, Rasagiline reduced the long-term progression and symptoms in PD (Hauser et al., <xref ref-type="bibr" rid="B110">2009</xref>; Olanow et al., <xref ref-type="bibr" rid="B190">2009</xref>). In a promising recent study, Rasagiline delayed the need for antiparkinsonian drugs and patients had lower scores on the PD rating scale in a Phase III study (Rascol et al., <xref ref-type="bibr" rid="B213">2011</xref>).</p><p>Rasagiline suppresses mitochondrial apoptosis by inhibiting caspase-3 and nuclear poly [ADP-ribose] polymerase 1 (PARP-1) activation, translocation of glyceraldehyde-3-phosphate dehydrogenase (GAPDH), the opening of the MPT and DNA fragmentation (Figure <xref ref-type="fig" rid="F1">1</xref>; Youdim and Weinstock, <xref ref-type="bibr" rid="B293">2001</xref>; Youdim et al., <xref ref-type="bibr" rid="B292">2001b</xref>, <xref ref-type="bibr" rid="B290">2003</xref>; Akao et al., <xref ref-type="bibr" rid="B5">2002a</xref>; Bar Am et al., <xref ref-type="bibr" rid="B20">2004</xref>; Bar-Am et al., <xref ref-type="bibr" rid="B21">2004</xref>; Weinreb et al., <xref ref-type="bibr" rid="B273">2004</xref>). Rasagiline also increases the expression of the anti-apoptotic proteins Bcl-2 and B-cell lymphoma-extra large (Bcl-XL) through the PKC pathway, in addition to down-regulating the pro-apoptotic Bcl-2-associated death promoter (Bad) and Bcl-2-associated X protein (BAX) (Youdim et al., <xref ref-type="bibr" rid="B291">2001a</xref>, <xref ref-type="bibr" rid="B290">2003</xref>; Akao et al., <xref ref-type="bibr" rid="B6">2002b</xref>; Yogev-Falach et al., <xref ref-type="bibr" rid="B287">2003</xref>; Bar Am et al., <xref ref-type="bibr" rid="B20">2004</xref>; Bar-Am et al., <xref ref-type="bibr" rid="B21">2004</xref>; Weinreb et al., <xref ref-type="bibr" rid="B273">2004</xref>).</p><p>Minocycline is a semi-synthetic second-generation tetracycline that exerts anti-inflammatory and antioxidant effects (Ryan and Ashley, <xref ref-type="bibr" rid="B222">1998</xref>; Ryan et al., <xref ref-type="bibr" rid="B223">1998</xref>; Faust et al., <xref ref-type="bibr" rid="B85">2009</xref>). Minocycline works by inhibiting the activation of microglia and attenuating the p38 MAPK cascade which reduces inflammatory cytokine synthesis (Figure <xref ref-type="fig" rid="F1">1</xref>; Yrjanheikki et al., <xref ref-type="bibr" rid="B294">1998</xref>; Tikka et al., <xref ref-type="bibr" rid="B263">2001</xref>; Wu et al., <xref ref-type="bibr" rid="B275">2002</xref>). It is thought that Minocycline&#x02019;s neuroprotective properties may result from inhibition of NO-mediated neurotoxicity (Du et al., <xref ref-type="bibr" rid="B73">2001</xref>). Additionally, Minocycline may be able to chelate metal ions.</p><p>In rodents, Minocycline blocked MPTP-induced degeneration of DA neurons in the SNpc, preventing loss of striatal DA, and its metabolites (Du et al., <xref ref-type="bibr" rid="B73">2001</xref>). Minocycline treatment also inhibited MPP+ mediated inducible NO synthase expression <italic>in vivo</italic> and potently blocked NO-induced neurotoxicity <italic>in vitro</italic> (Du et al., <xref ref-type="bibr" rid="B73">2001</xref>). Potent DA neuroprotection by Minocycline was also observed in a <italic>Drosophila</italic> model of PD (Faust et al., <xref ref-type="bibr" rid="B85">2009</xref>) and after chronic rotenone toxicity in rodents (Radad et al., <xref ref-type="bibr" rid="B212">2010</xref>). In addition, Minocycline administration reduced the number of apomorphine-induced rotations in 6-OHDA-lesioned rats, reduced TH-positive cell loss and increased the size and fiber density of the remaining nigral cells (Quintero et al., <xref ref-type="bibr" rid="B211">2006</xref>).</p><p>Although Minocycline inhibits microglial activation (Wu et al., <xref ref-type="bibr" rid="B275">2002</xref>), other studies have shown it to significantly exacerbate MPTP-induced damage to DA neurons <italic>in vitro</italic> and <italic>in vivo</italic> (Yang et al., <xref ref-type="bibr" rid="B285">2003</xref>). Similarly, Minocycline treatment of monkeys and mice produced more severe and rapid parkinsonism, behavior deficits, and greater loss of nerve endings (Diguet et al., <xref ref-type="bibr" rid="B70">2004</xref>). Lack of neuroprotection was shown to be due to the inability of Minocycline to abolish the activation of TNF-&#x003b1; and its receptors, thereby failing to modulate TNF signaling after MPTP administration (Sriram et al., <xref ref-type="bibr" rid="B256">2006</xref>). Minocycline administration in TNF-&#x003b1; knockout MPTP-treated mice increased leakage of the BBB, but these animals did not exhibit a greater loss of neurons (Zhao et al., <xref ref-type="bibr" rid="B297">2007</xref>). In a phase II clinical trial, Minocycline was deemed effective in slowing the progression of PD in patients (Investigators, <xref ref-type="bibr" rid="B126">2006</xref>) and an 18-month follow up study showed no safety concerns, thus paving the way to a phase III trial (Investigators, <xref ref-type="bibr" rid="B128">2008</xref>). Additionally, neuroprotective effects of Minocycline combined with creatine demonstrate additive benefits in reducing PD progression in patients, and is currently in clinical trials (NET-PD, <xref ref-type="bibr" rid="B186">2006</xref>).</p></sec><sec><title>Concluding Remarks</title><p>Some neuroprotective agents show promising results for slowing the progression of PD and these are summarized in Table <xref ref-type="table" rid="T1">1</xref>. In general, these agents reduce oxidative stress, mitochondrial dysfunction, protein aggregation, inflammation, excitotoxicity, cell death, iron accumulation, or stimulate neurotrophic factors. In an earlier review, caffeine, CoQ10, creatine, Minocycline, and Rasagiline were identified as the top candidates for preventing neurodegenerative diseases (Ravina et al., <xref ref-type="bibr" rid="B214">2003</xref>). However, current research suggests that Minocycline, creatine, and Rasagiline are the most promising agents for neuroprotection in PD and all three are now in Phase III trials. In addition, a combination of Minocycline and creatine is in Phase III trials and CoQ10 and creatine is in Phase II. Other promising neuroprotective agents for PD include nicotine, caffeine, Ibuprofen, and DHA since they show strong neuroprotection. More moderate protective effects are observed with melatonin, vitamin D, and UA. In contrast, vitamin E, vitamin C, NSAIDs, aspirin, GSH, and CoQ10 alone show limited and/or inconsistent results for slowing disease progression. Of the remaining agents, IP6, riboflavin, beta-carotene, Liraglutide, Ex-4, Phenylbutyrate, and Isradipine show promising results in reducing the risk of PD, but further studies are needed to determine if they are neuroprotective in humans. Additionally, caffeine and UA may be promising, but only in male PD patients. These sex-specific effects are a reminder that it is important to assess each PD patient&#x02019;s response to neuroprotective agents clinically since other unidentified variables, such as single nucleotide polymorphisms (SNPs) and hormones, may also affect an individual&#x02019;s response. Further research addressing the mechanism of the sex differences and how SNPs play a role in the response to neuroprotective agents is needed to optimize a therapeutic approach for treating PD.</p><table-wrap id="T1" position="float"><label>Table 1</label><caption><p><bold>Neuroprotective agents in PD models</bold>.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="1" colspan="1">Neuroprotective agents</th><th colspan="2" align="center" rowspan="1">Cell culture and animal studies<hr/></th><th colspan="2" align="center" rowspan="1">Human and epidemiological studies<hr/></th></tr><tr><th align="left" rowspan="1" colspan="1"/><th align="left" rowspan="1" colspan="1">Study</th><th align="left" rowspan="1" colspan="1">Results</th><th align="left" rowspan="1" colspan="1">Study</th><th align="left" rowspan="1" colspan="1">Results</th></tr></thead><tbody><tr><td align="left" rowspan="5" valign="top" colspan="1">Caffeine</td><td align="left" valign="top" rowspan="1" colspan="1">A (van den Pol, <xref ref-type="bibr" rid="B269">1986</xref>; Kachroo et al., <xref ref-type="bibr" rid="B136">2010</xref>)</td><td align="left" valign="top" rowspan="1" colspan="1">Decreased dopaminergic neuron toxicity in MPTP</td><td align="left" valign="top" rowspan="1" colspan="1">E (Ross et al., <xref ref-type="bibr" rid="B221">2000</xref>; Ascherio et al., <xref ref-type="bibr" rid="B18">2001</xref>)*, (Saaksjarvi et al., <xref ref-type="bibr" rid="B224">2008</xref>; Costa et al., <xref ref-type="bibr" rid="B61">2010</xref>)*</td><td align="left" valign="top" rowspan="1" colspan="1">Caffeinated beverages decreased the risk of PD</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">A (Chen et al., <xref ref-type="bibr" rid="B50">2001</xref>; Joghataie et al., <xref ref-type="bibr" rid="B133">2004</xref>; Aguiar et al., <xref ref-type="bibr" rid="B4">2006</xref>)</td><td align="left" valign="top" rowspan="1" colspan="1">Decreased DA loss and restored DA levels in MPTP and 6-OHDA</td><td align="left" valign="top" rowspan="1" colspan="1">E (Xu et al., <xref ref-type="bibr" rid="B279">2006</xref>)</td><td align="left" valign="top" rowspan="1" colspan="1">Caffeinated beverages have no effect on PD risk</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">A (Joghataie et al., <xref ref-type="bibr" rid="B133">2004</xref>; Aguiar et al., <xref ref-type="bibr" rid="B4">2006</xref>)</td><td align="left" valign="top" rowspan="1" colspan="1">Decreased motor dysfunctions in 6-OHDA</td><td align="left" valign="top" rowspan="1" colspan="1">H (Ascherio et al., <xref ref-type="bibr" rid="B16">2003</xref>)</td><td align="left" valign="top" rowspan="1" colspan="1">A decrease in PD risk among women consuming caffeine and not taking hormone-replacement therapy</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">A (Xu et al., <xref ref-type="bibr" rid="B280">2002</xref>, <xref ref-type="bibr" rid="B281">2010</xref>)</td><td align="left" valign="top" rowspan="1" colspan="1">Caffeine increased metabolites associated with prevention of DA loss</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">A (Xu et al., <xref ref-type="bibr" rid="B279">2006</xref>)</td><td align="left" valign="top" rowspan="1" colspan="1">Estrogen and caffeine prevented neuroprotection</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Caffeine&#x02009;+&#x02009;nicotine</td><td align="left" valign="top" rowspan="1" colspan="1">A (Trinh et al., <xref ref-type="bibr" rid="B268">2010</xref>)</td><td align="left" valign="top" rowspan="1" colspan="1">Decaffeinated coffee and nicotine-free tobacco were neuroprotective in <italic>Drosophila</italic></td><td align="left" valign="top" rowspan="1" colspan="1">E (Tan et al., <xref ref-type="bibr" rid="B258">2003</xref>)</td><td align="left" valign="top" rowspan="1" colspan="1">Caffeine and nicotine combined reduced the rate of PD</td></tr><tr><td align="left" valign="top" rowspan="4" colspan="1">Nicotine</td><td align="left" valign="top" rowspan="1" colspan="1">A (Ferger et al., <xref ref-type="bibr" rid="B86">1998</xref>; Costa et al., <xref ref-type="bibr" rid="B60">2001</xref>)</td><td align="left" valign="top" rowspan="1" colspan="1">Nicotine reduced DA depletion resulting from MPTP and 6-OHDA</td><td align="left" valign="top" rowspan="1" colspan="1">E (Quick, <xref ref-type="bibr" rid="B208">2004</xref>; Simon et al., <xref ref-type="bibr" rid="B249">2009</xref>)</td><td align="left" valign="top" rowspan="1" colspan="1">Nicotine lowered the risk of developing PD</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">A (Meshul et al., <xref ref-type="bibr" rid="B176">2002</xref>)</td><td align="left" valign="top" rowspan="1" colspan="1">Nicotine minimized parkinsonian contralateral rotations in 6-OHDA</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">A (Quik et al., <xref ref-type="bibr" rid="B210">2006</xref>)</td><td align="left" valign="top" rowspan="1" colspan="1">Non-human primates maintained dopaminergic function and cell loss in the SNpc was prevented with nicotine administration</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">A (Carr and Rowell, <xref ref-type="bibr" rid="B41">1990</xref>)*</td><td align="left" valign="top" rowspan="1" colspan="1">Tobacco smoke prior to MPTP treatment reduced the loss of striatal DA in mice</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Urate and UA</td><td align="left" valign="top" rowspan="1" colspan="1">A/C (Jones et al., <xref ref-type="bibr" rid="B134">2000</xref>; Duan et al., <xref ref-type="bibr" rid="B74">2002</xref>)</td><td align="left" valign="top" rowspan="1" colspan="1">UA protects against DA-induced apoptosis</td><td align="left" valign="top" rowspan="1" colspan="1">E (de Lau et al., <xref ref-type="bibr" rid="B64">2005</xref>; Alonso et al., <xref ref-type="bibr" rid="B9">2007</xref>; Annanmaki et al., <xref ref-type="bibr" rid="B13">2007</xref>; Chen et al., <xref ref-type="bibr" rid="B48">2009</xref>)*, (Schwarzschild et al., <xref ref-type="bibr" rid="B239">2008</xref>)*, (Andreadou et al., <xref ref-type="bibr" rid="B12">2009</xref>)*</td><td align="left" valign="top" rowspan="1" colspan="1">Decreased risk of PD with UA and urate</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1">H (Ascherio et al., <xref ref-type="bibr" rid="B17">2009</xref>)</td><td align="left" valign="top" rowspan="1" colspan="1">Slower rates of clinical progression of PD were seen with UA intake</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1">H (de Lau et al., <xref ref-type="bibr" rid="B64">2005</xref>; Schwarzschild et al., <xref ref-type="bibr" rid="B239">2008</xref>)</td><td align="left" valign="top" rowspan="1" colspan="1">Serum UA correlates with a decreased risk of PD</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Vitamin E</td><td align="left" valign="top" rowspan="1" colspan="1">A (Odunze et al., <xref ref-type="bibr" rid="B188">1990</xref>)</td><td align="left" valign="top" rowspan="1" colspan="1">Vitamin E deficiency increases MPTP toxicity</td><td align="left" valign="top" rowspan="1" colspan="1">E (Zhang et al., <xref ref-type="bibr" rid="B296">2002</xref>; Etminan et al., <xref ref-type="bibr" rid="B78">2005</xref>)*</td><td align="left" valign="top" rowspan="1" colspan="1">Protection from PD with moderate vitamin E intake</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1">A (Lan and Jiang, <xref ref-type="bibr" rid="B150">1997</xref>; Roghani and Behzadi, <xref ref-type="bibr" rid="B220">2001</xref>)</td><td align="left" valign="top" rowspan="1" colspan="1">Vitamin E supplementation protected DA neurons in the SNpc and reduced DA loss</td><td align="left" valign="top" rowspan="1" colspan="1">H (Fernandez-Calle et al., <xref ref-type="bibr" rid="B88">1992</xref>; LeWitt, <xref ref-type="bibr" rid="B155">1994</xref>; Morens et al., <xref ref-type="bibr" rid="B180">1996</xref>)</td><td align="left" valign="top" rowspan="1" colspan="1">Clinical trials also show no neuroprotective benefit of taking vitamin E</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1">A (Gong et al., <xref ref-type="bibr" rid="B101">1991</xref>; Chi et al., <xref ref-type="bibr" rid="B51">1992</xref>)</td><td align="left" valign="top" rowspan="1" colspan="1">Striatal DA was not attenuated by pretreatment of vitamin E</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1">C (Offen et al., <xref ref-type="bibr" rid="B189">1996</xref>)</td><td align="left" valign="top" rowspan="1" colspan="1">Vitamin E has no protective effects against DA-induced toxicity in PC12 cells</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1">A (Perry et al., <xref ref-type="bibr" rid="B201">1987</xref>)</td><td align="left" valign="top" rowspan="1" colspan="1">Vitamin E partially protected DA neurons in MPTP rodents</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Vitamin E&#x02009;+&#x02009;vitamin C</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1">H (Fahn, <xref ref-type="bibr" rid="B83">1992</xref>)</td><td align="left" valign="top" rowspan="1" colspan="1">Both vitamins combined decreased PD progression in early stage patients</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Vitamin C</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1">H (Scheider et al., <xref ref-type="bibr" rid="B235">1997</xref>; Zhang et al., <xref ref-type="bibr" rid="B296">2002</xref>; Etminan et al., <xref ref-type="bibr" rid="B78">2005</xref>)</td><td align="left" valign="top" rowspan="1" colspan="1">Few beneficial effects are seen with vitamin C and even an increased risk of PD</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1">H (Perlmutter, <xref ref-type="bibr" rid="B195">1988</xref>)</td><td align="left" valign="top" rowspan="1" colspan="1">Vitamin C intake reduced the risk of PD by 40%</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Vitamin D</td><td align="left" valign="top" rowspan="1" colspan="1">C (Butler et al., <xref ref-type="bibr" rid="B37">2011</xref>)</td><td align="left" valign="top" rowspan="1" colspan="1">Disruption of Vitamin D&#x02019;s Ca<sup>2+</sup> homeostasis properties accelerated SNpc dopaminergic neuron loss</td><td align="left" valign="top" rowspan="1" colspan="1">E (Anderson et al., <xref ref-type="bibr" rid="B11">1999</xref>)</td><td align="left" valign="top" rowspan="1" colspan="1">An increased risk of PD is associated with high consumption of vitamin D</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1">H/A (Gash et al., <xref ref-type="bibr" rid="B98">1996</xref>; Kordower et al., <xref ref-type="bibr" rid="B145">2000</xref>), (Gill et al., <xref ref-type="bibr" rid="B99">2003</xref>)</td><td align="left" valign="top" rowspan="1" colspan="1">GDNF stimulation by Vitamin D can alleviated PD symptoms in primates and PD patients</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1">C/A (Wang et al., <xref ref-type="bibr" rid="B271">2001</xref>; Smith et al., <xref ref-type="bibr" rid="B253">2006</xref>)</td><td align="left" valign="top" rowspan="1" colspan="1">Vitamin D produced beneficial effects against PD characteristics</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1">A (Holick, <xref ref-type="bibr" rid="B116">2007</xref>)</td><td align="left" valign="top" rowspan="1" colspan="1">Vitamin D increased neuromuscular function in parkinsonian rodents</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Beta-carotene</td><td align="left" valign="top" rowspan="1" colspan="1">(Perry et al., <xref ref-type="bibr" rid="B200">1985</xref>, <xref ref-type="bibr" rid="B201">1987</xref>; Yong et al., <xref ref-type="bibr" rid="B289">1986</xref>)</td><td align="left" valign="top" rowspan="1" colspan="1">Beta-carotene protected against MPTP neurotoxicity in mice, but not primates</td><td align="left" valign="top" rowspan="1" colspan="1">E (Perlmutter, <xref ref-type="bibr" rid="B195">1988</xref>)</td><td align="left" valign="top" rowspan="1" colspan="1">A decrease in the risk of PD was seen with high B-carotene intake</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Riboflavin</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1">E (Perlmutter, <xref ref-type="bibr" rid="B195">1988</xref>; Murakami et al., <xref ref-type="bibr" rid="B182">2010</xref>)</td><td align="left" valign="top" rowspan="1" colspan="1">Reduced risk of PD, with high riboflavin intake by 51%</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1">E (Coimbra and Junqueira, <xref ref-type="bibr" rid="B59">2003</xref>)</td><td align="left" valign="top" rowspan="1" colspan="1">Riboflavin supplementation improved motor capacity of PD patients</td></tr><tr><td align="left" valign="top" rowspan="2" colspan="1">CoQ10</td><td align="left" valign="top" rowspan="1" colspan="1">A (Shults et al., <xref ref-type="bibr" rid="B245">1999</xref>)</td><td align="left" valign="top" rowspan="1" colspan="1">CoQ10 protected nigrostriatal dopaminergic neurons in MPTP</td><td align="left" valign="top" rowspan="1" colspan="1">H (Shults et al., <xref ref-type="bibr" rid="B247">2002</xref>; Shults, <xref ref-type="bibr" rid="B243">2003</xref>; Galpern and Cudkowicz, <xref ref-type="bibr" rid="B92">2007</xref>)</td><td align="left" valign="top" rowspan="1" colspan="1">Chronic administration of CoQ10 delayed progression of PD in patients with no adverse affects in Phase II</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">A (Cleren et al., <xref ref-type="bibr" rid="B58">2008</xref>)</td><td align="left" valign="top" rowspan="1" colspan="1">CoQ10 supplementation diminished neural tissue damage and prevented DA depletion in SNpc</td><td align="left" valign="top" rowspan="1" colspan="1">Investigators (<xref ref-type="bibr" rid="B127">2007</xref>)</td><td align="left" valign="top" rowspan="1" colspan="1">Inconclusive results of CoQ10 supplement showing neuroprotection in PD patients</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">CoQ10&#x02009;+&#x02009;vitamin E</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1">H (Shults et al., <xref ref-type="bibr" rid="B244">2004</xref>)</td><td align="left" valign="top" rowspan="1" colspan="1">Combination showed beneficial for PD patients, however, Phase III trials deemed it futile (NINDS, see text footnote 1)</td></tr><tr><td align="left" valign="top" rowspan="2" colspan="1">Creatine</td><td align="left" valign="top" rowspan="1" colspan="1">A (Matthews et al., <xref ref-type="bibr" rid="B169">1999</xref>)</td><td align="left" valign="top" rowspan="1" colspan="1">Creatine protected against MPTP-induced DA depletion in the SNpc</td><td align="left" valign="top" rowspan="1" colspan="1">Investigators (<xref ref-type="bibr" rid="B126">2006</xref>)</td><td align="left" valign="top" rowspan="1" colspan="1">Creatine delayed the progression of PD by 50%</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Investigators (<xref ref-type="bibr" rid="B128">2008</xref>)</td><td align="left" valign="top" rowspan="1" colspan="1">Creatine showed efficacy as a neuroprotective agent in PD and is currently in Phase III trials (NET-PDLS, see text footnote 2)</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">CoQ10&#x02009;+&#x02009;creatine</td><td align="left" valign="top" rowspan="1" colspan="1">A/H (Yang et al., <xref ref-type="bibr" rid="B284">2009</xref>)</td><td align="left" valign="top" rowspan="1" colspan="1">Combination showed a neuroprotective effect in chronic MPTP and humans</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="5" colspan="1">DHA</td><td align="left" valign="top" rowspan="1" colspan="1">A (Bousquet et al., <xref ref-type="bibr" rid="B32">2008</xref>)</td><td align="left" valign="top" rowspan="1" colspan="1">DHA supplements replaced omega-6 fatty acids after MPTP</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">C (Wang et al., <xref ref-type="bibr" rid="B272">2003</xref>)</td><td align="left" valign="top" rowspan="1" colspan="1">Neurons were protected against cytotoxicity with DHA intake</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">A (Ozsoy et al., <xref ref-type="bibr" rid="B191">2011</xref>)</td><td align="left" valign="top" rowspan="1" colspan="1">DHA decreased apoptosis of dopaminergic cells in MPTP</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">A (Samadi et al., <xref ref-type="bibr" rid="B230">2006</xref>)</td><td align="left" valign="top" rowspan="1" colspan="1">DHA reduced 40% of the levodopa-induced dyskinesias in Parkinsonian primates</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">A (Bousquet et al., <xref ref-type="bibr" rid="B32">2008</xref>)</td><td align="left" valign="top" rowspan="1" colspan="1">DHA preserved DA levels from MPTP-induced neurotoxicity in mice</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="2" colspan="1">DHA&#x02009;+&#x02009;uridine</td><td align="left" valign="top" rowspan="1" colspan="1">A (Wurtman et al., <xref ref-type="bibr" rid="B277">2006</xref>; Sakamoto et al., <xref ref-type="bibr" rid="B228">2007</xref>)</td><td align="left" valign="top" rowspan="1" colspan="1">This combination increased levels of neural phosphatides, proteins in synaptic membranes, and dendritic spines in rodents</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">A (Cansev et al., <xref ref-type="bibr" rid="B40">2008</xref>)</td><td align="left" valign="top" rowspan="1" colspan="1">DHA and uridine administration also reduced parkinsonian related behaviors and elevated DA levels in 6-OHDA rats</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="3" colspan="1">Melatonin</td><td align="left" valign="top" rowspan="1" colspan="1">A (Acuna-Castroviejo et al., <xref ref-type="bibr" rid="B2">1997</xref>; Kim et al., <xref ref-type="bibr" rid="B143">1998</xref>; Maharaj et al., <xref ref-type="bibr" rid="B162">2006a</xref>)</td><td align="left" valign="top" rowspan="1" colspan="1">Neuronal cell death damage induced by MPTP, 6-OHDA, and iron was protected with Melatonin administration</td><td align="left" valign="top" rowspan="1" colspan="1">H (Dowling et al., <xref ref-type="bibr" rid="B71">2005</xref>)</td><td align="left" valign="top" rowspan="1" colspan="1">Melatonin improved duration of sleep and reduced sleep disturbances in PD patients</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">A (Mayo et al., <xref ref-type="bibr" rid="B172">1998</xref>, <xref ref-type="bibr" rid="B170">1999</xref>)</td><td align="left" valign="top" rowspan="1" colspan="1">Melatonin blocked apoptosis and necrosis in 6-OHDA and PC12 cells</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">A (Tapias et al., <xref ref-type="bibr" rid="B259">2010</xref>)</td><td align="left" valign="top" rowspan="1" colspan="1">Striatal DA depletion and DA neuron loss increased after melatonin treatment of rotenone-induced Parkinsonism</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="4" colspan="1">GSH</td><td align="left" valign="top" rowspan="1" colspan="1">A (Garrido et al., <xref ref-type="bibr" rid="B97">2011</xref>)</td><td align="left" valign="top" rowspan="1" colspan="1">Excessive or reduced GSH levels initiated degeneration of DA neurons</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1">C (Schulz et al., <xref ref-type="bibr" rid="B238">2000</xref>)</td><td align="left" valign="top" rowspan="1" colspan="1">Decreased GSH increased neuron susceptibility to neurotoxins, but did not correlate to DA viability or striatal terminals</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1">A (Klivenyi et al., <xref ref-type="bibr" rid="B144">2000</xref>)</td><td align="left" valign="top" rowspan="1" colspan="1">Depletion of DA was seen after MPTP treatment in GSH peroxidase-deficient mice</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1">A (Pileblad et al., <xref ref-type="bibr" rid="B202">1989</xref>; Seaton et al., <xref ref-type="bibr" rid="B240">1996</xref>; Wullner et al., <xref ref-type="bibr" rid="B276">1996</xref>)</td><td align="left" valign="top" rowspan="1" colspan="1">Low levels of GSH reduced DA neurons after toxin administration</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">IP6</td><td align="left" valign="top" rowspan="1" colspan="1">A/C (Xu et al., <xref ref-type="bibr" rid="B282">2008</xref>, <xref ref-type="bibr" rid="B283">2011</xref>)</td><td align="left" valign="top" rowspan="1" colspan="1">IP6 inhibited MPTP, 6-OHDA, and iron toxicity in cell culture</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1">A (Xu et al., <xref ref-type="bibr" rid="B282">2008</xref>)</td><td align="left" valign="top" rowspan="1" colspan="1">IP6 increased cell survival in MPTP</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1">A (Obata, <xref ref-type="bibr" rid="B187">2003</xref>)</td><td align="left" valign="top" rowspan="1" colspan="1">IP6 suppressed hydroxyl radical formation after MPP+ treatment in rats</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">NSAID (ibuprofen&#x02009;+&#x02009;aspirin)</td><td align="left" valign="top" rowspan="1" colspan="1">A/C (Bilodeau et al., <xref ref-type="bibr" rid="B28">1995</xref>; Kaufmann et al., <xref ref-type="bibr" rid="B139">1997</xref>; Aubin et al., <xref ref-type="bibr" rid="B19">1998</xref>; Saini et al., <xref ref-type="bibr" rid="B226">1998</xref>; Casper et al., <xref ref-type="bibr" rid="B43">2000</xref>; Sairam et al., <xref ref-type="bibr" rid="B227">2003</xref>)</td><td align="left" valign="top" rowspan="1" colspan="1">NSAID&#x02019;s protected against neuronal death and dopaminergic neurotoxicity</td><td align="left" valign="top" rowspan="1" colspan="1">E (Chen et al., <xref ref-type="bibr" rid="B49">2003</xref>; Ton et al., <xref ref-type="bibr" rid="B265">2006</xref>; Wahner et al., <xref ref-type="bibr" rid="B270">2007</xref>; Gao et al., <xref ref-type="bibr" rid="B94">2011</xref>)</td><td align="left" valign="top" rowspan="1" colspan="1">NSAID&#x02019;s lowered the risk of PD</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1">E (Chen et al., <xref ref-type="bibr" rid="B47">2005</xref>; Ton et al., <xref ref-type="bibr" rid="B265">2006</xref>; Driver et al., <xref ref-type="bibr" rid="B72">2011</xref>; Gao et al., <xref ref-type="bibr" rid="B94">2011</xref>)</td><td align="left" valign="top" rowspan="1" colspan="1">A reduction in PD risk was observed with Ibuprofen, but not NSAIDS or Acetaminophen</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1">A/C (Esposito et al., <xref ref-type="bibr" rid="B77">2007</xref>)</td><td align="left" valign="top" rowspan="1" colspan="1">NSAIDS showed neuroprotection in MPTP, 6-OHDA, and <italic>in vitro</italic></td><td align="left" valign="top" rowspan="1" colspan="1">E (Becker et al., <xref ref-type="bibr" rid="B25">2011</xref>)</td><td align="left" valign="top" rowspan="1" colspan="1">NSAID&#x02019;s and aspirin showed no association with altering the risk of PD</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1">A (Casper et al., <xref ref-type="bibr" rid="B43">2000</xref>; Morioka et al., <xref ref-type="bibr" rid="B181">2004</xref>, Carrasco et al., <xref ref-type="bibr" rid="B42">2005</xref>)</td><td align="left" valign="top" rowspan="1" colspan="1">Ibuprofen protected DA neurons against glutamate toxicity and decreased MPTP toxicity</td><td align="left" valign="top" rowspan="1" colspan="1">E (Bower et al., <xref ref-type="bibr" rid="B35">2006</xref>; Hernan et al., <xref ref-type="bibr" rid="B113">2006</xref>)<break/>E (Samii et al., <xref ref-type="bibr" rid="B231">2009</xref>; Gao et al., <xref ref-type="bibr" rid="B94">2011</xref>)</td><td align="left" valign="top" rowspan="1" colspan="1">Increased risk of PD shown with moderate aspirin intake<break/>Ibuprofen reduced the risk of developing PD in humans by 40%</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Isradipine</td><td align="left" valign="top" rowspan="1" colspan="1">A (Ilijic et al., <xref ref-type="bibr" rid="B124">2011</xref>)</td><td align="left" valign="top" rowspan="1" colspan="1">Isradipine showed neuroprotection against 6-OHDA</td><td align="left" valign="top" rowspan="1" colspan="1">H (Simuni et al., <xref ref-type="bibr" rid="B250">2010</xref>)</td><td align="left" valign="top" rowspan="1" colspan="1">Isradipine was deemed futile for human trials</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Phenylbutyrate</td><td align="left" valign="top" rowspan="1" colspan="1">C (Gardian et al., <xref ref-type="bibr" rid="B96">2004</xref>; Zhou et al., <xref ref-type="bibr" rid="B298">2011</xref>)</td><td align="left" valign="top" rowspan="1" colspan="1">Phenylbutyrate protected DA neurons in the SNpc</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1">A (Zhou et al., <xref ref-type="bibr" rid="B298">2011</xref>)</td><td align="left" valign="top" rowspan="1" colspan="1">Reduced deterioration in motor and cognitive function in mice</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Ex-4</td><td align="left" valign="top" rowspan="1" colspan="1">A (Li et al., <xref ref-type="bibr" rid="B157">2009</xref>)</td><td align="left" valign="top" rowspan="1" colspan="1">Protected DA neuron degeneration, preserved DA levels, and improved motor function in rodents</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1">A/C (Harkavyi et al., <xref ref-type="bibr" rid="B106">2008</xref>; Li et al., <xref ref-type="bibr" rid="B157">2009</xref>)</td><td align="left" valign="top" rowspan="1" colspan="1">Ex-4 protected ventral mesencephalic dopaminergic cells in culture, reverse nigral lesions, and protected against 6-OHDA toxicity</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Rasagiline</td><td align="left" valign="top" rowspan="1" colspan="1">C:, (Heikkila et al., <xref ref-type="bibr" rid="B112">1985</xref>; Huang et al., <xref ref-type="bibr" rid="B120">1999</xref>; Speiser et al., <xref ref-type="bibr" rid="B255">1999</xref>; Maruyama et al., <xref ref-type="bibr" rid="B166">2000</xref>; Sagi et al., <xref ref-type="bibr" rid="B225">2001</xref>; Youdim et al., <xref ref-type="bibr" rid="B291">2001a</xref>)</td><td align="left" valign="top" rowspan="1" colspan="1">Reduces MPTP and 6-OHDA toxicity in PC12 and SH-SY5Y cells</td><td align="left" valign="top" rowspan="1" colspan="1">H (Hauser et al., <xref ref-type="bibr" rid="B110">2009</xref>; Olanow et al., <xref ref-type="bibr" rid="B190">2009</xref>)</td><td align="left" valign="top" rowspan="1" colspan="1">Rasagiline reduced the long-term progression and symptoms in PD</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1">A (Kupsch et al., <xref ref-type="bibr" rid="B148">2001</xref>; Sagi et al., <xref ref-type="bibr" rid="B225">2001</xref>).</td><td align="left" valign="top" rowspan="1" colspan="1">Rasagiline prevented nigrostriatal damage induced by MPTP in primates</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1">A (Blandini et al., <xref ref-type="bibr" rid="B29">2004</xref>)</td><td align="left" valign="top" rowspan="1" colspan="1">Rasagiline increased DA neuron survival in lesioned SNpc and improved motor impairments</td><td align="left" valign="top" rowspan="1" colspan="1">H (Rascol et al., <xref ref-type="bibr" rid="B213">2011</xref>)</td><td align="left" valign="top" rowspan="1" colspan="1">Rasagiline in a Phase III delayed the need for antiparkinsonian drugs and patients had lower scores on the Parkinson&#x02019;s disease rating scale</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1">C (Murer et al., <xref ref-type="bibr" rid="B183">2001</xref>)</td><td align="left" valign="top" rowspan="1" colspan="1">Rasagiline increased expression of neurotrophins</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Minocycline</td><td align="left" valign="top" rowspan="1" colspan="1">A/C (Du et al., <xref ref-type="bibr" rid="B73">2001</xref>).</td><td align="left" valign="top" rowspan="1" colspan="1">Minocycline blocked MPTP-induced degeneration of DA neurons in the SNpc&#x0223c; preventing loss of striatal DA and its metabolites. Minocycline treatment also inhibited MPP+ mediated inducible NO synthase expression <italic>in vivo</italic> and blocked NO-induced neurotoxicity <italic>in vitro</italic></td><td align="left" valign="top" rowspan="1" colspan="1">H (Investigators, <xref ref-type="bibr" rid="B126">2006</xref>)</td><td align="left" valign="top" rowspan="1" colspan="1">Minocycline was deemed effective in Phase II slowing the progression of PD in patients. An 18-month follow up study showed no safety concerns with its use (Investigators, <xref ref-type="bibr" rid="B128">2008</xref>), leading to Phase III trials</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1">A (Faust et al., <xref ref-type="bibr" rid="B85">2009</xref>; Radad et al., <xref ref-type="bibr" rid="B212">2010</xref>)</td><td align="left" valign="top" rowspan="1" colspan="1">DA neuroprotection by Minocycline was seen in a <italic>Drosophila</italic> model of PD and after rotenone toxicity in rodents</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1">A (Quintero et al., <xref ref-type="bibr" rid="B211">2006</xref>).</td><td align="left" valign="top" rowspan="1" colspan="1">Reduced the number of apomorphine-induced rotations in 6-OHDA-lesioned rats</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">A/C (Yang et al., <xref ref-type="bibr" rid="B285">2003</xref>)</td><td align="left" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1">Minocycline exacerbated MPTP damage to DA neurons <italic>in vitro</italic> and <italic>in vivo</italic></td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1">A (Diguet et al., <xref ref-type="bibr" rid="B70">2004</xref>)</td><td align="left" valign="top" rowspan="1" colspan="1">Minocycline treatment in primates and mice produced more severe/rapid parkinsonism, behavior deficits, and greater loss of nerve endings</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Minocycline&#x02009;+&#x02009;creatine</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1">H (NET-PD, <xref ref-type="bibr" rid="B186">2006</xref>)</td><td align="left" valign="top" rowspan="1" colspan="1">Reduced progression in PD patients in Phase II</td></tr></tbody></table><table-wrap-foot><p><italic>C, cell culture; A, animal; H, human; and E, epidemiological. Studies showing gender specificity, where males show favorable results are denoted (*)</italic>.</p></table-wrap-foot></table-wrap></sec><sec><title>Conflict of Interest Statement</title><p>The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.</p></sec></body><back><ack><p>The authors thank Jose Santiago and Mich Beales for critical review of the manuscript. This work was supported by the US Army Medical Research and Materiel Command under award number W81XWH-09-0708. Opinions, conclusions, interpretations and recommendations are those of the author and are not necessarily endorsed by the U.S. Army.</p></ack><fn-group><fn id="fn1"><p><sup>1</sup><uri xlink:type="simple" xlink:href="http://www.ninds.nih.gov/disorders/clinical_trials/CoQ10-Trial-Update.htm">http://www.ninds.nih.gov/disorders/clinical_trials/CoQ10-Trial-Update.htm</uri></p></fn><fn id="fn2"><p><sup>2</sup><uri xlink:type="simple" xlink:href="http://clinicaltrials.gov/ct2/show/NCT00449865">http://clinicaltrials.gov/ct2/show/NCT00449865</uri></p></fn></fn-group><ref-list><title>References</title><ref id="B1"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Abdin</surname><given-names>A. A.</given-names></name><name><surname>Hamouda</surname><given-names>H. E.</given-names></name></person-group> (<year>2008</year>). <article-title>Mechanism of the neuroprotective role of coenzyme Q10 with or without L-dopa in rotenone-induced parkinsonism</article-title>. <source>Neuropharmacology</source> <volume>55</volume>, <fpage>1340</fpage>&#x02013;<lpage>1346</lpage><pub-id pub-id-type="doi">10.1016/j.neuropharm.2008.08.033</pub-id><pub-id pub-id-type="pmid">18817789</pub-id></mixed-citation></ref><ref id="B2"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Acuna-Castroviejo</surname><given-names>D.</given-names></name><name><surname>Coto-Montes</surname><given-names>A.</given-names></name><name><surname>Gaia Monti</surname><given-names>M.</given-names></name><name><surname>Ortiz</surname><given-names>G. G.</given-names></name><name><surname>Reiter</surname><given-names>R. J.</given-names></name></person-group> (<year>1997</year>). <article-title>Melatonin is protective against MPTP-induced striatal and hippocampal lesions</article-title>. <source>Life Sci.</source> <volume>60</volume>, <fpage>PL23</fpage>&#x02013;<lpage>PL29</lpage><pub-id pub-id-type="doi">10.1016/S0024-3205(96)00606-6</pub-id><pub-id pub-id-type="pmid">9000122</pub-id></mixed-citation></ref><ref id="B3"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Adhihetty</surname><given-names>P. J.</given-names></name><name><surname>Beal</surname><given-names>M. F.</given-names></name></person-group> (<year>2008</year>). <article-title>Creatine and its potential therapeutic value for targeting cellular energy impairment in neurodegenerative diseases</article-title>. <source>Neuromolecular Med.</source> <volume>10</volume>, <fpage>275</fpage>&#x02013;<lpage>290</lpage><pub-id pub-id-type="doi">10.1007/s12017-008-8053-y</pub-id><pub-id pub-id-type="pmid">19005780</pub-id></mixed-citation></ref><ref id="B4"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Aguiar</surname><given-names>L. M.</given-names></name><name><surname>Nobre</surname><given-names>H. V.</given-names><suffix>Jr.</suffix></name><name><surname>Macedo</surname><given-names>D. S.</given-names></name><name><surname>Oliveira</surname><given-names>A. A.</given-names></name><name><surname>Freitas</surname><given-names>R. M.</given-names></name><name><surname>Vasconcelos</surname><given-names>S. M.</given-names></name><name><surname>Cunha</surname><given-names>G. M.</given-names></name><name><surname>Sousa</surname><given-names>F. C.</given-names></name><name><surname>Viana</surname><given-names>G. S.</given-names></name></person-group> (<year>2006</year>). <article-title>Neuroprotective effects of caffeine in the model of 6-hydroxydopamine lesion in rats</article-title>. <source>Pharmacol. Biochem. Behav.</source> <volume>84</volume>, <fpage>415</fpage>&#x02013;<lpage>419</lpage><pub-id pub-id-type="doi">10.1016/j.pbb.2006.05.027</pub-id><pub-id pub-id-type="pmid">16844208</pub-id></mixed-citation></ref><ref id="B5"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Akao</surname><given-names>Y.</given-names></name><name><surname>Maruyama</surname><given-names>W.</given-names></name><name><surname>Shimizu</surname><given-names>S.</given-names></name><name><surname>Yi</surname><given-names>H.</given-names></name><name><surname>Nakagawa</surname><given-names>Y.</given-names></name><name><surname>Shamoto-Nagai</surname><given-names>M.</given-names></name><name><surname>Youdim</surname><given-names>M. B.</given-names></name><name><surname>Tsujimoto</surname><given-names>Y.</given-names></name><name><surname>Naoi</surname><given-names>M.</given-names></name></person-group> (<year>2002a</year>). <article-title>Mitochondrial permeability transition mediates apoptosis induced by N-methyl(R)salsolinol, an endogenous neurotoxin, and is inhibited by Bcl-2 and rasagiline, N-propargyl-1(R)-aminoindan</article-title>. <source>J. Neurochem.</source> <volume>82</volume>, <fpage>913</fpage>&#x02013;<lpage>923</lpage><pub-id pub-id-type="doi">10.1046/j.1471-4159.2002.01047.x</pub-id><pub-id pub-id-type="pmid">12358797</pub-id></mixed-citation></ref><ref id="B6"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Akao</surname><given-names>Y.</given-names></name><name><surname>Maruyama</surname><given-names>W.</given-names></name><name><surname>Yi</surname><given-names>H.</given-names></name><name><surname>Shamoto-Nagai</surname><given-names>M.</given-names></name><name><surname>Youdim</surname><given-names>M. B.</given-names></name><name><surname>Naoi</surname><given-names>M.</given-names></name></person-group> (<year>2002b</year>). <article-title>An anti-Parkinson&#x02019;s disease drug, N-propargyl-1(R)-aminoindan (rasagiline), enhances expression of anti-apoptotic bcl-2 in human dopaminergic SH-SY5Y cells</article-title>. <source>Neurosci. Lett.</source> <volume>326</volume>, <fpage>105</fpage>&#x02013;<lpage>108</lpage><pub-id pub-id-type="doi">10.1016/S0304-3940(02)00332-4</pub-id><pub-id pub-id-type="pmid">12057839</pub-id></mixed-citation></ref><ref id="B7"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Akbar</surname><given-names>M.</given-names></name><name><surname>Calderon</surname><given-names>F.</given-names></name><name><surname>Wen</surname><given-names>Z.</given-names></name><name><surname>Kim</surname><given-names>H. Y.</given-names></name></person-group> (<year>2005</year>). <article-title>Docosahexaenoic acid: a positive modulator of Akt signaling in neuronal survival</article-title>. <source>Proc. Natl. Acad. Sci. U.S.A.</source> <volume>102</volume>, <fpage>10858</fpage>&#x02013;<lpage>10863</lpage><pub-id pub-id-type="doi">10.1073/pnas.0502903102</pub-id><pub-id pub-id-type="pmid">16040805</pub-id></mixed-citation></ref><ref id="B8"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Akbar</surname><given-names>M.</given-names></name><name><surname>Kim</surname><given-names>H. Y.</given-names></name></person-group> (<year>2002</year>). <article-title>Protective effects of docosahexaenoic acid in staurosporine-induced apoptosis: involvement of phosphatidylinositol-3 kinase pathway</article-title>. <source>J. Neurochem.</source> <volume>82</volume>, <fpage>655</fpage>&#x02013;<lpage>665</lpage><pub-id pub-id-type="doi">10.1046/j.1471-4159.2002.01015.x</pub-id><pub-id pub-id-type="pmid">12153489</pub-id></mixed-citation></ref><ref id="B9"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Alonso</surname><given-names>A.</given-names></name><name><surname>Rodriguez</surname><given-names>L. A.</given-names></name><name><surname>Logroscino</surname><given-names>G.</given-names></name><name><surname>Hernan</surname><given-names>M. A.</given-names></name></person-group> (<year>2007</year>). <article-title>Gout and risk of Parkinson disease: a prospective study</article-title>. <source>Neurology</source> <volume>69</volume>, <fpage>1696</fpage>&#x02013;<lpage>1700</lpage><pub-id pub-id-type="doi">10.1212/01.wnl.0000279518.10072.df</pub-id><pub-id pub-id-type="pmid">17954784</pub-id></mixed-citation></ref><ref id="B10"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ames</surname><given-names>B. N.</given-names></name><name><surname>Cathcart</surname><given-names>R.</given-names></name><name><surname>Schwiers</surname><given-names>E.</given-names></name><name><surname>Hochstein</surname><given-names>P.</given-names></name></person-group> (<year>1981</year>). <article-title>Uric acid provides an antioxidant defense in humans against oxidant- and radical-caused aging and cancer: a hypothesis</article-title>. <source>Proc. Natl. Acad. Sci. U.S.A.</source> <volume>78</volume>, <fpage>6858</fpage>&#x02013;<lpage>6862</lpage><pub-id pub-id-type="doi">10.1073/pnas.78.11.6858</pub-id><pub-id pub-id-type="pmid">6947260</pub-id></mixed-citation></ref><ref id="B11"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Anderson</surname><given-names>C.</given-names></name><name><surname>Checkoway</surname><given-names>H.</given-names></name><name><surname>Franklin</surname><given-names>G. M.</given-names></name><name><surname>Beresford</surname><given-names>S.</given-names></name><name><surname>Smith-Weller</surname><given-names>T.</given-names></name><name><surname>Swanson</surname><given-names>P. D.</given-names></name></person-group> (<year>1999</year>). <article-title>Dietary factors in Parkinson&#x02019;s disease: the role of food groups and specific foods</article-title>. <source>Mov. Disord.</source> <volume>14</volume>, <fpage>21</fpage>&#x02013;<lpage>27</lpage><pub-id pub-id-type="doi">10.1002/1531-8257(199901)14:1&#x0003c;21::AID-MDS1006&#x0003e;3.3.CO;2-P</pub-id><pub-id pub-id-type="pmid">9918340</pub-id></mixed-citation></ref><ref id="B12"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Andreadou</surname><given-names>E.</given-names></name><name><surname>Nikolaou</surname><given-names>C.</given-names></name><name><surname>Gournaras</surname><given-names>F.</given-names></name><name><surname>Rentzos</surname><given-names>M.</given-names></name><name><surname>Boufidou</surname><given-names>F.</given-names></name><name><surname>Tsoutsou</surname><given-names>A.</given-names></name><name><surname>Zournas</surname><given-names>C.</given-names></name><name><surname>Zissimopoulos</surname><given-names>V.</given-names></name><name><surname>Vassilopoulos</surname><given-names>D.</given-names></name></person-group> (<year>2009</year>). <article-title>Serum uric acid levels in patients with Parkinson&#x02019;s disease: their relationship to treatment and disease duration</article-title>. <source>Clin. Neurol. Neurosurg.</source> <volume>111</volume>, <fpage>724</fpage>&#x02013;<lpage>728</lpage><pub-id pub-id-type="doi">10.1016/j.clineuro.2009.06.012</pub-id><pub-id pub-id-type="pmid">19632030</pub-id></mixed-citation></ref><ref id="B13"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Annanmaki</surname><given-names>T.</given-names></name><name><surname>Muuronen</surname><given-names>A.</given-names></name><name><surname>Murros</surname><given-names>K.</given-names></name></person-group> (<year>2007</year>). <article-title>Low plasma uric acid level in Parkinson&#x02019;s disease</article-title>. <source>Mov. Disord.</source> <volume>22</volume>, <fpage>1133</fpage>&#x02013;<lpage>1137</lpage><pub-id pub-id-type="doi">10.1002/mds.21502</pub-id><pub-id pub-id-type="pmid">17443703</pub-id></mixed-citation></ref><ref id="B14"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Antolin</surname><given-names>I.</given-names></name><name><surname>Mayo</surname><given-names>J. C.</given-names></name><name><surname>Sainz</surname><given-names>R. M.</given-names></name><name><surname>del Brio Mde</surname><given-names>L.</given-names></name><name><surname>Herrera</surname><given-names>F.</given-names></name><name><surname>Martin</surname><given-names>V.</given-names></name><name><surname>Rodriguez</surname><given-names>C.</given-names></name></person-group> (<year>2002</year>). <article-title>Protective effect of melatonin in a chronic experimental model of Parkinson&#x02019;s disease</article-title>. <source>Brain Res.</source> <volume>943</volume>, <fpage>163</fpage>&#x02013;<lpage>173</lpage><pub-id pub-id-type="doi">10.1016/S0006-8993(02)02551-9</pub-id><pub-id pub-id-type="pmid">12101038</pub-id></mixed-citation></ref><ref id="B15"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Arvanitakis</surname><given-names>Z.</given-names></name><name><surname>Wilson</surname><given-names>R. S.</given-names></name><name><surname>Bienias</surname><given-names>J. L.</given-names></name><name><surname>Evans</surname><given-names>D. A.</given-names></name><name><surname>Bennett</surname><given-names>D. A.</given-names></name></person-group> (<year>2004</year>). <article-title>Diabetes mellitus and risk of Alzheimer disease and decline in cognitive function</article-title>. <source>Arch. Neurol.</source> <volume>61</volume>, <fpage>661</fpage>&#x02013;<lpage>666</lpage><pub-id pub-id-type="doi">10.1001/archneur.61.5.661</pub-id><pub-id pub-id-type="pmid">15148141</pub-id></mixed-citation></ref><ref id="B16"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ascherio</surname><given-names>A.</given-names></name><name><surname>Chen</surname><given-names>H.</given-names></name><name><surname>Schwarzschild</surname><given-names>M. A.</given-names></name><name><surname>Zhang</surname><given-names>S. M.</given-names></name><name><surname>Colditz</surname><given-names>G. A.</given-names></name><name><surname>Speizer</surname><given-names>F. E.</given-names></name></person-group> (<year>2003</year>). <article-title>Caffeine, postmenopausal estrogen, and risk of Parkinson&#x02019;s disease</article-title>. <source>Neurology</source> <volume>60</volume>, <fpage>790</fpage>&#x02013;<lpage>795</lpage><pub-id pub-id-type="pmid">12629235</pub-id></mixed-citation></ref><ref id="B17"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ascherio</surname><given-names>A.</given-names></name><name><surname>LeWitt</surname><given-names>P. A.</given-names></name><name><surname>Xu</surname><given-names>K.</given-names></name><name><surname>Eberly</surname><given-names>S.</given-names></name><name><surname>Watts</surname><given-names>A.</given-names></name><name><surname>Matson</surname><given-names>W. R.</given-names></name><name><surname>Marras</surname><given-names>C.</given-names></name><name><surname>Kieburtz</surname><given-names>K.</given-names></name><name><surname>Rudolph</surname><given-names>A.</given-names></name><name><surname>Bogdanov</surname><given-names>M. B.</given-names></name><name><surname>Schwid</surname><given-names>S. R.</given-names></name><name><surname>Tennis</surname><given-names>M.</given-names></name><name><surname>Tanner</surname><given-names>C. M.</given-names></name><name><surname>Beal</surname><given-names>M. F.</given-names></name><name><surname>Lang</surname><given-names>A. E.</given-names></name><name><surname>Oakes</surname><given-names>D.</given-names></name><name><surname>Fahn</surname><given-names>S.</given-names></name><name><surname>Shoulson</surname><given-names>I.</given-names></name><name><surname>Schwarzschild</surname><given-names>M. A.</given-names></name></person-group> (<year>2009</year>). <article-title>Urate as a predictor of the rate of clinical decline in Parkinson disease</article-title>. <source>Arch. Neurol.</source> <volume>66</volume>, <fpage>1460</fpage>&#x02013;<lpage>1468</lpage><pub-id pub-id-type="doi">10.1001/archneurol.2009.247</pub-id><pub-id pub-id-type="pmid">19822770</pub-id></mixed-citation></ref><ref id="B18"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ascherio</surname><given-names>A.</given-names></name><name><surname>Zhang</surname><given-names>S. M.</given-names></name><name><surname>Hernan</surname><given-names>M. A.</given-names></name><name><surname>Kawachi</surname><given-names>I.</given-names></name><name><surname>Colditz</surname><given-names>G. A.</given-names></name><name><surname>Speizer</surname><given-names>F. E.</given-names></name><name><surname>Willett</surname><given-names>W. C.</given-names></name></person-group> (<year>2001</year>). <article-title>Prospective study of caffeine consumption and risk of Parkinson&#x02019;s disease in men and women</article-title>. <source>Ann. Neurol.</source> <volume>50</volume>, <fpage>56</fpage>&#x02013;<lpage>63</lpage><pub-id pub-id-type="doi">10.1002/ana.1052</pub-id><pub-id pub-id-type="pmid">11456310</pub-id></mixed-citation></ref><ref id="B19"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Aubin</surname><given-names>N.</given-names></name><name><surname>Curet</surname><given-names>O.</given-names></name><name><surname>Deffois</surname><given-names>A.</given-names></name><name><surname>Carter</surname><given-names>C.</given-names></name></person-group> (<year>1998</year>). <article-title>Aspirin and salicylate protect against MPTP-induced dopamine depletion in mice</article-title>. <source>J. Neurochem.</source> <volume>71</volume>, <fpage>1635</fpage>&#x02013;<lpage>1642</lpage><pub-id pub-id-type="doi">10.1046/j.1471-4159.1998.71041635.x</pub-id><pub-id pub-id-type="pmid">9751197</pub-id></mixed-citation></ref><ref id="B20"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bar Am</surname><given-names>O.</given-names></name><name><surname>Amit</surname><given-names>T.</given-names></name><name><surname>Youdim</surname><given-names>M. B.</given-names></name></person-group> (<year>2004</year>). <article-title>Contrasting neuroprotective and neurotoxic actions of respective metabolites of anti-Parkinson drugs rasagiline and selegiline</article-title>. <source>Neurosci. Lett.</source> <volume>355</volume>, <fpage>169</fpage>&#x02013;<lpage>172</lpage><pub-id pub-id-type="doi">10.1016/j.neulet.2003.10.067</pub-id><pub-id pub-id-type="pmid">14732458</pub-id></mixed-citation></ref><ref id="B21"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bar-Am</surname><given-names>O.</given-names></name><name><surname>Yogev-Falach</surname><given-names>M.</given-names></name><name><surname>Amit</surname><given-names>T.</given-names></name><name><surname>Sagi</surname><given-names>Y.</given-names></name><name><surname>Youdim</surname><given-names>M. B.</given-names></name></person-group> (<year>2004</year>). <article-title>Regulation of protein kinase C by the anti-Parkinson drug, MAO-B inhibitor, rasagiline and its derivatives, in vivo</article-title>. <source>J. Neurochem.</source> <volume>89</volume>, <fpage>1119</fpage>&#x02013;<lpage>1125</lpage><pub-id pub-id-type="doi">10.1111/j.1471-4159.2004.02425.x</pub-id><pub-id pub-id-type="pmid">15147504</pub-id></mixed-citation></ref><ref id="B22"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Barhwal</surname><given-names>K.</given-names></name><name><surname>Hota</surname><given-names>S. K.</given-names></name><name><surname>Baitharu</surname><given-names>I.</given-names></name><name><surname>Prasad</surname><given-names>D.</given-names></name><name><surname>Singh</surname><given-names>S. B.</given-names></name><name><surname>Ilavazhagan</surname><given-names>G.</given-names></name></person-group> (<year>2009</year>). <article-title>Isradipine antagonizes hypobaric hypoxia induced CA1 damage and memory impairment: complementary roles of L-type calcium channel and NMDA receptors</article-title>. <source>Neurobiol. Dis.</source> <volume>34</volume>, <fpage>230</fpage>&#x02013;<lpage>244</lpage><pub-id pub-id-type="doi">10.1016/j.nbd.2009.01.008</pub-id><pub-id pub-id-type="pmid">19385055</pub-id></mixed-citation></ref><ref id="B23"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bazan</surname><given-names>N. G.</given-names></name></person-group> (<year>2005</year>). <article-title>Neuroprotectin D1 (NPD1): a DHA-derived mediator that protects brain and retina against cell injury-induced oxidative stress</article-title>. <source>Brain Pathol.</source> <volume>15</volume>, <fpage>159</fpage>&#x02013;<lpage>166</lpage><pub-id pub-id-type="doi">10.1111/j.1750-3639.2005.tb00513.x</pub-id><pub-id pub-id-type="pmid">15912889</pub-id></mixed-citation></ref><ref id="B24"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Beal</surname><given-names>M. F.</given-names></name><name><surname>Shults</surname><given-names>C. W.</given-names></name></person-group> (<year>2003</year>). <article-title>Effects of coenzyme Q10 in Huntington&#x02019;s disease and early Parkinson&#x02019;s disease</article-title>. <source>Biofactors</source> <volume>18</volume>, <fpage>153</fpage>&#x02013;<lpage>161</lpage><pub-id pub-id-type="doi">10.1002/biof.5520180218</pub-id><pub-id pub-id-type="pmid">14695931</pub-id></mixed-citation></ref><ref id="B25"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Becker</surname><given-names>C.</given-names></name><name><surname>Jick</surname><given-names>S. S.</given-names></name><name><surname>Meier</surname><given-names>C. R.</given-names></name></person-group> (<year>2011</year>). <article-title>NSAID use and risk of Parkinson disease: a population-based case-control study</article-title>. <source>Eur. J. Neurol.</source> <volume>18</volume>, <fpage>1336</fpage>&#x02013;<lpage>1342</lpage><pub-id pub-id-type="doi">10.1111/j.1468-1331.2010.03176.x</pub-id><pub-id pub-id-type="pmid">21457177</pub-id></mixed-citation></ref><ref id="B26"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bertilsson</surname><given-names>G.</given-names></name><name><surname>Patrone</surname><given-names>C.</given-names></name><name><surname>Zachrisson</surname><given-names>O.</given-names></name><name><surname>Andersson</surname><given-names>A.</given-names></name><name><surname>Dannaeus</surname><given-names>K.</given-names></name><name><surname>Heidrich</surname><given-names>J.</given-names></name><name><surname>Kortesmaa</surname><given-names>J.</given-names></name><name><surname>Mercer</surname><given-names>A.</given-names></name><name><surname>Nielsen</surname><given-names>E.</given-names></name><name><surname>Ronnholm</surname><given-names>H.</given-names></name><name><surname>Wikstrom</surname><given-names>L.</given-names></name></person-group> (<year>2008</year>). <article-title>Peptide hormone exendin-4 stimulates subventricular zone neurogenesis in the adult rodent brain and induces recovery in an animal model of Parkinson&#x02019;s disease</article-title>. <source>J. Neurosci. Res.</source> <volume>86</volume>, <fpage>326</fpage>&#x02013;<lpage>338</lpage><pub-id pub-id-type="doi">10.1002/jnr.21483</pub-id><pub-id pub-id-type="pmid">17803225</pub-id></mixed-citation></ref><ref id="B27"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bharath</surname><given-names>S.</given-names></name><name><surname>Hsu</surname><given-names>M.</given-names></name><name><surname>Kaur</surname><given-names>D.</given-names></name><name><surname>Rajagopalan</surname><given-names>S.</given-names></name><name><surname>Andersen</surname><given-names>J. K.</given-names></name></person-group> (<year>2002</year>). <article-title>Glutathione, iron and Parkinson&#x02019;s disease</article-title>. <source>Biochem. Pharmacol.</source> <volume>64</volume>, <fpage>1037</fpage>&#x02013;<lpage>1048</lpage><pub-id pub-id-type="doi">10.1016/S0006-2952(02)01174-7</pub-id><pub-id pub-id-type="pmid">12213603</pub-id></mixed-citation></ref><ref id="B28"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bilodeau</surname><given-names>J. F.</given-names></name><name><surname>Wang</surname><given-names>M.</given-names></name><name><surname>Chung</surname><given-names>F. L.</given-names></name><name><surname>Castonguay</surname><given-names>A.</given-names></name></person-group> (<year>1995</year>). <article-title>Effects of nonsteroidal antiinflammatory drugs on oxidative pathways in A/J mice</article-title>. <source>Free Radic. Biol. Med.</source> <volume>18</volume>, <fpage>47</fpage>&#x02013;<lpage>54</lpage><pub-id pub-id-type="doi">10.1016/0891-5849(94)00099-6</pub-id><pub-id pub-id-type="pmid">7896170</pub-id></mixed-citation></ref><ref id="B29"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Blandini</surname><given-names>F.</given-names></name><name><surname>Armentero</surname><given-names>M. T.</given-names></name><name><surname>Fancellu</surname><given-names>R.</given-names></name><name><surname>Blaugrund</surname><given-names>E.</given-names></name><name><surname>Nappi</surname><given-names>G.</given-names></name></person-group> (<year>2004</year>). <article-title>Neuroprotective effect of rasagiline in a rodent model of Parkinson&#x02019;s disease</article-title>. <source>Exp. Neurol.</source> <volume>187</volume>, <fpage>455</fpage>&#x02013;<lpage>459</lpage><pub-id pub-id-type="doi">10.1016/j.expneurol.2004.03.005</pub-id><pub-id pub-id-type="pmid">15144871</pub-id></mixed-citation></ref><ref id="B30"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bonifati</surname><given-names>V.</given-names></name><name><surname>Rizzu</surname><given-names>P.</given-names></name><name><surname>Squitieri</surname><given-names>F.</given-names></name><name><surname>Krieger</surname><given-names>E.</given-names></name><name><surname>Vanacore</surname><given-names>N.</given-names></name><name><surname>van Swieten</surname><given-names>J. C.</given-names></name><name><surname>Brice</surname><given-names>A.</given-names></name><name><surname>van Duijn</surname><given-names>C. M.</given-names></name><name><surname>Oostra</surname><given-names>B.</given-names></name><name><surname>Meco</surname><given-names>G.</given-names></name><name><surname>Heutink</surname><given-names>P.</given-names></name></person-group> (<year>2003</year>). <article-title>DJ-1(PARK7), a novel gene for autosomal recessive, early onset parkinsonism</article-title>. <source>Neurol. Sci.</source> <volume>24</volume>, <fpage>159</fpage>&#x02013;<lpage>160</lpage><pub-id pub-id-type="doi">10.1007/s10072-003-0108-0</pub-id><pub-id pub-id-type="pmid">14598065</pub-id></mixed-citation></ref><ref id="B31"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bousquet</surname><given-names>M.</given-names></name><name><surname>Calon</surname><given-names>F.</given-names></name><name><surname>Cicchetti</surname><given-names>F.</given-names></name></person-group> (<year>2011</year>). <article-title>Impact of omega-3 fatty acids in Parkinson&#x02019;s disease</article-title>. <source>Ageing Res. Rev.</source> <volume>10</volume>, <fpage>453</fpage>&#x02013;<lpage>463</lpage><pub-id pub-id-type="doi">10.1016/j.arr.2011.03.001</pub-id><pub-id pub-id-type="pmid">21414422</pub-id></mixed-citation></ref><ref id="B32"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bousquet</surname><given-names>M.</given-names></name><name><surname>Saint-Pierre</surname><given-names>M.</given-names></name><name><surname>Julien</surname><given-names>C.</given-names></name><name><surname>Salem</surname><given-names>N.</given-names><suffix>Jr.</suffix></name><name><surname>Cicchetti</surname><given-names>F.</given-names></name><name><surname>Calon</surname><given-names>F.</given-names></name></person-group> (<year>2008</year>). <article-title>Beneficial effects of dietary omega-3 polyunsaturated fatty acid on toxin-induced neuronal degeneration in an animal model of Parkinson&#x02019;s disease</article-title>. <source>FASEB J.</source> <volume>22</volume>, <fpage>1213</fpage>&#x02013;<lpage>1225</lpage><pub-id pub-id-type="doi">10.1096/fj.07-9677com</pub-id><pub-id pub-id-type="pmid">18032633</pub-id></mixed-citation></ref><ref id="B33"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bove</surname><given-names>J.</given-names></name><name><surname>Prou</surname><given-names>D.</given-names></name><name><surname>Perier</surname><given-names>C.</given-names></name><name><surname>Przedborski</surname><given-names>S.</given-names></name></person-group> (<year>2005a</year>). <article-title>Toxin-induced models of Parkinson&#x02019;s disease</article-title>. <source>NeuroRx</source> <volume>2</volume>, <fpage>484</fpage>&#x02013;<lpage>494</lpage><pub-id pub-id-type="doi">10.1602/neurorx.2.3.484</pub-id><pub-id pub-id-type="pmid">16389312</pub-id></mixed-citation></ref><ref id="B34"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bove</surname><given-names>J.</given-names></name><name><surname>Serrats</surname><given-names>J.</given-names></name><name><surname>Mengod</surname><given-names>G.</given-names></name><name><surname>Cortes</surname><given-names>R.</given-names></name><name><surname>Tolosa</surname><given-names>E.</given-names></name><name><surname>Marin</surname><given-names>C.</given-names></name></person-group> (<year>2005b</year>). <article-title>Neuroprotection induced by the adenosine A2A antagonist CSC in the 6-OHDA rat model of parkinsonism: effect on the activity of striatal output pathways</article-title>. <source>Exp. Brain Res.</source> <volume>165</volume>, <fpage>362</fpage>&#x02013;<lpage>374</lpage><pub-id pub-id-type="doi">10.1007/s00221-005-2302-1</pub-id><pub-id pub-id-type="pmid">15968457</pub-id></mixed-citation></ref><ref id="B35"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bower</surname><given-names>J. H.</given-names></name><name><surname>Maraganore</surname><given-names>D. M.</given-names></name><name><surname>Peterson</surname><given-names>B. J.</given-names></name><name><surname>Ahlskog</surname><given-names>J. E.</given-names></name><name><surname>Rocca</surname><given-names>W. A.</given-names></name></person-group> (<year>2006</year>). <article-title>Immunologic diseases, anti-inflammatory drugs, and Parkinson disease: a case-control study</article-title>. <source>Neurology</source> <volume>67</volume>, <fpage>494</fpage>&#x02013;<lpage>496</lpage><pub-id pub-id-type="doi">10.1212/01.wnl.0000227906.99570.cc</pub-id><pub-id pub-id-type="pmid">16894114</pub-id></mixed-citation></ref><ref id="B36"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Burton</surname><given-names>G. W.</given-names></name><name><surname>Joyce</surname><given-names>A.</given-names></name><name><surname>Ingold</surname><given-names>K. U.</given-names></name></person-group> (<year>1983</year>). <article-title>Is vitamin E the only lipid-soluble, chain-breaking antioxidant in human blood plasma and erythrocyte membranes?</article-title> <source>Arch. Biochem. Biophys.</source> <volume>221</volume>, <fpage>281</fpage>&#x02013;<lpage>290</lpage><pub-id pub-id-type="doi">10.1016/0003-9861(83)90145-5</pub-id><pub-id pub-id-type="pmid">6830261</pub-id></mixed-citation></ref><ref id="B37"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Butler</surname><given-names>M. W.</given-names></name><name><surname>Burt</surname><given-names>A.</given-names></name><name><surname>Edwards</surname><given-names>T. L.</given-names></name><name><surname>Zuchner</surname><given-names>S.</given-names></name><name><surname>Scott</surname><given-names>W. K.</given-names></name><name><surname>Martin</surname><given-names>E. R.</given-names></name><name><surname>Vance</surname><given-names>J. M.</given-names></name><name><surname>Wang</surname><given-names>L.</given-names></name></person-group> (<year>2011</year>). <article-title>Vitamin D receptor gene as a candidate gene for Parkinson disease</article-title>. <source>Ann. Hum. Genet.</source> <volume>75</volume>, <fpage>201</fpage>&#x02013;<lpage>210</lpage><pub-id pub-id-type="doi">10.1111/j.1469-1809.2010.00631.x</pub-id><pub-id pub-id-type="pmid">21309754</pub-id></mixed-citation></ref><ref id="B38"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Calon</surname><given-names>F.</given-names></name><name><surname>Lim</surname><given-names>G. P.</given-names></name><name><surname>Morihara</surname><given-names>T.</given-names></name><name><surname>Yang</surname><given-names>F.</given-names></name><name><surname>Ubeda</surname><given-names>O.</given-names></name><name><surname>Salem</surname><given-names>N.</given-names><suffix>Jr.</suffix></name><name><surname>Frautschy</surname><given-names>S. A.</given-names></name><name><surname>Cole</surname><given-names>G. M.</given-names></name></person-group> (<year>2005</year>). <article-title>Dietary n-3 polyunsaturated fatty acid depletion activates caspases and decreases NMDA receptors in the brain of a transgenic mouse model of Alzheimer&#x02019;s disease</article-title>. <source>Eur. J. Neurosci.</source> <volume>22</volume>, <fpage>617</fpage>&#x02013;<lpage>626</lpage><pub-id pub-id-type="doi">10.1111/j.1460-9568.2005.04253.x</pub-id><pub-id pub-id-type="pmid">16101743</pub-id></mixed-citation></ref><ref id="B39"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Calon</surname><given-names>F.</given-names></name><name><surname>Lim</surname><given-names>G. P.</given-names></name><name><surname>Yang</surname><given-names>F.</given-names></name><name><surname>Morihara</surname><given-names>T.</given-names></name><name><surname>Teter</surname><given-names>B.</given-names></name><name><surname>Ubeda</surname><given-names>O.</given-names></name><name><surname>Rostaing</surname><given-names>P.</given-names></name><name><surname>Triller</surname><given-names>A.</given-names></name><name><surname>Salem</surname><given-names>N.</given-names><suffix>Jr.</suffix></name><name><surname>Ashe</surname><given-names>K. H.</given-names></name><name><surname>Frautschy</surname><given-names>S. A.</given-names></name><name><surname>Cole</surname><given-names>G. M.</given-names></name></person-group> (<year>2004</year>). <article-title>Docosahexaenoic acid protects from dendritic pathology in an Alzheimer&#x02019;s disease mouse model</article-title>. <source>Neuron</source> <volume>43</volume>, <fpage>633</fpage>&#x02013;<lpage>645</lpage><pub-id pub-id-type="doi">10.1016/j.neuron.2004.08.013</pub-id><pub-id pub-id-type="pmid">15339646</pub-id></mixed-citation></ref><ref id="B40"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cansev</surname><given-names>M.</given-names></name><name><surname>Ulus</surname><given-names>I. H.</given-names></name><name><surname>Wang</surname><given-names>L.</given-names></name><name><surname>Maher</surname><given-names>T. J.</given-names></name><name><surname>Wurtman</surname><given-names>R. J.</given-names></name></person-group> (<year>2008</year>). <article-title>Restorative effects of uridine plus docosahexaenoic acid in a rat model of Parkinson&#x02019;s disease</article-title>. <source>Neurosci. Res.</source> <volume>62</volume>, <fpage>206</fpage>&#x02013;<lpage>209</lpage><pub-id pub-id-type="doi">10.1016/j.neures.2008.07.005</pub-id><pub-id pub-id-type="pmid">18761383</pub-id></mixed-citation></ref><ref id="B41"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Carr</surname><given-names>L. A.</given-names></name><name><surname>Rowell</surname><given-names>P. P.</given-names></name></person-group> (<year>1990</year>). <article-title>Attenuation of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced neurotoxicity by tobacco smoke</article-title>. <source>Neuropharmacology</source> <volume>29</volume>, <fpage>311</fpage>&#x02013;<lpage>314</lpage><pub-id pub-id-type="doi">10.1016/0028-3908(90)90019-N</pub-id><pub-id pub-id-type="pmid">2325834</pub-id></mixed-citation></ref><ref id="B42"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Carrasco</surname><given-names>E.</given-names></name><name><surname>Casper</surname><given-names>D.</given-names></name><name><surname>Werner</surname><given-names>P.</given-names></name></person-group> (<year>2005</year>). <article-title>Dopaminergic neurotoxicity by 6-OHDA and MPP+: differential requirement for neuronal cyclooxygenase activity</article-title>. <source>J. Neurosci. Res.</source> <volume>81</volume>, <fpage>121</fpage>&#x02013;<lpage>131</lpage><pub-id pub-id-type="doi">10.1002/jnr.20541</pub-id><pub-id pub-id-type="pmid">15931668</pub-id></mixed-citation></ref><ref id="B43"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Casper</surname><given-names>D.</given-names></name><name><surname>Yaparpalvi</surname><given-names>U.</given-names></name><name><surname>Rempel</surname><given-names>N.</given-names></name><name><surname>Werner</surname><given-names>P.</given-names></name></person-group> (<year>2000</year>). <article-title>Ibuprofen protects dopaminergic neurons against glutamate toxicity in vitro</article-title>. <source>Neurosci. Lett.</source> <volume>289</volume>, <fpage>201</fpage>&#x02013;<lpage>204</lpage><pub-id pub-id-type="doi">10.1016/S0304-3940(00)01294-5</pub-id><pub-id pub-id-type="pmid">10961664</pub-id></mixed-citation></ref><ref id="B44"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chan</surname><given-names>C. S.</given-names></name><name><surname>Gertler</surname><given-names>T. S.</given-names></name><name><surname>Surmeier</surname><given-names>D. J.</given-names></name></person-group> (<year>2009</year>). <article-title>Calcium homeostasis, selective vulnerability and Parkinson&#x02019;s disease</article-title>. <source>Trends Neurosci.</source> <volume>32</volume>, <fpage>249</fpage>&#x02013;<lpage>256</lpage><pub-id pub-id-type="doi">10.1016/j.tins.2009.01.006</pub-id><pub-id pub-id-type="pmid">19307031</pub-id></mixed-citation></ref><ref id="B45"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chan</surname><given-names>C. S.</given-names></name><name><surname>Guzman</surname><given-names>J. N.</given-names></name><name><surname>Ilijic</surname><given-names>E.</given-names></name><name><surname>Mercer</surname><given-names>J. N.</given-names></name><name><surname>Rick</surname><given-names>C.</given-names></name><name><surname>Tkatch</surname><given-names>T.</given-names></name><name><surname>Meredith</surname><given-names>G. E.</given-names></name><name><surname>Surmeier</surname><given-names>D. J.</given-names></name></person-group> (<year>2007</year>). <article-title>&#x02018;Rejuvenation&#x02019; protects neurons in mouse models of Parkinson&#x02019;s disease</article-title>. <source>Nature</source> <volume>447</volume>, <fpage>1081</fpage>&#x02013;<lpage>1086</lpage><pub-id pub-id-type="doi">10.1038/nature05865</pub-id><pub-id pub-id-type="pmid">17558391</pub-id></mixed-citation></ref><ref id="B46"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cheeseman</surname><given-names>K. H.</given-names></name><name><surname>Emery</surname><given-names>S.</given-names></name><name><surname>Maddix</surname><given-names>S. P.</given-names></name><name><surname>Slater</surname><given-names>T. F.</given-names></name><name><surname>Burton</surname><given-names>G. W.</given-names></name><name><surname>Ingold</surname><given-names>K. U.</given-names></name></person-group> (<year>1988</year>). <article-title>Studies on lipid peroxidation in normal and tumour tissues. The Yoshida rat liver tumour</article-title>. <source>Biochem. J.</source> <volume>250</volume>, <fpage>247</fpage>&#x02013;<lpage>252</lpage><pub-id pub-id-type="pmid">3128276</pub-id></mixed-citation></ref><ref id="B47"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>H.</given-names></name><name><surname>Jacobs</surname><given-names>E.</given-names></name><name><surname>Schwarzschild</surname><given-names>M. A.</given-names></name><name><surname>McCullough</surname><given-names>M. L.</given-names></name><name><surname>Calle</surname><given-names>E. E.</given-names></name><name><surname>Thun</surname><given-names>M. J.</given-names></name><name><surname>Ascherio</surname><given-names>A.</given-names></name></person-group> (<year>2005</year>). <article-title>Nonsteroidal antiinflammatory drug use and the risk for Parkinson&#x02019;s disease</article-title>. <source>Ann. Neurol.</source> <volume>58</volume>, <fpage>963</fpage>&#x02013;<lpage>967</lpage><pub-id pub-id-type="doi">10.1002/ana.20603</pub-id><pub-id pub-id-type="pmid">16240369</pub-id></mixed-citation></ref><ref id="B48"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>H.</given-names></name><name><surname>Mosley</surname><given-names>T. H.</given-names></name><name><surname>Alonso</surname><given-names>A.</given-names></name><name><surname>Huang</surname><given-names>X.</given-names></name></person-group> (<year>2009</year>). <article-title>Plasma urate and Parkinson&#x02019;s disease in the atherosclerosis risk in communities (ARIC) study</article-title>. <source>Am. J. Epidemiol.</source> <volume>169</volume>, <fpage>1064</fpage>&#x02013;<lpage>1069</lpage><pub-id pub-id-type="doi">10.1093/aje/kwp033</pub-id><pub-id pub-id-type="pmid">19299404</pub-id></mixed-citation></ref><ref id="B49"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>H.</given-names></name><name><surname>Zhang</surname><given-names>S. M.</given-names></name><name><surname>Hernan</surname><given-names>M. A.</given-names></name><name><surname>Schwarzschild</surname><given-names>M. A.</given-names></name><name><surname>Willett</surname><given-names>W. C.</given-names></name><name><surname>Colditz</surname><given-names>G. A.</given-names></name><name><surname>Speizer</surname><given-names>F. E.</given-names></name><name><surname>Ascherio</surname><given-names>A.</given-names></name></person-group> (<year>2003</year>). <article-title>Nonsteroidal anti-inflammatory drugs and the risk of Parkinson disease</article-title>. <source>Arch. Neurol.</source> <volume>60</volume>, <fpage>1059</fpage>&#x02013;<lpage>1064</lpage><pub-id pub-id-type="doi">10.1001/archneur.60.8.1059</pub-id><pub-id pub-id-type="pmid">12925360</pub-id></mixed-citation></ref><ref id="B50"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>J. F.</given-names></name><name><surname>Xu</surname><given-names>K.</given-names></name><name><surname>Petzer</surname><given-names>J. P.</given-names></name><name><surname>Staal</surname><given-names>R.</given-names></name><name><surname>Xu</surname><given-names>Y. H.</given-names></name><name><surname>Beilstein</surname><given-names>M.</given-names></name><name><surname>Sonsalla</surname><given-names>P. K.</given-names></name><name><surname>Castagnoli</surname><given-names>K.</given-names></name><name><surname>Castagnoli</surname><given-names>N.</given-names><suffix>Jr.</suffix></name><name><surname>Schwarzschild</surname><given-names>M. A.</given-names></name></person-group> (<year>2001</year>). <article-title>Neuroprotection by caffeine and A(2A) adenosine receptor inactivation in a model of Parkinson&#x02019;s disease</article-title>. <source>J. Neurosci.</source> <volume>21</volume>, <fpage>RC143</fpage><pub-id pub-id-type="pmid">11319241</pub-id></mixed-citation></ref><ref id="B51"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chi</surname><given-names>D. S.</given-names></name><name><surname>Gong</surname><given-names>L.</given-names></name><name><surname>Daigneault</surname><given-names>E. A.</given-names></name><name><surname>Kostrzewa</surname><given-names>R. M.</given-names></name></person-group> (<year>1992</year>). <article-title>Effects of MPTP and vitamin E treatments on immune function in mice</article-title>. <source>Int. J. Immunopharmacol.</source> <volume>14</volume>, <fpage>739</fpage>&#x02013;<lpage>746</lpage><pub-id pub-id-type="doi">10.1016/0192-0561(92)90070-2</pub-id><pub-id pub-id-type="pmid">1512070</pub-id></mixed-citation></ref><ref id="B52"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chinta</surname><given-names>S. J.</given-names></name><name><surname>Andersen</surname><given-names>J. K.</given-names></name></person-group> (<year>2006</year>). <article-title>Reversible inhibition of mitochondrial complex I activity following chronic dopaminergic glutathione depletion in vitro: implications for Parkinson&#x02019;s disease</article-title>. <source>Free Radic. Biol. Med.</source> <volume>41</volume>, <fpage>1442</fpage>&#x02013;<lpage>1448</lpage><pub-id pub-id-type="doi">10.1016/j.freeradbiomed.2006.08.002</pub-id><pub-id pub-id-type="pmid">17023271</pub-id></mixed-citation></ref><ref id="B53"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chinta</surname><given-names>S. J.</given-names></name><name><surname>Kumar</surname><given-names>M. J.</given-names></name><name><surname>Hsu</surname><given-names>M.</given-names></name><name><surname>Rajagopalan</surname><given-names>S.</given-names></name><name><surname>Kaur</surname><given-names>D.</given-names></name><name><surname>Rane</surname><given-names>A.</given-names></name><name><surname>Nicholls</surname><given-names>D. G.</given-names></name><name><surname>Choi</surname><given-names>J.</given-names></name><name><surname>Andersen</surname><given-names>J. K.</given-names></name></person-group> (<year>2007</year>). <article-title>Inducible alterations of glutathione levels in adult dopaminergic midbrain neurons result in nigrostriatal degeneration</article-title>. <source>J. Neurosci.</source> <volume>27</volume>, <fpage>13997</fpage>&#x02013;<lpage>14006</lpage><pub-id pub-id-type="doi">10.1523/JNEUROSCI.3885-07.2007</pub-id><pub-id pub-id-type="pmid">18094238</pub-id></mixed-citation></ref><ref id="B54"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Choi</surname><given-names>H. K.</given-names></name><name><surname>Atkinson</surname><given-names>K.</given-names></name><name><surname>Karlson</surname><given-names>E. W.</given-names></name><name><surname>Willett</surname><given-names>W.</given-names></name><name><surname>Curhan</surname><given-names>G.</given-names></name></person-group> (<year>2004</year>). <article-title>Alcohol intake and risk of incident gout in men: a prospective study</article-title>. <source>Lancet</source> <volume>363</volume>, <fpage>1277</fpage>&#x02013;<lpage>1281</lpage><pub-id pub-id-type="doi">10.1016/S0140-6736(04)16000-5</pub-id><pub-id pub-id-type="pmid">15094272</pub-id></mixed-citation></ref><ref id="B55"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Choi</surname><given-names>H. K.</given-names></name><name><surname>Liu</surname><given-names>S.</given-names></name><name><surname>Curhan</surname><given-names>G.</given-names></name></person-group> (<year>2005</year>). <article-title>Intake of purine-rich foods, protein, and dairy products and relationship to serum levels of uric acid: the Third National Health and Nutrition Examination Survey</article-title>. <source>Arthritis Rheum.</source> <volume>52</volume>, <fpage>283</fpage>&#x02013;<lpage>289</lpage><pub-id pub-id-type="doi">10.1002/art.20761</pub-id><pub-id pub-id-type="pmid">15641075</pub-id></mixed-citation></ref><ref id="B56"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chow</surname><given-names>C. K.</given-names></name></person-group> (<year>1991</year>). <article-title>Vitamin E and oxidative stress</article-title>. <source>Free Radic. Biol. Med.</source> <volume>11</volume>, <fpage>215</fpage>&#x02013;<lpage>232</lpage><pub-id pub-id-type="doi">10.1016/0891-5849(91)90174-2</pub-id><pub-id pub-id-type="pmid">1937140</pub-id></mixed-citation></ref><ref id="B57"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Church</surname><given-names>W. H.</given-names></name><name><surname>Ward</surname><given-names>V. L.</given-names></name></person-group> (<year>1994</year>). <article-title>Uric acid is reduced in the substantia nigra in Parkinson&#x02019;s disease: effect on dopamine oxidation</article-title>. <source>Brain Res. Bull.</source> <volume>33</volume>, <fpage>419</fpage>&#x02013;<lpage>425</lpage><pub-id pub-id-type="doi">10.1016/0361-9230(94)90285-2</pub-id><pub-id pub-id-type="pmid">8124580</pub-id></mixed-citation></ref><ref id="B58"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cleren</surname><given-names>C.</given-names></name><name><surname>Yang</surname><given-names>L.</given-names></name><name><surname>Lorenzo</surname><given-names>B.</given-names></name><name><surname>Calingasan</surname><given-names>N. Y.</given-names></name><name><surname>Schomer</surname><given-names>A.</given-names></name><name><surname>Sireci</surname><given-names>A.</given-names></name><name><surname>Wille</surname><given-names>E. J.</given-names></name><name><surname>Beal</surname><given-names>M. F.</given-names></name></person-group> (<year>2008</year>). <article-title>Therapeutic effects of coenzyme Q10 (CoQ10) and reduced CoQ10 in the MPTP model of Parkinsonism</article-title>. <source>J. Neurochem.</source> <volume>104</volume>, <fpage>1613</fpage>&#x02013;<lpage>1621</lpage><pub-id pub-id-type="doi">10.1111/j.1471-4159.2007.05097.x</pub-id><pub-id pub-id-type="pmid">17973981</pub-id></mixed-citation></ref><ref id="B59"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Coimbra</surname><given-names>C. G.</given-names></name><name><surname>Junqueira</surname><given-names>V. B.</given-names></name></person-group> (<year>2003</year>). <article-title>High doses of riboflavin and the elimination of dietary red meat promote the recovery of some motor functions in Parkinson&#x02019;s disease patients</article-title>. <source>Braz. J. Med. Biol. Res.</source> <volume>36</volume>, <fpage>1409</fpage>&#x02013;<lpage>1417</lpage><pub-id pub-id-type="doi">10.1590/S0100-879X2003001000019</pub-id><pub-id pub-id-type="pmid">14502375</pub-id></mixed-citation></ref><ref id="B60"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Costa</surname><given-names>G.</given-names></name><name><surname>Abin-Carriquiry</surname><given-names>J. A.</given-names></name><name><surname>Dajas</surname><given-names>F.</given-names></name></person-group> (<year>2001</year>). <article-title>Nicotine prevents striatal dopamine loss produced by 6-hydroxydopamine lesion in the substantia nigra</article-title>. <source>Brain Res.</source> <volume>888</volume>, <fpage>336</fpage>&#x02013;<lpage>342</lpage><pub-id pub-id-type="doi">10.1016/S0006-8993(00)03087-0</pub-id><pub-id pub-id-type="pmid">11150495</pub-id></mixed-citation></ref><ref id="B61"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Costa</surname><given-names>J.</given-names></name><name><surname>Lunet</surname><given-names>N.</given-names></name><name><surname>Santos</surname><given-names>C.</given-names></name><name><surname>Santos</surname><given-names>J.</given-names></name><name><surname>Vaz-Carneiro</surname><given-names>A.</given-names></name></person-group> (<year>2010</year>). <article-title>Caffeine exposure and the risk of Parkinson&#x02019;s disease: a systematic review and meta-analysis of observational studies</article-title>. <source>J. Alzheimers Dis.</source> <volume>20</volume>(<issue>Suppl. 1</issue>), <fpage>S221</fpage>&#x02013;<lpage>S238</lpage><pub-id pub-id-type="pmid">20182023</pub-id></mixed-citation></ref><ref id="B62"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>da Silva</surname><given-names>T. M.</given-names></name><name><surname>Munhoz</surname><given-names>R. P.</given-names></name><name><surname>Alvarez</surname><given-names>C.</given-names></name><name><surname>Naliwaiko</surname><given-names>K.</given-names></name><name><surname>Kiss</surname><given-names>A.</given-names></name><name><surname>Andreatini</surname><given-names>R.</given-names></name><name><surname>Ferraz</surname><given-names>A. C.</given-names></name></person-group> (<year>2008</year>). <article-title>Depression in Parkinson&#x02019;s disease: a double-blind, randomized, placebo-controlled pilot study of omega-3 fatty-acid supplementation</article-title>. <source>J. Affect. Disord.</source> <volume>111</volume>, <fpage>351</fpage>&#x02013;<lpage>359</lpage><pub-id pub-id-type="doi">10.1016/j.jad.2008.03.008</pub-id><pub-id pub-id-type="pmid">18485485</pub-id></mixed-citation></ref><ref id="B63"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Davies</surname><given-names>K. J.</given-names></name><name><surname>Sevanian</surname><given-names>A.</given-names></name><name><surname>Muakkassah-Kelly</surname><given-names>S. F.</given-names></name><name><surname>Hochstein</surname><given-names>P.</given-names></name></person-group> (<year>1986</year>). <article-title>Uric acid-iron ion complexes. A new aspect of the antioxidant functions of uric acid</article-title>. <source>Biochem. J.</source> <volume>235</volume>, <fpage>747</fpage>&#x02013;<lpage>754</lpage><pub-id pub-id-type="pmid">3753442</pub-id></mixed-citation></ref><ref id="B64"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>de Lau</surname><given-names>L. M.</given-names></name><name><surname>Koudstaal</surname><given-names>P. J.</given-names></name><name><surname>Hofman</surname><given-names>A.</given-names></name><name><surname>Breteler</surname><given-names>M. M.</given-names></name></person-group> (<year>2005</year>). <article-title>Serum uric acid levels and the risk of Parkinson disease</article-title>. <source>Ann. Neurol.</source> <volume>58</volume>, <fpage>797</fpage>&#x02013;<lpage>800</lpage><pub-id pub-id-type="doi">10.1002/ana.20663</pub-id><pub-id pub-id-type="pmid">16240356</pub-id></mixed-citation></ref><ref id="B65"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>de Urquiza</surname><given-names>A. M.</given-names></name><name><surname>Liu</surname><given-names>S.</given-names></name><name><surname>Sjoberg</surname><given-names>M.</given-names></name><name><surname>Zetterstrom</surname><given-names>R. H.</given-names></name><name><surname>Griffiths</surname><given-names>W.</given-names></name><name><surname>Sjovall</surname><given-names>J.</given-names></name><name><surname>Perlmann</surname><given-names>T.</given-names></name></person-group> (<year>2000</year>). <article-title>Docosahexaenoic acid, a ligand for the retinoid X receptor in mouse brain</article-title>. <source>Science</source> <volume>290</volume>, <fpage>2140</fpage>&#x02013;<lpage>2144</lpage><pub-id pub-id-type="doi">10.1126/science.290.5499.2140</pub-id><pub-id pub-id-type="pmid">11118147</pub-id></mixed-citation></ref><ref id="B66"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dedeoglu</surname><given-names>A.</given-names></name><name><surname>Kubilus</surname><given-names>J. K.</given-names></name><name><surname>Yang</surname><given-names>L.</given-names></name><name><surname>Ferrante</surname><given-names>K. L.</given-names></name><name><surname>Hersch</surname><given-names>S. M.</given-names></name><name><surname>Beal</surname><given-names>M. F.</given-names></name><name><surname>Ferrante</surname><given-names>R. J.</given-names></name></person-group> (<year>2003</year>). <article-title>Creatine therapy provides neuroprotection after onset of clinical symptoms in Huntington&#x02019;s disease transgenic mice</article-title>. <source>J. Neurochem.</source> <volume>85</volume>, <fpage>1359</fpage>&#x02013;<lpage>1367</lpage><pub-id pub-id-type="doi">10.1046/j.1471-4159.2003.01706.x</pub-id><pub-id pub-id-type="pmid">12787055</pub-id></mixed-citation></ref><ref id="B67"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dexter</surname><given-names>D. T.</given-names></name><name><surname>Ward</surname><given-names>R. J.</given-names></name><name><surname>Wells</surname><given-names>F. R.</given-names></name><name><surname>Daniel</surname><given-names>S. E.</given-names></name><name><surname>Lees</surname><given-names>A. J.</given-names></name><name><surname>Peters</surname><given-names>T. J.</given-names></name><name><surname>Jenner</surname><given-names>P.</given-names></name><name><surname>Marsden</surname><given-names>C. D.</given-names></name></person-group> (<year>1992</year>). <article-title>Alpha-tocopherol levels in brain are not altered in Parkinson&#x02019;s disease</article-title>. <source>Ann. Neurol.</source> <volume>32</volume>, <fpage>591</fpage>&#x02013;<lpage>593</lpage><pub-id pub-id-type="doi">10.1002/ana.410320716</pub-id><pub-id pub-id-type="pmid">1456747</pub-id></mixed-citation></ref><ref id="B68"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Di Matteo</surname><given-names>V.</given-names></name><name><surname>Pierucci</surname><given-names>M.</given-names></name><name><surname>Di Giovanni</surname><given-names>G.</given-names></name><name><surname>Di Santo</surname><given-names>A.</given-names></name><name><surname>Poggi</surname><given-names>A.</given-names></name><name><surname>Benigno</surname><given-names>A.</given-names></name><name><surname>Esposito</surname><given-names>E.</given-names></name></person-group> (<year>2006</year>). <article-title>Aspirin protects striatal dopaminergic neurons from neurotoxin-induced degeneration: an in vivo microdialysis study</article-title>. <source>Brain Res.</source> <volume>1095</volume>, <fpage>167</fpage>&#x02013;<lpage>177</lpage><pub-id pub-id-type="doi">10.1016/j.brainres.2006.04.013</pub-id><pub-id pub-id-type="pmid">16712818</pub-id></mixed-citation></ref><ref id="B69"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Di Monte</surname><given-names>D. A.</given-names></name></person-group> (<year>1991</year>). <article-title>Mitochondrial DNA and Parkinson&#x02019;s disease</article-title>. <source>Neurology</source> <volume>41</volume>, <fpage>38</fpage>&#x02013;<lpage>42</lpage>; discussion 42&#x02013;33.<pub-id pub-id-type="pmid">1904141</pub-id></mixed-citation></ref><ref id="B70"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Diguet</surname><given-names>E.</given-names></name><name><surname>Fernagut</surname><given-names>P. O.</given-names></name><name><surname>Wei</surname><given-names>X.</given-names></name><name><surname>Du</surname><given-names>Y.</given-names></name><name><surname>Rouland</surname><given-names>R.</given-names></name><name><surname>Gross</surname><given-names>C.</given-names></name><name><surname>Bezard</surname><given-names>E.</given-names></name><name><surname>Tison</surname><given-names>F.</given-names></name></person-group> (<year>2004</year>). <article-title>Deleterious effects of minocycline in animal models of Parkinson&#x02019;s disease and Huntington&#x02019;s disease</article-title>. <source>Eur. J. Neurosci.</source> <volume>19</volume>, <fpage>3266</fpage>&#x02013;<lpage>3276</lpage><pub-id pub-id-type="doi">10.1111/j.0953-816X.2004.03372.x</pub-id><pub-id pub-id-type="pmid">15217383</pub-id></mixed-citation></ref><ref id="B71"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dowling</surname><given-names>G. A.</given-names></name><name><surname>Mastick</surname><given-names>J.</given-names></name><name><surname>Colling</surname><given-names>E.</given-names></name><name><surname>Carter</surname><given-names>J. H.</given-names></name><name><surname>Singer</surname><given-names>C. M.</given-names></name><name><surname>Aminoff</surname><given-names>M. J.</given-names></name></person-group> (<year>2005</year>). <article-title>Melatonin for sleep disturbances in Parkinson&#x02019;s disease</article-title>. <source>Sleep Med.</source> <volume>6</volume>, <fpage>459</fpage>&#x02013;<lpage>466</lpage><pub-id pub-id-type="doi">10.1016/j.sleep.2005.04.004</pub-id><pub-id pub-id-type="pmid">16084125</pub-id></mixed-citation></ref><ref id="B72"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Driver</surname><given-names>J. A.</given-names></name><name><surname>Logroscino</surname><given-names>G.</given-names></name><name><surname>Lu</surname><given-names>L.</given-names></name><name><surname>Gaziano</surname><given-names>J. M.</given-names></name><name><surname>Kurth</surname><given-names>T.</given-names></name></person-group> (<year>2011</year>). <article-title>Use of non-steroidal anti-inflammatory drugs and risk of Parkinson&#x02019;s disease: nested case-control study</article-title>. <source>BMJ</source> <volume>342</volume>, <fpage>d198</fpage><pub-id pub-id-type="doi">10.1136/bmj.d198</pub-id><pub-id pub-id-type="pmid">21252104</pub-id></mixed-citation></ref><ref id="B73"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Du</surname><given-names>Y.</given-names></name><name><surname>Ma</surname><given-names>Z.</given-names></name><name><surname>Lin</surname><given-names>S.</given-names></name><name><surname>Dodel</surname><given-names>R. C.</given-names></name><name><surname>Gao</surname><given-names>F.</given-names></name><name><surname>Bales</surname><given-names>K. R.</given-names></name><name><surname>Triarhou</surname><given-names>L. C.</given-names></name><name><surname>Chernet</surname><given-names>E.</given-names></name><name><surname>Perry</surname><given-names>K. W.</given-names></name><name><surname>Nelson</surname><given-names>D. L.</given-names></name><name><surname>Luecke</surname><given-names>S.</given-names></name><name><surname>Phebus</surname><given-names>L. A.</given-names></name><name><surname>Bymaster</surname><given-names>F. P.</given-names></name><name><surname>Paul</surname><given-names>S. M.</given-names></name></person-group> (<year>2001</year>). <article-title>Minocycline prevents nigrostriatal dopaminergic neurodegeneration in the MPTP model of Parkinson&#x02019;s disease</article-title>. <source>Proc. Natl. Acad. Sci. U.S.A.</source> <volume>98</volume>, <fpage>14669</fpage>&#x02013;<lpage>14674</lpage><pub-id pub-id-type="doi">10.1073/pnas.251341998</pub-id><pub-id pub-id-type="pmid">11724929</pub-id></mixed-citation></ref><ref id="B74"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Duan</surname><given-names>W.</given-names></name><name><surname>Ladenheim</surname><given-names>B.</given-names></name><name><surname>Cutler</surname><given-names>R. G.</given-names></name><name><surname>Kruman</surname><suffix>II</suffix></name><name><surname>Cadet</surname><given-names>J. L.</given-names></name><name><surname>Mattson</surname><given-names>M. P.</given-names></name></person-group> (<year>2002</year>). <article-title>Dietary folate deficiency and elevated homocysteine levels endanger dopaminergic neurons in models of Parkinson&#x02019;s disease</article-title>. <source>J. Neurochem.</source> <volume>80</volume>, <fpage>101</fpage>&#x02013;<lpage>110</lpage><pub-id pub-id-type="doi">10.1046/j.0022-3042.2001.00676.x</pub-id><pub-id pub-id-type="pmid">11796748</pub-id></mixed-citation></ref><ref id="B75"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>During</surname><given-names>M. J.</given-names></name><name><surname>Cao</surname><given-names>L.</given-names></name><name><surname>Zuzga</surname><given-names>D. S.</given-names></name><name><surname>Francis</surname><given-names>J. S.</given-names></name><name><surname>Fitzsimons</surname><given-names>H. L.</given-names></name><name><surname>Jiao</surname><given-names>X.</given-names></name><name><surname>Bland</surname><given-names>R. J.</given-names></name><name><surname>Klugmann</surname><given-names>M.</given-names></name><name><surname>Banks</surname><given-names>W. A.</given-names></name><name><surname>Drucker</surname><given-names>D. J.</given-names></name><name><surname>Haile</surname><given-names>C. N.</given-names></name></person-group> (<year>2003</year>). <article-title>Glucagon-like peptide-1 receptor is involved in learning and neuroprotection</article-title>. <source>Nat. Med.</source> <volume>9</volume>, <fpage>1173</fpage>&#x02013;<lpage>1179</lpage><pub-id pub-id-type="doi">10.1038/nm919</pub-id><pub-id pub-id-type="pmid">12925848</pub-id></mixed-citation></ref><ref id="B76"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ebadi</surname><given-names>M.</given-names></name><name><surname>Sharma</surname><given-names>S. K.</given-names></name><name><surname>Wanpen</surname><given-names>S.</given-names></name><name><surname>Amornpan</surname><given-names>A.</given-names></name></person-group> (<year>2004</year>). <article-title>Coenzyme Q10 inhibits mitochondrial complex-1 down-regulation and nuclear factor-kappa B activation</article-title>. <source>J. Cell. Mol. Med.</source> <volume>8</volume>, <fpage>213</fpage>&#x02013;<lpage>222</lpage><pub-id pub-id-type="doi">10.1111/j.1582-4934.2004.tb00276.x</pub-id><pub-id pub-id-type="pmid">15256069</pub-id></mixed-citation></ref><ref id="B77"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Esposito</surname><given-names>E.</given-names></name><name><surname>Di Matteo</surname><given-names>V.</given-names></name><name><surname>Benigno</surname><given-names>A.</given-names></name><name><surname>Pierucci</surname><given-names>M.</given-names></name><name><surname>Crescimanno</surname><given-names>G.</given-names></name><name><surname>Di Giovanni</surname><given-names>G.</given-names></name></person-group> (<year>2007</year>). <article-title>Non-steroidal anti-inflammatory drugs in Parkinson&#x02019;s disease</article-title>. <source>Exp. Neurol.</source> <volume>205</volume>, <fpage>295</fpage>&#x02013;<lpage>312</lpage><pub-id pub-id-type="doi">10.1016/j.expneurol.2007.02.008</pub-id><pub-id pub-id-type="pmid">17433296</pub-id></mixed-citation></ref><ref id="B78"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Etminan</surname><given-names>M.</given-names></name><name><surname>Gill</surname><given-names>S. S.</given-names></name><name><surname>Samii</surname><given-names>A.</given-names></name></person-group> (<year>2005</year>). <article-title>Intake of vitamin E, vitamin C, and carotenoids and the risk of Parkinson&#x02019;s disease: a meta-analysis</article-title>. <source>Lancet Neurol.</source> <volume>4</volume>, <fpage>362</fpage>&#x02013;<lpage>365</lpage><pub-id pub-id-type="doi">10.1016/S1474-4422(05)70097-1</pub-id><pub-id pub-id-type="pmid">15907740</pub-id></mixed-citation></ref><ref id="B79"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Evans</surname><given-names>R. M.</given-names></name></person-group> (<year>1988</year>). <article-title>The steroid and thyroid hormone receptor superfamily</article-title>. <source>Science</source> <volume>240</volume>, <fpage>889</fpage>&#x02013;<lpage>895</lpage><pub-id pub-id-type="doi">10.1126/science.3358127</pub-id><pub-id pub-id-type="pmid">3283939</pub-id></mixed-citation></ref><ref id="B80"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Everse</surname><given-names>J.</given-names></name><name><surname>Coates</surname><given-names>P. W.</given-names></name></person-group> (<year>2004</year>). <article-title>The cytotoxic activity of lactoperoxidase: enhancement and inhibition by neuroactive compounds</article-title>. <source>Free Radic. Biol. Med.</source> <volume>37</volume>, <fpage>839</fpage>&#x02013;<lpage>849</lpage><pub-id pub-id-type="doi">10.1016/j.freeradbiomed.2004.06.017</pub-id><pub-id pub-id-type="pmid">15384204</pub-id></mixed-citation></ref><ref id="B81"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Eyles</surname><given-names>D.</given-names></name><name><surname>Brown</surname><given-names>J.</given-names></name><name><surname>Mackay-Sim</surname><given-names>A.</given-names></name><name><surname>McGrath</surname><given-names>J.</given-names></name><name><surname>Feron</surname><given-names>F.</given-names></name></person-group> (<year>2003</year>). <article-title>Vitamin D3 and brain development</article-title>. <source>Neuroscience</source> <volume>118</volume>, <fpage>641</fpage>&#x02013;<lpage>653</lpage><pub-id pub-id-type="doi">10.1016/S0306-4522(03)00040-X</pub-id><pub-id pub-id-type="pmid">12710973</pub-id></mixed-citation></ref><ref id="B82"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Eyles</surname><given-names>D. W.</given-names></name><name><surname>Smith</surname><given-names>S.</given-names></name><name><surname>Kinobe</surname><given-names>R.</given-names></name><name><surname>Hewison</surname><given-names>M.</given-names></name><name><surname>McGrath</surname><given-names>J. J.</given-names></name></person-group> (<year>2005</year>). <article-title>Distribution of the vitamin D receptor and 1 alpha-hydroxylase in human brain</article-title>. <source>J. Chem. Neuroanat.</source> <volume>29</volume>, <fpage>21</fpage>&#x02013;<lpage>30</lpage><pub-id pub-id-type="doi">10.1016/j.jchemneu.2004.08.006</pub-id><pub-id pub-id-type="pmid">15589699</pub-id></mixed-citation></ref><ref id="B83"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fahn</surname><given-names>S.</given-names></name></person-group> (<year>1992</year>). <article-title>A pilot trial of high-dose alpha-tocopherol and ascorbate in early Parkinson&#x02019;s disease</article-title>. <source>Ann. Neurol.</source> <volume>32</volume>(<issue>Suppl.</issue>), <fpage>S128</fpage>&#x02013;<lpage>S132</lpage><pub-id pub-id-type="doi">10.1002/ana.410320616</pub-id><pub-id pub-id-type="pmid">1510371</pub-id></mixed-citation></ref><ref id="B84"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fariss</surname><given-names>M. W.</given-names></name><name><surname>Zhang</surname><given-names>J. G.</given-names></name></person-group> (<year>2003</year>). <article-title>Vitamin E therapy in Parkinson&#x02019;s disease</article-title>. <source>Toxicology</source> <volume>189</volume>, <fpage>129</fpage>&#x02013;<lpage>146</lpage><pub-id pub-id-type="doi">10.1016/S0300-483X(03)00158-6</pub-id><pub-id pub-id-type="pmid">12821288</pub-id></mixed-citation></ref><ref id="B85"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Faust</surname><given-names>K.</given-names></name><name><surname>Gehrke</surname><given-names>S.</given-names></name><name><surname>Yang</surname><given-names>Y.</given-names></name><name><surname>Yang</surname><given-names>L.</given-names></name><name><surname>Beal</surname><given-names>M. F.</given-names></name><name><surname>Lu</surname><given-names>B.</given-names></name></person-group> (<year>2009</year>). <article-title>Neuroprotective effects of compounds with antioxidant and anti-inflammatory properties in a <italic>Drosophila</italic> model of Parkinson&#x02019;s disease</article-title>. <source>BMC Neurosci.</source> <volume>10</volume>, <fpage>109</fpage><pub-id pub-id-type="doi">10.1186/1471-2202-10-109</pub-id><pub-id pub-id-type="pmid">19723328</pub-id></mixed-citation></ref><ref id="B86"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ferger</surname><given-names>B.</given-names></name><name><surname>Spratt</surname><given-names>C.</given-names></name><name><surname>Earl</surname><given-names>C. D.</given-names></name><name><surname>Teismann</surname><given-names>P.</given-names></name><name><surname>Oertel</surname><given-names>W. H.</given-names></name><name><surname>Kuschinsky</surname><given-names>K.</given-names></name></person-group> (<year>1998</year>). <article-title>Effects of nicotine on hydroxyl free radical formation in vitro and on MPTP-induced neurotoxicity in vivo</article-title>. <source>Naunyn Schmiedebergs Arch. Pharmacol.</source> <volume>358</volume>, <fpage>351</fpage>&#x02013;<lpage>359</lpage><pub-id pub-id-type="doi">10.1007/PL00005264</pub-id><pub-id pub-id-type="pmid">9774223</pub-id></mixed-citation></ref><ref id="B87"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fernandez-Calle</surname><given-names>P.</given-names></name><name><surname>Jimenez-Jimenez</surname><given-names>F. J.</given-names></name><name><surname>Molina</surname><given-names>J. A.</given-names></name><name><surname>Cabrera-Valdivia</surname><given-names>F.</given-names></name><name><surname>Vazquez</surname><given-names>A.</given-names></name><name><surname>Garcia Urra</surname><given-names>D.</given-names></name><name><surname>Bermejo</surname><given-names>F.</given-names></name><name><surname>Cruz Matallana</surname><given-names>M.</given-names></name><name><surname>Codoceo</surname><given-names>R.</given-names></name></person-group> (<year>1993</year>). <article-title>Serum levels of ascorbic acid (vitamin C) in patients with Parkinson&#x02019;s disease</article-title>. <source>J. Neurol. Sci.</source> <volume>118</volume>, <fpage>25</fpage>&#x02013;<lpage>28</lpage><pub-id pub-id-type="doi">10.1016/0022-510X(93)90240-Y</pub-id><pub-id pub-id-type="pmid">8229047</pub-id></mixed-citation></ref><ref id="B88"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fernandez-Calle</surname><given-names>P.</given-names></name><name><surname>Molina</surname><given-names>J. A.</given-names></name><name><surname>Jimenez-Jimenez</surname><given-names>F. J.</given-names></name><name><surname>Vazquez</surname><given-names>A.</given-names></name><name><surname>Pondal</surname><given-names>M.</given-names></name><name><surname>Garcia-Ruiz</surname><given-names>P. J.</given-names></name><name><surname>Urra</surname><given-names>D. G.</given-names></name><name><surname>Domingo</surname><given-names>J.</given-names></name><name><surname>Codoceo</surname><given-names>R.</given-names></name></person-group> (<year>1992</year>). <article-title>Serum levels of alpha-tocopherol (vitamin E) in Parkinson&#x02019;s disease</article-title>. <source>Neurology</source> <volume>42</volume>, <fpage>1064</fpage>&#x02013;<lpage>1066</lpage><pub-id pub-id-type="pmid">1579230</pub-id></mixed-citation></ref><ref id="B89"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ferrea</surname><given-names>S.</given-names></name><name><surname>Winterer</surname><given-names>G.</given-names></name></person-group> (<year>2009</year>). <article-title>Neuroprotective and neurotoxic effects of nicotine</article-title>. <source>Pharmacopsychiatry</source> <volume>42</volume>, <fpage>255</fpage>&#x02013;<lpage>265</lpage><pub-id pub-id-type="doi">10.1055/s-0029-1224138</pub-id><pub-id pub-id-type="pmid">19924585</pub-id></mixed-citation></ref><ref id="B90"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fertl</surname><given-names>E.</given-names></name><name><surname>Auff</surname><given-names>E.</given-names></name><name><surname>Doppelbauer</surname><given-names>A.</given-names></name><name><surname>Waldhauser</surname><given-names>F.</given-names></name></person-group> (<year>1993</year>). <article-title>Circadian secretion pattern of melatonin in de novo parkinsonian patients: evidence for phase-shifting properties of l-dopa</article-title>. <source>J. Neural Transm. Park. Dis. Dement. Sect.</source> <volume>5</volume>, <fpage>227</fpage>&#x02013;<lpage>234</lpage><pub-id pub-id-type="doi">10.1007/BF02257677</pub-id><pub-id pub-id-type="pmid">8369102</pub-id></mixed-citation></ref><ref id="B91"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fowler</surname><given-names>J. S.</given-names></name><name><surname>Volkow</surname><given-names>N. D.</given-names></name><name><surname>Wang</surname><given-names>G. J.</given-names></name><name><surname>Pappas</surname><given-names>N.</given-names></name><name><surname>Logan</surname><given-names>J.</given-names></name><name><surname>MacGregor</surname><given-names>R.</given-names></name><name><surname>Alexoff</surname><given-names>D.</given-names></name><name><surname>Shea</surname><given-names>C.</given-names></name><name><surname>Schlyer</surname><given-names>D.</given-names></name><name><surname>Wolf</surname><given-names>A. P.</given-names></name><name><surname>Warner</surname><given-names>D.</given-names></name><name><surname>Zezulkova</surname><given-names>I.</given-names></name><name><surname>Cilento</surname><given-names>R.</given-names></name></person-group> (<year>1996</year>). <article-title>Inhibition of monoamine oxidase B in the brains of smokers</article-title>. <source>Nature</source> <volume>379</volume>, <fpage>733</fpage>&#x02013;<lpage>736</lpage><pub-id pub-id-type="doi">10.1038/379733a0</pub-id><pub-id pub-id-type="pmid">8602220</pub-id></mixed-citation></ref><ref id="B92"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Galpern</surname><given-names>W. R.</given-names></name><name><surname>Cudkowicz</surname><given-names>M. E.</given-names></name></person-group> (<year>2007</year>). <article-title>Coenzyme Q treatment of neurodegenerative diseases of aging</article-title>. <source>Mitochondrion</source> <volume>7</volume>(<issue>Suppl.</issue>), <fpage>S146</fpage>&#x02013;<lpage>S153</lpage><pub-id pub-id-type="doi">10.1016/j.mito.2007.01.004</pub-id><pub-id pub-id-type="pmid">17485247</pub-id></mixed-citation></ref><ref id="B93"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gao</surname><given-names>X.</given-names></name><name><surname>Chen</surname><given-names>H.</given-names></name><name><surname>Choi</surname><given-names>H. K.</given-names></name><name><surname>Curhan</surname><given-names>G.</given-names></name><name><surname>Schwarzschild</surname><given-names>M. A.</given-names></name><name><surname>Ascherio</surname><given-names>A.</given-names></name></person-group> (<year>2008</year>). <article-title>Diet, urate, and Parkinson&#x02019;s disease risk in men</article-title>. <source>Am. J. Epidemiol.</source> <volume>167</volume>, <fpage>831</fpage>&#x02013;<lpage>838</lpage><pub-id pub-id-type="doi">10.1093/aje/kwm385</pub-id><pub-id pub-id-type="pmid">18326873</pub-id></mixed-citation></ref><ref id="B94"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gao</surname><given-names>X.</given-names></name><name><surname>Chen</surname><given-names>H.</given-names></name><name><surname>Schwarzschild</surname><given-names>M. A.</given-names></name><name><surname>Ascherio</surname><given-names>A.</given-names></name></person-group> (<year>2011</year>). <article-title>Use of ibuprofen and risk of Parkinson disease</article-title>. <source>Neurology</source> <volume>76</volume>, <fpage>863</fpage>&#x02013;<lpage>869</lpage><pub-id pub-id-type="doi">10.1212/WNL.0b013e31820f2d79</pub-id><pub-id pub-id-type="pmid">21368281</pub-id></mixed-citation></ref><ref id="B95"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Garcion</surname><given-names>E.</given-names></name><name><surname>Wion-Barbot</surname><given-names>N.</given-names></name><name><surname>Montero-Menei</surname><given-names>C. N.</given-names></name><name><surname>Berger</surname><given-names>F.</given-names></name><name><surname>Wion</surname><given-names>D.</given-names></name></person-group> (<year>2002</year>). <article-title>New clues about vitamin D functions in the nervous system</article-title>. <source>Trends Endocrinol. Metab.</source> <volume>13</volume>, <fpage>100</fpage>&#x02013;<lpage>105</lpage><pub-id pub-id-type="doi">10.1016/S1043-2760(01)00547-1</pub-id><pub-id pub-id-type="pmid">11893522</pub-id></mixed-citation></ref><ref id="B96"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gardian</surname><given-names>G.</given-names></name><name><surname>Yang</surname><given-names>L.</given-names></name><name><surname>Cleren</surname><given-names>C.</given-names></name><name><surname>Calingasan</surname><given-names>N. Y.</given-names></name><name><surname>Klivenyi</surname><given-names>P.</given-names></name><name><surname>Beal</surname><given-names>M. F.</given-names></name></person-group> (<year>2004</year>). <article-title>Neuroprotective effects of phenylbutyrate against MPTP neurotoxicity</article-title>. <source>Neuromolecular Med.</source> <volume>5</volume>, <fpage>235</fpage>&#x02013;<lpage>241</lpage><pub-id pub-id-type="doi">10.1385/NMM:5:3:235</pub-id><pub-id pub-id-type="pmid">15626823</pub-id></mixed-citation></ref><ref id="B97"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Garrido</surname><given-names>M.</given-names></name><name><surname>Tereshchenko</surname><given-names>Y.</given-names></name><name><surname>Zhevtsova</surname><given-names>Z.</given-names></name><name><surname>Taschenberger</surname><given-names>G.</given-names></name><name><surname>Bahr</surname><given-names>M.</given-names></name><name><surname>Kugler</surname><given-names>S.</given-names></name></person-group> (<year>2011</year>). <article-title>Glutathione depletion and overproduction both initiate degeneration of nigral dopaminergic neurons</article-title>. <source>Acta Neuropathol.</source> <volume>121</volume>, <fpage>475</fpage>&#x02013;<lpage>485</lpage><pub-id pub-id-type="doi">10.1007/s00401-010-0791-x</pub-id><pub-id pub-id-type="pmid">21191602</pub-id></mixed-citation></ref><ref id="B98"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gash</surname><given-names>D. M.</given-names></name><name><surname>Zhang</surname><given-names>Z.</given-names></name><name><surname>Ovadia</surname><given-names>A.</given-names></name><name><surname>Cass</surname><given-names>W. A.</given-names></name><name><surname>Yi</surname><given-names>A.</given-names></name><name><surname>Simmerman</surname><given-names>L.</given-names></name><name><surname>Russell</surname><given-names>D.</given-names></name><name><surname>Martin</surname><given-names>D.</given-names></name><name><surname>Lapchak</surname><given-names>P. A.</given-names></name><name><surname>Collins</surname><given-names>F.</given-names></name><name><surname>Hoffer</surname><given-names>B. J.</given-names></name><name><surname>Gerhardt</surname><given-names>G. A.</given-names></name></person-group> (<year>1996</year>). <article-title>Functional recovery in parkinsonian monkeys treated with GDNF</article-title>. <source>Nature</source> <volume>380</volume>, <fpage>252</fpage>&#x02013;<lpage>255</lpage><pub-id pub-id-type="doi">10.1038/380252a0</pub-id><pub-id pub-id-type="pmid">8637574</pub-id></mixed-citation></ref><ref id="B99"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gill</surname><given-names>S. S.</given-names></name><name><surname>Patel</surname><given-names>N. K.</given-names></name><name><surname>Hotton</surname><given-names>G. R.</given-names></name><name><surname>O&#x02019;Sullivan</surname><given-names>K.</given-names></name><name><surname>McCarter</surname><given-names>R.</given-names></name><name><surname>Bunnage</surname><given-names>M.</given-names></name><name><surname>Brooks</surname><given-names>D. J.</given-names></name><name><surname>Svendsen</surname><given-names>C. N.</given-names></name><name><surname>Heywood</surname><given-names>P.</given-names></name></person-group> (<year>2003</year>). <article-title>Direct brain infusion of glial cell line-derived neurotrophic factor in Parkinson disease</article-title>. <source>Nat. Med.</source> <volume>9</volume>, <fpage>589</fpage>&#x02013;<lpage>595</lpage><pub-id pub-id-type="doi">10.1038/nm850</pub-id><pub-id pub-id-type="pmid">12669033</pub-id></mixed-citation></ref><ref id="B100"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Glover</surname><given-names>J.</given-names></name></person-group> (<year>1960</year>). <article-title>The conversion of beta-carotene into vitamin A</article-title>. <source>Vitam. Horm.</source> <volume>18</volume>, <fpage>371</fpage>&#x02013;<lpage>386</lpage><pub-id pub-id-type="doi">10.1016/S0083-6729(08)60869-9</pub-id><pub-id pub-id-type="pmid">13706096</pub-id></mixed-citation></ref><ref id="B101"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gong</surname><given-names>L.</given-names></name><name><surname>Daigneault</surname><given-names>E. A.</given-names></name><name><surname>Acuff</surname><given-names>R. V.</given-names></name><name><surname>Kostrzewa</surname><given-names>R. M.</given-names></name></person-group> (<year>1991</year>). <article-title>Vitamin E supplements fail to protect mice from acute MPTP neurotoxicity</article-title>. <source>Neuroreport</source> <volume>2</volume>, <fpage>544</fpage>&#x02013;<lpage>546</lpage><pub-id pub-id-type="doi">10.1097/00001756-199109000-00012</pub-id><pub-id pub-id-type="pmid">1751810</pub-id></mixed-citation></ref><ref id="B102"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gotz</surname><given-names>M. E.</given-names></name><name><surname>Gerstner</surname><given-names>A.</given-names></name><name><surname>Harth</surname><given-names>R.</given-names></name><name><surname>Dirr</surname><given-names>A.</given-names></name><name><surname>Janetzky</surname><given-names>B.</given-names></name><name><surname>Kuhn</surname><given-names>W.</given-names></name><name><surname>Riederer</surname><given-names>P.</given-names></name><name><surname>Gerlach</surname><given-names>M.</given-names></name></person-group> (<year>2000</year>). <article-title>Altered redox state of platelet coenzyme Q10 in Parkinson&#x02019;s disease</article-title>. <source>J. Neural Transm.</source> <volume>107</volume>, <fpage>41</fpage>&#x02013;<lpage>48</lpage><pub-id pub-id-type="doi">10.1007/s007020050003</pub-id><pub-id pub-id-type="pmid">10809402</pub-id></mixed-citation></ref><ref id="B103"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Green</surname><given-names>K. N.</given-names></name><name><surname>Martinez-Coria</surname><given-names>H.</given-names></name><name><surname>Khashwji</surname><given-names>H.</given-names></name><name><surname>Hall</surname><given-names>E. B.</given-names></name><name><surname>Yurko-Mauro</surname><given-names>K. A.</given-names></name><name><surname>Ellis</surname><given-names>L.</given-names></name><name><surname>LaFerla</surname><given-names>F. M.</given-names></name></person-group> (<year>2007</year>). <article-title>Dietary docosahexaenoic acid and docosapentaenoic acid ameliorate amyloid-beta and tau pathology via a mechanism involving presenilin 1 levels</article-title>. <source>J. Neurosci.</source> <volume>27</volume>, <fpage>4385</fpage>&#x02013;<lpage>4395</lpage><pub-id pub-id-type="doi">10.1523/JNEUROSCI.3822-06.2007</pub-id><pub-id pub-id-type="pmid">17442823</pub-id></mixed-citation></ref><ref id="B104"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Grunewald</surname><given-names>R. A.</given-names></name></person-group> (<year>1993</year>). <article-title>Ascorbic acid in the brain</article-title>. <source>Brain Res. Brain Res. Rev.</source> <volume>18</volume>, <fpage>123</fpage>&#x02013;<lpage>133</lpage><pub-id pub-id-type="doi">10.1016/0165-0173(93)90010-W</pub-id><pub-id pub-id-type="pmid">8467348</pub-id></mixed-citation></ref><ref id="B105"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hargreaves</surname><given-names>I. P.</given-names></name><name><surname>Lane</surname><given-names>A.</given-names></name><name><surname>Sleiman</surname><given-names>P. M.</given-names></name></person-group> (<year>2008</year>). <article-title>The coenzyme Q10 status of the brain regions of Parkinson&#x02019;s disease patients</article-title>. <source>Neurosci. Lett.</source> <volume>447</volume>, <fpage>17</fpage>&#x02013;<lpage>19</lpage><pub-id pub-id-type="doi">10.1016/j.neulet.2008.09.069</pub-id><pub-id pub-id-type="pmid">18840506</pub-id></mixed-citation></ref><ref id="B106"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Harkavyi</surname><given-names>A.</given-names></name><name><surname>Abuirmeileh</surname><given-names>A.</given-names></name><name><surname>Lever</surname><given-names>R.</given-names></name><name><surname>Kingsbury</surname><given-names>A. E.</given-names></name><name><surname>Biggs</surname><given-names>C. S.</given-names></name><name><surname>Whitton</surname><given-names>P. S.</given-names></name></person-group> (<year>2008</year>). <article-title>Glucagon-like peptide 1 receptor stimulation reverses key deficits in distinct rodent models of Parkinson&#x02019;s disease</article-title>. <source>J. Neuroinflammation</source> <volume>5</volume>, <fpage>19</fpage><pub-id pub-id-type="doi">10.1186/1742-2094-5-19</pub-id><pub-id pub-id-type="pmid">18492290</pub-id></mixed-citation></ref><ref id="B107"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Harkavyi</surname><given-names>A.</given-names></name><name><surname>Whitton</surname><given-names>P. S.</given-names></name></person-group> (<year>2010</year>). <article-title>Glucagon-like peptide 1 receptor stimulation as a means of neuroprotection</article-title>. <source>Br. J. Pharmacol.</source> <volume>159</volume>, <fpage>495</fpage>&#x02013;<lpage>501</lpage><pub-id pub-id-type="doi">10.1111/j.1476-5381.2009.00486.x</pub-id><pub-id pub-id-type="pmid">20128800</pub-id></mixed-citation></ref><ref id="B108"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hashimoto</surname><given-names>M.</given-names></name><name><surname>Hossain</surname><given-names>S.</given-names></name><name><surname>Shimada</surname><given-names>T.</given-names></name><name><surname>Sugioka</surname><given-names>K.</given-names></name><name><surname>Yamasaki</surname><given-names>H.</given-names></name><name><surname>Fujii</surname><given-names>Y.</given-names></name><name><surname>Ishibashi</surname><given-names>Y.</given-names></name><name><surname>Oka</surname><given-names>J.</given-names></name><name><surname>Shido</surname><given-names>O.</given-names></name></person-group> (<year>2002</year>). <article-title>Docosahexaenoic acid provides protection from impairment of learning ability in Alzheimer&#x02019;s disease model rats</article-title>. <source>J. Neurochem.</source> <volume>81</volume>, <fpage>1084</fpage>&#x02013;<lpage>1091</lpage><pub-id pub-id-type="doi">10.1046/j.1471-4159.2002.00905.x</pub-id><pub-id pub-id-type="pmid">12065621</pub-id></mixed-citation></ref><ref id="B109"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hashimoto</surname><given-names>M.</given-names></name><name><surname>Tanabe</surname><given-names>Y.</given-names></name><name><surname>Fujii</surname><given-names>Y.</given-names></name><name><surname>Kikuta</surname><given-names>T.</given-names></name><name><surname>Shibata</surname><given-names>H.</given-names></name><name><surname>Shido</surname><given-names>O.</given-names></name></person-group> (<year>2005</year>). <article-title>Chronic administration of docosahexaenoic acid ameliorates the impairment of spatial cognition learning ability in amyloid beta-infused rats</article-title>. <source>J. Nutr.</source> <volume>135</volume>, <fpage>549</fpage>&#x02013;<lpage>555</lpage><pub-id pub-id-type="pmid">15735092</pub-id></mixed-citation></ref><ref id="B110"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hauser</surname><given-names>R. A.</given-names></name><name><surname>Lew</surname><given-names>M. F.</given-names></name><name><surname>Hurtig</surname><given-names>H. I.</given-names></name><name><surname>Ondo</surname><given-names>W. G.</given-names></name><name><surname>Wojcieszek</surname><given-names>J.</given-names></name><name><surname>Fitzer-Attas</surname><given-names>C. J.</given-names></name></person-group> (<year>2009</year>). <article-title>Long-term outcome of early versus delayed rasagiline treatment in early Parkinson&#x02019;s disease</article-title>. <source>Mov. Disord.</source> <volume>24</volume>, <fpage>564</fpage>&#x02013;<lpage>573</lpage><pub-id pub-id-type="doi">10.1002/mds.22402</pub-id><pub-id pub-id-type="pmid">19086083</pub-id></mixed-citation></ref><ref id="B111"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Heales</surname><given-names>S. J.</given-names></name><name><surname>Menzes</surname><given-names>A.</given-names></name><name><surname>Davey</surname><given-names>G. P.</given-names></name></person-group> (<year>2011</year>). <article-title>Depletion of glutathione does not affect electron transport chain complex activity in brain mitochondria: implications for Parkinson disease and postmortem studies</article-title>. <source>Free Radic. Biol. Med.</source> <volume>50</volume>, <fpage>899</fpage>&#x02013;<lpage>902</lpage><pub-id pub-id-type="doi">10.1016/j.freeradbiomed.2010.11.032</pub-id><pub-id pub-id-type="pmid">21145387</pub-id></mixed-citation></ref><ref id="B112"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Heikkila</surname><given-names>R. E.</given-names></name><name><surname>Manzino</surname><given-names>L.</given-names></name><name><surname>Cabbat</surname><given-names>F. S.</given-names></name><name><surname>Duvoisin</surname><given-names>R. C.</given-names></name></person-group> (<year>1985</year>). <article-title>Studies on the oxidation of the dopaminergic neurotoxin 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine by monoamine oxidase B</article-title>. <source>J. Neurochem.</source> <volume>45</volume>, <fpage>1049</fpage>&#x02013;<lpage>1054</lpage><pub-id pub-id-type="doi">10.1111/j.1471-4159.1985.tb05522.x</pub-id><pub-id pub-id-type="pmid">3928814</pub-id></mixed-citation></ref><ref id="B113"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hernan</surname><given-names>M. A.</given-names></name><name><surname>Logroscino</surname><given-names>G.</given-names></name><name><surname>Garcia Rodriguez</surname><given-names>L. A.</given-names></name></person-group> (<year>2006</year>). <article-title>Nonsteroidal anti-inflammatory drugs and the incidence of Parkinson disease</article-title>. <source>Neurology</source> <volume>66</volume>, <fpage>1097</fpage>&#x02013;<lpage>1099</lpage><pub-id pub-id-type="doi">10.1212/01.wnl.0000204446.82823.28</pub-id><pub-id pub-id-type="pmid">16606925</pub-id></mixed-citation></ref><ref id="B114"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hink</surname><given-names>H. U.</given-names></name><name><surname>Santanam</surname><given-names>N.</given-names></name><name><surname>Dikalov</surname><given-names>S.</given-names></name><name><surname>McCann</surname><given-names>L.</given-names></name><name><surname>Nguyen</surname><given-names>A. D.</given-names></name><name><surname>Parthasarathy</surname><given-names>S.</given-names></name><name><surname>Harrison</surname><given-names>D. G.</given-names></name><name><surname>Fukai</surname><given-names>T.</given-names></name></person-group> (<year>2002</year>). <article-title>Peroxidase properties of extracellular superoxide dismutase: role of uric acid in modulating in vivo activity</article-title>. <source>Arterioscler. Thromb. Vasc. Biol.</source> <volume>22</volume>, <fpage>1402</fpage>&#x02013;<lpage>1408</lpage><pub-id pub-id-type="doi">10.1161/01.ATV.0000027524.86752.02</pub-id><pub-id pub-id-type="pmid">12231557</pub-id></mixed-citation></ref><ref id="B115"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hirsch</surname><given-names>E. C.</given-names></name><name><surname>Hunot</surname><given-names>S.</given-names></name></person-group> (<year>2009</year>). <article-title>Neuroinflammation in Parkinson&#x02019;s disease: a target for neuroprotection?</article-title> <source>Lancet Neurol.</source> <volume>8</volume>, <fpage>382</fpage>&#x02013;<lpage>397</lpage><pub-id pub-id-type="doi">10.1016/S1474-4422(09)70062-6</pub-id><pub-id pub-id-type="pmid">19296921</pub-id></mixed-citation></ref><ref id="B116"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Holick</surname><given-names>M. F.</given-names></name></person-group> (<year>2007</year>). <article-title>Vitamin D deficiency</article-title>. <source>N. Engl. J. Med.</source> <volume>357</volume>, <fpage>266</fpage>&#x02013;<lpage>281</lpage><pub-id pub-id-type="doi">10.1056/NEJMra070553</pub-id><pub-id pub-id-type="pmid">17634462</pub-id></mixed-citation></ref><ref id="B117"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Holmes</surname><given-names>A. D.</given-names></name><name><surname>Copland</surname><given-names>D. A.</given-names></name><name><surname>Silburn</surname><given-names>P. A.</given-names></name><name><surname>Chenery</surname><given-names>H. J.</given-names></name></person-group> (<year>2011</year>). <article-title>Acute nicotine enhances strategy-based semantic processing in Parkinson&#x02019;s disease</article-title>. <source>Int. J. Neuropsychopharmacol.</source> <volume>14</volume>, <fpage>877</fpage>&#x02013;<lpage>885</lpage><pub-id pub-id-type="doi">10.1017/S1461145710001665</pub-id><pub-id pub-id-type="pmid">21281557</pub-id></mixed-citation></ref><ref id="B118"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Holst</surname><given-names>J. J.</given-names></name><name><surname>Burcelin</surname><given-names>R.</given-names></name><name><surname>Nathanson</surname><given-names>E.</given-names></name></person-group> (<year>2011</year>). <article-title>Neuroprotective properties of GLP-1: theoretical and practical applications</article-title>. <source>Curr. Med. Res. Opin.</source> <volume>27</volume>, <fpage>547</fpage>&#x02013;<lpage>558</lpage><pub-id pub-id-type="doi">10.1185/03007995.2010.549466</pub-id><pub-id pub-id-type="pmid">21222567</pub-id></mixed-citation></ref><ref id="B119"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Horrocks</surname><given-names>L. A.</given-names></name><name><surname>Yeo</surname><given-names>Y. K.</given-names></name></person-group> (<year>1999</year>). <article-title>Health benefits of docosahexaenoic acid (DHA)</article-title>. <source>Pharmacol. Res.</source> <volume>40</volume>, <fpage>211</fpage>&#x02013;<lpage>225</lpage><pub-id pub-id-type="doi">10.1006/phrs.1999.0495</pub-id><pub-id pub-id-type="pmid">10479465</pub-id></mixed-citation></ref><ref id="B120"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Huang</surname><given-names>W.</given-names></name><name><surname>Chen</surname><given-names>Y.</given-names></name><name><surname>Shohami</surname><given-names>E.</given-names></name><name><surname>Weinstock</surname><given-names>M.</given-names></name></person-group> (<year>1999</year>). <article-title>Neuroprotective effect of rasagiline, a selective monoamine oxidase-B inhibitor, against closed head injury in the mouse</article-title>. <source>Eur. J. Pharmacol.</source> <volume>366</volume>, <fpage>127</fpage>&#x02013;<lpage>135</lpage><pub-id pub-id-type="doi">10.1016/S0014-2999(98)00918-2</pub-id><pub-id pub-id-type="pmid">10082192</pub-id></mixed-citation></ref><ref id="B121"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Huennekens</surname><given-names>F. M.</given-names></name></person-group> (<year>1956</year>). <article-title>Flavin nucleotides and flavoproteins</article-title>. <source>Experientia</source> <volume>12</volume>, <fpage>1</fpage>&#x02013;<lpage>6</lpage><pub-id pub-id-type="doi">10.1007/BF02156978</pub-id><pub-id pub-id-type="pmid">13305564</pub-id></mixed-citation></ref><ref id="B122"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ibanez</surname><given-names>P.</given-names></name><name><surname>De Michele</surname><given-names>G.</given-names></name><name><surname>Bonifati</surname><given-names>V.</given-names></name><name><surname>Lohmann</surname><given-names>E.</given-names></name><name><surname>Thobois</surname><given-names>S.</given-names></name><name><surname>Pollak</surname><given-names>P.</given-names></name><name><surname>Agid</surname><given-names>Y.</given-names></name><name><surname>Heutink</surname><given-names>P.</given-names></name><name><surname>Durr</surname><given-names>A.</given-names></name><name><surname>Brice</surname><given-names>A.</given-names></name></person-group> (<year>2003</year>). <article-title>Screening for DJ-1 mutations in early onset autosomal recessive parkinsonism</article-title>. <source>Neurology</source> <volume>61</volume>, <fpage>1429</fpage>&#x02013;<lpage>1431</lpage><pub-id pub-id-type="pmid">14638971</pub-id></mixed-citation></ref><ref id="B123"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Iida</surname><given-names>M.</given-names></name><name><surname>Miyazaki</surname><given-names>I.</given-names></name><name><surname>Tanaka</surname><given-names>K.</given-names></name><name><surname>Kabuto</surname><given-names>H.</given-names></name><name><surname>Iwata-Ichikawa</surname><given-names>E.</given-names></name><name><surname>Ogawa</surname><given-names>N.</given-names></name></person-group> (<year>1999</year>). <article-title>Dopamine D2 receptor-mediated antioxidant and neuroprotective effects of ropinirole, a dopamine agonist</article-title>. <source>Brain Res.</source> <volume>838</volume>, <fpage>51</fpage>&#x02013;<lpage>59</lpage><pub-id pub-id-type="doi">10.1016/S0006-8993(99)01688-1</pub-id><pub-id pub-id-type="pmid">10446316</pub-id></mixed-citation></ref><ref id="B124"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ilijic</surname><given-names>E.</given-names></name><name><surname>Guzman</surname><given-names>J. N.</given-names></name><name><surname>Surmeier</surname><given-names>D. J.</given-names></name></person-group> (<year>2011</year>). <article-title>The L-type channel antagonist isradipine is neuroprotective in a mouse model of Parkinson&#x02019;s disease</article-title>. <source>Neurobiol. Dis.</source> <volume>43</volume>, <fpage>364</fpage>&#x02013;<lpage>371</lpage><pub-id pub-id-type="doi">10.1016/j.nbd.2011.04.007</pub-id><pub-id pub-id-type="pmid">21515375</pub-id></mixed-citation></ref><ref id="B125"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Inden</surname><given-names>M.</given-names></name><name><surname>Kitamura</surname><given-names>Y.</given-names></name><name><surname>Takeuchi</surname><given-names>H.</given-names></name><name><surname>Yanagida</surname><given-names>T.</given-names></name><name><surname>Takata</surname><given-names>K.</given-names></name><name><surname>Kobayashi</surname><given-names>Y.</given-names></name><name><surname>Taniguchi</surname><given-names>T.</given-names></name><name><surname>Yoshimoto</surname><given-names>K.</given-names></name><name><surname>Kaneko</surname><given-names>M.</given-names></name><name><surname>Okuma</surname><given-names>Y.</given-names></name><name><surname>Taira</surname><given-names>T.</given-names></name><name><surname>Ariga</surname><given-names>H.</given-names></name><name><surname>Shimohama</surname><given-names>S.</given-names></name></person-group> (<year>2007</year>). <article-title>Neurodegeneration of mouse nigrostriatal dopaminergic system induced by repeated oral administration of rotenone is prevented by 4-phenylbutyrate, a chemical chaperone</article-title>. <source>J. Neurochem.</source> <volume>101</volume>, <fpage>1491</fpage>&#x02013;<lpage>1504</lpage><pub-id pub-id-type="doi">10.1111/j.1471-4159.2006.04440.x</pub-id><pub-id pub-id-type="pmid">17459145</pub-id></mixed-citation></ref><ref id="B126"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Investigators</surname><given-names>N. N.-P.</given-names></name></person-group> (<year>2006</year>). <article-title>A randomized, double-blind, futility clinical trial of creatine and minocycline in early Parkinson disease</article-title>. <source>Neurology</source> <volume>66</volume>, <fpage>664</fpage>&#x02013;<lpage>671</lpage><pub-id pub-id-type="doi">10.1212/01.wnl.0000201252.57661.e1</pub-id><pub-id pub-id-type="pmid">16481597</pub-id></mixed-citation></ref><ref id="B127"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Investigators</surname><given-names>N. N.-P.</given-names></name></person-group> (<year>2007</year>). <article-title>A randomized clinical trial of coenzyme Q10 and GPI-1485 in early Parkinson disease</article-title>. <source>Neurology</source> <volume>68</volume>, <fpage>20</fpage>&#x02013;<lpage>28</lpage><pub-id pub-id-type="doi">10.1212/01.wnl.0000250355.28474.8e</pub-id><pub-id pub-id-type="pmid">17200487</pub-id></mixed-citation></ref><ref id="B128"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Investigators</surname><given-names>N. N.-P.</given-names></name></person-group> (<year>2008</year>). <article-title>A pilot clinical trial of creatine and minocycline in early Parkinson disease: 18-month results</article-title>. <source>Clin. Neuropharmacol.</source> <volume>31</volume>, <fpage>141</fpage>&#x02013;<lpage>150</lpage><pub-id pub-id-type="doi">10.1097/WNF.0b013e3181342f32</pub-id><pub-id pub-id-type="pmid">18520981</pub-id></mixed-citation></ref><ref id="B129"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jeerakathil</surname><given-names>T.</given-names></name><name><surname>Johnson</surname><given-names>J. A.</given-names></name><name><surname>Simpson</surname><given-names>S. H.</given-names></name><name><surname>Majumdar</surname><given-names>S. R.</given-names></name></person-group> (<year>2007</year>). <article-title>Short-term risk for stroke is doubled in persons with newly treated type 2 diabetes compared with persons without diabetes: a population-based cohort study</article-title>. <source>Stroke</source> <volume>38</volume>, <fpage>1739</fpage>&#x02013;<lpage>1743</lpage><pub-id pub-id-type="doi">10.1161/STROKEAHA.106.481390</pub-id><pub-id pub-id-type="pmid">17478738</pub-id></mixed-citation></ref><ref id="B130"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jenner</surname><given-names>P.</given-names></name></person-group> (<year>2003</year>). <article-title>Oxidative stress in Parkinson&#x02019;s disease</article-title>. <source>Ann. Neurol.</source> <volume>53</volume>(<issue>Suppl. 3</issue>), <fpage>S26</fpage>&#x02013;<lpage>S36</lpage>; discussion S36&#x02013;S28.<pub-id pub-id-type="doi">10.1002/ana.10483</pub-id><pub-id pub-id-type="pmid">12666096</pub-id></mixed-citation></ref><ref id="B131"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jenner</surname><given-names>P.</given-names></name><name><surname>Schapira</surname><given-names>A. H.</given-names></name><name><surname>Marsden</surname><given-names>C. D.</given-names></name></person-group> (<year>1992</year>). <article-title>New insights into the cause of Parkinson&#x02019;s disease</article-title>. <source>Neurology</source> <volume>42</volume>, <fpage>2241</fpage>&#x02013;<lpage>2250</lpage><pub-id pub-id-type="pmid">1461374</pub-id></mixed-citation></ref><ref id="B132"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jimenez-Jimenez</surname><given-names>F. J.</given-names></name><name><surname>Molina</surname><given-names>J. A.</given-names></name><name><surname>Fernandez-Calle</surname><given-names>P.</given-names></name><name><surname>Vazquez</surname><given-names>A.</given-names></name><name><surname>Cabrera-Valdivia</surname><given-names>F.</given-names></name><name><surname>Catalan</surname><given-names>M. J.</given-names></name><name><surname>Garcia-Albea</surname><given-names>E.</given-names></name><name><surname>Bermejo</surname><given-names>F.</given-names></name><name><surname>Codoceo</surname><given-names>R.</given-names></name></person-group> (<year>1993</year>). <article-title>Serum levels of beta-carotene and other carotenoids in Parkinson&#x02019;s disease</article-title>. <source>Neurosci. Lett.</source> <volume>157</volume>, <fpage>103</fpage>&#x02013;<lpage>106</lpage><pub-id pub-id-type="doi">10.1016/0304-3940(93)90653-3</pub-id><pub-id pub-id-type="pmid">8233018</pub-id></mixed-citation></ref><ref id="B133"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Joghataie</surname><given-names>M. T.</given-names></name><name><surname>Roghani</surname><given-names>M.</given-names></name><name><surname>Negahdar</surname><given-names>F.</given-names></name><name><surname>Hashemi</surname><given-names>L.</given-names></name></person-group> (<year>2004</year>). <article-title>Protective effect of caffeine against neurodegeneration in a model of Parkinson&#x02019;s disease in rat: behavioral and histochemical evidence</article-title>. <source>Parkinsonism Relat. Disord.</source> <volume>10</volume>, <fpage>465</fpage>&#x02013;<lpage>468</lpage><pub-id pub-id-type="doi">10.1016/j.parkreldis.2004.06.004</pub-id><pub-id pub-id-type="pmid">15542005</pub-id></mixed-citation></ref><ref id="B134"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jones</surname><given-names>D. C.</given-names></name><name><surname>Gunasekar</surname><given-names>P. G.</given-names></name><name><surname>Borowitz</surname><given-names>J. L.</given-names></name><name><surname>Isom</surname><given-names>G. E.</given-names></name></person-group> (<year>2000</year>). <article-title>Dopamine-induced apoptosis is mediated by oxidative stress and is enhanced by cyanide in differentiated PC12 cells</article-title>. <source>J. Neurochem.</source> <volume>74</volume>, <fpage>2296</fpage>&#x02013;<lpage>2304</lpage><pub-id pub-id-type="doi">10.1046/j.1471-4159.2000.0742296.x</pub-id><pub-id pub-id-type="pmid">10820189</pub-id></mixed-citation></ref><ref id="B135"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jump</surname><given-names>D. B.</given-names></name></person-group> (<year>2002</year>). <article-title>Dietary polyunsaturated fatty acids and regulation of gene transcription</article-title>. <source>Curr. Opin. Lipidol.</source> <volume>13</volume>, <fpage>155</fpage>&#x02013;<lpage>164</lpage><pub-id pub-id-type="doi">10.1097/00041433-200204000-00007</pub-id><pub-id pub-id-type="pmid">11891418</pub-id></mixed-citation></ref><ref id="B136"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kachroo</surname><given-names>A.</given-names></name><name><surname>Irizarry</surname><given-names>M. C.</given-names></name><name><surname>Schwarzschild</surname><given-names>M. A.</given-names></name></person-group> (<year>2010</year>). <article-title>Caffeine protects against combined paraquat and maneb-induced dopaminergic neuron degeneration</article-title>. <source>Exp. Neurol.</source> <volume>223</volume>, <fpage>657</fpage>&#x02013;<lpage>661</lpage><pub-id pub-id-type="doi">10.1016/j.expneurol.2010.02.007</pub-id><pub-id pub-id-type="pmid">20188092</pub-id></mixed-citation></ref><ref id="B137"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kaempf-Rotzoll</surname><given-names>D. E.</given-names></name><name><surname>Traber</surname><given-names>M. G.</given-names></name><name><surname>Arai</surname><given-names>H.</given-names></name></person-group> (<year>2003</year>). <article-title>Vitamin E and transfer proteins</article-title>. <source>Curr. Opin. Lipidol.</source> <volume>14</volume>, <fpage>249</fpage>&#x02013;<lpage>254</lpage><pub-id pub-id-type="doi">10.1097/00041433-200306000-00004</pub-id><pub-id pub-id-type="pmid">12840655</pub-id></mixed-citation></ref><ref id="B138"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kartha</surname><given-names>V. N.</given-names></name><name><surname>Krishnamurthy</surname><given-names>S.</given-names></name></person-group> (<year>1977</year>). <article-title>Antioxidant function of vitamin A</article-title>. <source>Int. J. Vitam. Nutr. Res.</source> <volume>47</volume>, <fpage>394</fpage>&#x02013;<lpage>401</lpage><pub-id pub-id-type="pmid">22507</pub-id></mixed-citation></ref><ref id="B139"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kaufmann</surname><given-names>W. E.</given-names></name><name><surname>Andreasson</surname><given-names>K. I.</given-names></name><name><surname>Isakson</surname><given-names>P. C.</given-names></name><name><surname>Worley</surname><given-names>P. F.</given-names></name></person-group> (<year>1997</year>). <article-title>Cyclooxygenases and the central nervous system</article-title>. <source>Prostaglandins</source> <volume>54</volume>, <fpage>601</fpage>&#x02013;<lpage>624</lpage><pub-id pub-id-type="doi">10.1016/S0090-6980(97)00128-7</pub-id><pub-id pub-id-type="pmid">9373877</pub-id></mixed-citation></ref><ref id="B140"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Khaldy</surname><given-names>H.</given-names></name><name><surname>Escames</surname><given-names>G.</given-names></name><name><surname>Leon</surname><given-names>J.</given-names></name><name><surname>Vives</surname><given-names>F.</given-names></name><name><surname>Luna</surname><given-names>J. D.</given-names></name><name><surname>Acuna-Castroviejo</surname><given-names>D.</given-names></name></person-group> (<year>2000</year>). <article-title>Comparative effects of melatonin, L-deprenyl, Trolox and ascorbate in the suppression of hydroxyl radical formation during dopamine autoxidation in vitro</article-title>. <source>J. Pineal Res.</source> <volume>29</volume>, <fpage>100</fpage>&#x02013;<lpage>107</lpage><pub-id pub-id-type="doi">10.1034/j.1600-079X.2000.290206.x</pub-id><pub-id pub-id-type="pmid">10981823</pub-id></mixed-citation></ref><ref id="B141"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kim</surname><given-names>H. Y.</given-names></name></person-group> (<year>2007</year>). <article-title>Novel metabolism of docosahexaenoic acid in neural cells</article-title>. <source>J. Biol. Chem.</source> <volume>282</volume>, <fpage>18661</fpage>&#x02013;<lpage>18665</lpage><pub-id pub-id-type="doi">10.1074/jbc.R700015200</pub-id><pub-id pub-id-type="pmid">17488715</pub-id></mixed-citation></ref><ref id="B142"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kim</surname><given-names>S.</given-names></name><name><surname>Moon</surname><given-names>M.</given-names></name><name><surname>Park</surname><given-names>S.</given-names></name></person-group> (<year>2009</year>). <article-title>Exendin-4 protects dopaminergic neurons by inhibition of microglial activation and matrix metalloproteinase-3 expression in an animal model of Parkinson&#x02019;s disease</article-title>. <source>J. Endocrinol.</source> <volume>202</volume>, <fpage>431</fpage>&#x02013;<lpage>439</lpage><pub-id pub-id-type="doi">10.1677/JOE-09-0132</pub-id><pub-id pub-id-type="pmid">19570816</pub-id></mixed-citation></ref><ref id="B143"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kim</surname><given-names>Y. S.</given-names></name><name><surname>Joo</surname><given-names>W. S.</given-names></name><name><surname>Jin</surname><given-names>B. K.</given-names></name><name><surname>Cho</surname><given-names>Y. H.</given-names></name><name><surname>Baik</surname><given-names>H. H.</given-names></name><name><surname>Park</surname><given-names>C. W.</given-names></name></person-group> (<year>1998</year>). <article-title>Melatonin protects 6-OHDA-induced neuronal death of nigrostriatal dopaminergic system</article-title>. <source>Neuroreport</source> <volume>9</volume>, <fpage>2387</fpage>&#x02013;<lpage>2390</lpage><pub-id pub-id-type="doi">10.1097/00001756-199807130-00043</pub-id><pub-id pub-id-type="pmid">9694233</pub-id></mixed-citation></ref><ref id="B144"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Klivenyi</surname><given-names>P.</given-names></name><name><surname>Andreassen</surname><given-names>O. A.</given-names></name><name><surname>Ferrante</surname><given-names>R. J.</given-names></name><name><surname>Dedeoglu</surname><given-names>A.</given-names></name><name><surname>Mueller</surname><given-names>G.</given-names></name><name><surname>Lancelot</surname><given-names>E.</given-names></name><name><surname>Bogdanov</surname><given-names>M.</given-names></name><name><surname>Andersen</surname><given-names>J. K.</given-names></name><name><surname>Jiang</surname><given-names>D.</given-names></name><name><surname>Beal</surname><given-names>M. F.</given-names></name></person-group> (<year>2000</year>). <article-title>Mice deficient in cellular glutathione peroxidase show increased vulnerability to malonate, 3-nitropropionic acid, and 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine</article-title>. <source>J. Neurosci.</source> <volume>20</volume>, <fpage>1</fpage>&#x02013;<lpage>7</lpage><pub-id pub-id-type="pmid">10627575</pub-id></mixed-citation></ref><ref id="B145"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kordower</surname><given-names>J. H.</given-names></name><name><surname>Emborg</surname><given-names>M. E.</given-names></name><name><surname>Bloch</surname><given-names>J.</given-names></name><name><surname>Ma</surname><given-names>S. Y.</given-names></name><name><surname>Chu</surname><given-names>Y.</given-names></name><name><surname>Leventhal</surname><given-names>L.</given-names></name><name><surname>McBride</surname><given-names>J.</given-names></name><name><surname>Chen</surname><given-names>E. Y.</given-names></name><name><surname>Palfi</surname><given-names>S.</given-names></name><name><surname>Roitberg</surname><given-names>B. Z.</given-names></name><name><surname>Brown</surname><given-names>W. D.</given-names></name><name><surname>Holden</surname><given-names>J. E.</given-names></name><name><surname>Pyzalski</surname><given-names>R.</given-names></name><name><surname>Taylor</surname><given-names>M. D.</given-names></name><name><surname>Carvey</surname><given-names>P.</given-names></name><name><surname>Ling</surname><given-names>Z.</given-names></name><name><surname>Trono</surname><given-names>D.</given-names></name><name><surname>Hantraye</surname><given-names>P.</given-names></name><name><surname>Deglon</surname><given-names>N.</given-names></name><name><surname>Aebischer</surname><given-names>P.</given-names></name></person-group> (<year>2000</year>). <article-title>Neurodegeneration prevented by lentiviral vector delivery of GDNF in primate models of Parkinson&#x02019;s disease</article-title>. <source>Science</source> <volume>290</volume>, <fpage>767</fpage>&#x02013;<lpage>773</lpage><pub-id pub-id-type="doi">10.1126/science.290.5492.767</pub-id><pub-id pub-id-type="pmid">11052933</pub-id></mixed-citation></ref><ref id="B146"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kumar</surname><given-names>C.</given-names></name><name><surname>Igbaria</surname><given-names>A.</given-names></name><name><surname>D&#x02019;Autreaux</surname><given-names>B.</given-names></name><name><surname>Planson</surname><given-names>A. G.</given-names></name><name><surname>Junot</surname><given-names>C.</given-names></name><name><surname>Godat</surname><given-names>E.</given-names></name><name><surname>Bachhawat</surname><given-names>A. K.</given-names></name><name><surname>Delaunay-Moisan</surname><given-names>A.</given-names></name><name><surname>Toledano</surname><given-names>M. B.</given-names></name></person-group> (<year>2011</year>). <article-title>Glutathione revisited: a vital function in iron metabolism and ancillary role in thiol-redox control</article-title>. <source>EMBO J.</source> <volume>30</volume>, <fpage>2044</fpage>&#x02013;<lpage>2056</lpage><pub-id pub-id-type="doi">10.1038/emboj.2011.138</pub-id><pub-id pub-id-type="pmid">21478822</pub-id></mixed-citation></ref><ref id="B147"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kupsch</surname><given-names>A.</given-names></name><name><surname>Gerlach</surname><given-names>M.</given-names></name><name><surname>Pupeter</surname><given-names>S. C.</given-names></name><name><surname>Sautter</surname><given-names>J.</given-names></name><name><surname>Dirr</surname><given-names>A.</given-names></name><name><surname>Arnold</surname><given-names>G.</given-names></name><name><surname>Opitz</surname><given-names>W.</given-names></name><name><surname>Przuntek</surname><given-names>H.</given-names></name><name><surname>Riederer</surname><given-names>P.</given-names></name><name><surname>Oertel</surname><given-names>W. H.</given-names></name></person-group> (<year>1995</year>). <article-title>Pretreatment with nimodipine prevents MPTP-induced neurotoxicity at the nigral, but not at the striatal level in mice</article-title>. <source>Neuroreport</source> <volume>6</volume>, <fpage>621</fpage>&#x02013;<lpage>625</lpage><pub-id pub-id-type="doi">10.1097/00001756-199503000-00009</pub-id><pub-id pub-id-type="pmid">7605913</pub-id></mixed-citation></ref><ref id="B148"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kupsch</surname><given-names>A.</given-names></name><name><surname>Sautter</surname><given-names>J.</given-names></name><name><surname>Gotz</surname><given-names>M. E.</given-names></name><name><surname>Breithaupt</surname><given-names>W.</given-names></name><name><surname>Schwarz</surname><given-names>J.</given-names></name><name><surname>Youdim</surname><given-names>M. B.</given-names></name><name><surname>Riederer</surname><given-names>P.</given-names></name><name><surname>Gerlach</surname><given-names>M.</given-names></name><name><surname>Oertel</surname><given-names>W. H.</given-names></name></person-group> (<year>2001</year>). <article-title>Monoamine oxidase-inhibition and MPTP-induced neurotoxicity in the non-human primate: comparison of rasagiline (TVP 1012) with selegiline</article-title>. <source>J. Neural Transm.</source> <volume>108</volume>, <fpage>985</fpage>&#x02013;<lpage>1009</lpage><pub-id pub-id-type="doi">10.1007/s007020170018</pub-id><pub-id pub-id-type="pmid">11716151</pub-id></mixed-citation></ref><ref id="B149"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kupsch</surname><given-names>A.</given-names></name><name><surname>Sautter</surname><given-names>J.</given-names></name><name><surname>Schwarz</surname><given-names>J.</given-names></name><name><surname>Riederer</surname><given-names>P.</given-names></name><name><surname>Gerlach</surname><given-names>M.</given-names></name><name><surname>Oertel</surname><given-names>W. H.</given-names></name></person-group> (<year>1996</year>). <article-title>1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced neurotoxicity in non-human primates is antagonized by pretreatment with nimodipine at the nigral, but not at the striatal level</article-title>. <source>Brain Res.</source> <volume>741</volume>, <fpage>185</fpage>&#x02013;<lpage>196</lpage><pub-id pub-id-type="doi">10.1016/S0006-8993(96)00917-1</pub-id><pub-id pub-id-type="pmid">9001722</pub-id></mixed-citation></ref><ref id="B150"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lan</surname><given-names>J.</given-names></name><name><surname>Jiang</surname><given-names>D. H.</given-names></name></person-group> (<year>1997</year>). <article-title>Desferrioxamine and vitamin E protect against iron and MPTP-induced neurodegeneration in mice</article-title>. <source>J. Neural Transm.</source> <volume>104</volume>, <fpage>469</fpage>&#x02013;<lpage>481</lpage><pub-id pub-id-type="doi">10.1007/BF01291883</pub-id><pub-id pub-id-type="pmid">9295179</pub-id></mixed-citation></ref><ref id="B151"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lang</surname><given-names>A. E.</given-names></name><name><surname>Lozano</surname><given-names>A. M.</given-names></name></person-group> (<year>1998</year>). <article-title>Parkinson&#x02019;s disease. First of two parts</article-title>. <source>N. Engl. J. Med.</source> <volume>339</volume>, <fpage>1044</fpage>&#x02013;<lpage>1053</lpage><pub-id pub-id-type="doi">10.1056/NEJM199810153391607</pub-id><pub-id pub-id-type="pmid">9761807</pub-id></mixed-citation></ref><ref id="B152"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Langston</surname><given-names>J. W.</given-names></name></person-group> (<year>1998</year>). <article-title>Epidemiology versus genetics in Parkinson&#x02019;s disease: progress in resolving an age-old debate</article-title>. <source>Ann. Neurol.</source> <volume>44</volume>, <fpage>S45</fpage>&#x02013;<lpage>S52</lpage><pub-id pub-id-type="doi">10.1002/ana.410440239</pub-id><pub-id pub-id-type="pmid">9749572</pub-id></mixed-citation></ref><ref id="B153"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lawler</surname><given-names>J. M.</given-names></name><name><surname>Barnes</surname><given-names>W. S.</given-names></name><name><surname>Wu</surname><given-names>G.</given-names></name><name><surname>Song</surname><given-names>W.</given-names></name><name><surname>Demaree</surname><given-names>S.</given-names></name></person-group> (<year>2002</year>). <article-title>Direct antioxidant properties of creatine</article-title>. <source>Biochem. Biophys. Res. Commun.</source> <volume>290</volume>, <fpage>47</fpage>&#x02013;<lpage>52</lpage><pub-id pub-id-type="doi">10.1006/bbrc.2001.6164</pub-id><pub-id pub-id-type="pmid">11779131</pub-id></mixed-citation></ref><ref id="B154"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lazaroff</surname><given-names>M.</given-names></name><name><surname>Patankar</surname><given-names>S.</given-names></name><name><surname>Yoon</surname><given-names>S. O.</given-names></name><name><surname>Chikaraishi</surname><given-names>D. M.</given-names></name></person-group> (<year>1995</year>). <article-title>The cyclic AMP response element directs tyrosine hydroxylase expression in catecholaminergic central and peripheral nervous system cell lines from transgenic mice</article-title>. <source>J. Biol. Chem.</source> <volume>270</volume>, <fpage>21579</fpage>&#x02013;<lpage>21589</lpage><pub-id pub-id-type="doi">10.1074/jbc.270.37.21579</pub-id><pub-id pub-id-type="pmid">7665571</pub-id></mixed-citation></ref><ref id="B155"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>LeWitt</surname><given-names>P. A.</given-names></name></person-group> (<year>1994</year>). <article-title>Clinical trials of neuroprotection in Parkinson&#x02019;s disease: long-term selegiline and alpha-tocopherol treatment</article-title>. <source>J. Neural Transm. Suppl.</source> <volume>43</volume>, <fpage>171</fpage>&#x02013;<lpage>181</lpage><pub-id pub-id-type="pmid">7884399</pub-id></mixed-citation></ref><ref id="B156"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>Y.</given-names></name><name><surname>Liu</surname><given-names>L.</given-names></name><name><surname>Barger</surname><given-names>S. W.</given-names></name><name><surname>Mrak</surname><given-names>R. E.</given-names></name><name><surname>Griffin</surname><given-names>W. S.</given-names></name></person-group> (<year>2001</year>). <article-title>Vitamin E suppression of microglial activation is neuroprotective</article-title>. <source>J. Neurosci. Res.</source> <volume>66</volume>, <fpage>163</fpage>&#x02013;<lpage>170</lpage><pub-id pub-id-type="doi">10.1002/jnr.1208</pub-id><pub-id pub-id-type="pmid">11592111</pub-id></mixed-citation></ref><ref id="B157"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>Y.</given-names></name><name><surname>Perry</surname><given-names>T.</given-names></name><name><surname>Kindy</surname><given-names>M. S.</given-names></name><name><surname>Harvey</surname><given-names>B. K.</given-names></name><name><surname>Tweedie</surname><given-names>D.</given-names></name><name><surname>Holloway</surname><given-names>H. W.</given-names></name><name><surname>Powers</surname><given-names>K.</given-names></name><name><surname>Shen</surname><given-names>H.</given-names></name><name><surname>Egan</surname><given-names>J. M.</given-names></name><name><surname>Sambamurti</surname><given-names>K.</given-names></name><name><surname>Brossi</surname><given-names>A.</given-names></name><name><surname>Lahiri</surname><given-names>D. K.</given-names></name><name><surname>Mattson</surname><given-names>M. P.</given-names></name><name><surname>Hoffer</surname><given-names>B. J.</given-names></name><name><surname>Wang</surname><given-names>Y.</given-names></name><name><surname>Greig</surname><given-names>N. H.</given-names></name></person-group> (<year>2009</year>). <article-title>GLP-1 receptor stimulation preserves primary cortical and dopaminergic neurons in cellular and rodent models of stroke and Parkinsonism</article-title>. <source>Proc. Natl. Acad. Sci. U.S.A.</source> <volume>106</volume>, <fpage>1285</fpage>&#x02013;<lpage>1290</lpage><pub-id pub-id-type="doi">10.1073/pnas.0900922106</pub-id><pub-id pub-id-type="pmid">19164583</pub-id></mixed-citation></ref><ref id="B158"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lim</surname><given-names>G. P.</given-names></name><name><surname>Calon</surname><given-names>F.</given-names></name><name><surname>Morihara</surname><given-names>T.</given-names></name><name><surname>Yang</surname><given-names>F.</given-names></name><name><surname>Teter</surname><given-names>B.</given-names></name><name><surname>Ubeda</surname><given-names>O.</given-names></name><name><surname>Salem</surname><given-names>N.</given-names><suffix>Jr.</suffix></name><name><surname>Frautschy</surname><given-names>S. A.</given-names></name><name><surname>Cole</surname><given-names>G. M.</given-names></name></person-group> (<year>2005</year>). <article-title>A diet enriched with the omega-3 fatty acid docosahexaenoic acid reduces amyloid burden in an aged Alzheimer mouse model</article-title>. <source>J. Neurosci.</source> <volume>25</volume>, <fpage>3032</fpage>&#x02013;<lpage>3040</lpage><pub-id pub-id-type="doi">10.1523/JNEUROSCI.4474-04.2005</pub-id><pub-id pub-id-type="pmid">15788759</pub-id></mixed-citation></ref><ref id="B159"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Linville</surname><given-names>D. G.</given-names></name><name><surname>Williams</surname><given-names>S.</given-names></name><name><surname>Raszkiewicz</surname><given-names>J. L.</given-names></name><name><surname>Arneric</surname><given-names>S. P.</given-names></name></person-group> (<year>1993</year>). <article-title>Nicotinic agonists modulate basal forebrain control of cortical cerebral blood flow in anesthetized rats</article-title>. <source>J. Pharmacol. Exp. Ther.</source> <volume>267</volume>, <fpage>440</fpage>&#x02013;<lpage>448</lpage><pub-id pub-id-type="pmid">8229773</pub-id></mixed-citation></ref><ref id="B160"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Logroscino</surname><given-names>G.</given-names></name><name><surname>Marder</surname><given-names>K.</given-names></name><name><surname>Graziano</surname><given-names>J.</given-names></name><name><surname>Freyer</surname><given-names>G.</given-names></name><name><surname>Slavkovich</surname><given-names>V.</given-names></name><name><surname>LoIacono</surname><given-names>N.</given-names></name><name><surname>Cote</surname><given-names>L.</given-names></name><name><surname>Mayeux</surname><given-names>R.</given-names></name></person-group> (<year>1997</year>). <article-title>Altered systemic iron metabolism in Parkinson&#x02019;s disease</article-title>. <source>Neurology</source> <volume>49</volume>, <fpage>714</fpage>&#x02013;<lpage>717</lpage><pub-id pub-id-type="pmid">9305329</pub-id></mixed-citation></ref><ref id="B161"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Maggio</surname><given-names>R.</given-names></name><name><surname>Riva</surname><given-names>M.</given-names></name><name><surname>Vaglini</surname><given-names>F.</given-names></name><name><surname>Fornai</surname><given-names>F.</given-names></name><name><surname>Racagni</surname><given-names>G.</given-names></name><name><surname>Corsini</surname><given-names>G. U.</given-names></name></person-group> (<year>1997</year>). <article-title>Striatal increase of neurotrophic factors as a mechanism of nicotine protection in experimental parkinsonism</article-title>. <source>J. Neural Transm.</source> <volume>104</volume>, <fpage>1113</fpage>&#x02013;<lpage>1123</lpage><pub-id pub-id-type="doi">10.1007/BF01273324</pub-id><pub-id pub-id-type="pmid">9503263</pub-id></mixed-citation></ref><ref id="B162"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Maharaj</surname><given-names>D. S.</given-names></name><name><surname>Maharaj</surname><given-names>H.</given-names></name><name><surname>Daya</surname><given-names>S.</given-names></name><name><surname>Glass</surname><given-names>B. D.</given-names></name></person-group> (<year>2006a</year>). <article-title>Melatonin and 6-hydroxymelatonin protect against iron-induced neurotoxicity</article-title>. <source>J. Neurochem.</source> <volume>96</volume>, <fpage>78</fpage>&#x02013;<lpage>81</lpage><pub-id pub-id-type="doi">10.1111/j.1471-4159.2005.03532.x</pub-id><pub-id pub-id-type="pmid">16300638</pub-id></mixed-citation></ref><ref id="B163"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Maharaj</surname><given-names>H.</given-names></name><name><surname>Maharaj</surname><given-names>D. S.</given-names></name><name><surname>Daya</surname><given-names>S.</given-names></name></person-group> (<year>2006b</year>). <article-title>Acetylsalicylic acid and acetaminophen protect against MPP+-induced mitochondrial damage and superoxide anion generation</article-title>. <source>Life Sci.</source> <volume>78</volume>, <fpage>2438</fpage>&#x02013;<lpage>2443</lpage><pub-id pub-id-type="doi">10.1016/j.lfs.2005.10.002</pub-id><pub-id pub-id-type="pmid">16318861</pub-id></mixed-citation></ref><ref id="B164"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Martin</surname><given-names>H. L.</given-names></name><name><surname>Teismann</surname><given-names>P.</given-names></name></person-group> (<year>2009</year>). <article-title>Glutathione &#x02013; a review on its role and significance in Parkinson&#x02019;s disease</article-title>. <source>FASEB J.</source> <volume>23</volume>, <fpage>3263</fpage>&#x02013;<lpage>3272</lpage><pub-id pub-id-type="doi">10.1096/fj.08-119628</pub-id><pub-id pub-id-type="pmid">19542204</pub-id></mixed-citation></ref><ref id="B165"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Martin</surname><given-names>V.</given-names></name><name><surname>Sainz</surname><given-names>R. M.</given-names></name><name><surname>Antolin</surname><given-names>I.</given-names></name><name><surname>Mayo</surname><given-names>J. C.</given-names></name><name><surname>Herrera</surname><given-names>F.</given-names></name><name><surname>Rodriguez</surname><given-names>C.</given-names></name></person-group> (<year>2002</year>). <article-title>Several antioxidant pathways are involved in astrocyte protection by melatonin</article-title>. <source>J. Pineal Res.</source> <volume>33</volume>, <fpage>204</fpage>&#x02013;<lpage>212</lpage><pub-id pub-id-type="doi">10.1034/j.1600-079X.2002.02113.x</pub-id><pub-id pub-id-type="pmid">12390502</pub-id></mixed-citation></ref><ref id="B166"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Maruyama</surname><given-names>W.</given-names></name><name><surname>Akao</surname><given-names>Y.</given-names></name><name><surname>Youdim</surname><given-names>M. B.</given-names></name><name><surname>Naoi</surname><given-names>M.</given-names></name></person-group> (<year>2000</year>). <article-title>Neurotoxins induce apoptosis in dopamine neurons: protection by N-propargylamine-1(R)- and (S)-aminoindan, rasagiline and TV1022</article-title>. <source>J. Neural Transm. Suppl.</source> <volume>60</volume>, <fpage>171</fpage>&#x02013;<lpage>186</lpage><pub-id pub-id-type="pmid">11205138</pub-id></mixed-citation></ref><ref id="B167"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Massaro</surname><given-names>M.</given-names></name><name><surname>Habib</surname><given-names>A.</given-names></name><name><surname>Lubrano</surname><given-names>L.</given-names></name><name><surname>Del Turco</surname><given-names>S.</given-names></name><name><surname>Lazzerini</surname><given-names>G.</given-names></name><name><surname>Bourcier</surname><given-names>T.</given-names></name><name><surname>Weksler</surname><given-names>B. B.</given-names></name><name><surname>De Caterina</surname><given-names>R.</given-names></name></person-group> (<year>2006</year>). <article-title>The omega-3 fatty acid docosahexaenoate attenuates endothelial cyclooxygenase-2 induction through both NADP(H) oxidase and PKC epsilon inhibition</article-title>. <source>Proc. Natl. Acad. Sci. U.S.A.</source> <volume>103</volume>, <fpage>15184</fpage>&#x02013;<lpage>15189</lpage><pub-id pub-id-type="doi">10.1073/pnas.0510086103</pub-id><pub-id pub-id-type="pmid">17018645</pub-id></mixed-citation></ref><ref id="B168"><mixed-citation publication-type="book"><person-group person-group-type="author"><name><surname>Matsubara</surname><given-names>T.</given-names></name><name><surname>Azums</surname><given-names>T.</given-names></name><name><surname>Yoshids</surname><given-names>S.</given-names></name><name><surname>Yamegami</surname><given-names>T.</given-names></name></person-group> (<year>1991</year>). <source>Biomedical and Clinical Aspects of Coenzyme Q</source>, Vol. <volume>16</volume> <publisher-loc>Amsterdam</publisher-loc>: <publisher-name>Elsevier Science</publisher-name>, <fpage>159</fpage>&#x02013;<lpage>166</lpage></mixed-citation></ref><ref id="B169"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Matthews</surname><given-names>R. T.</given-names></name><name><surname>Ferrante</surname><given-names>R. J.</given-names></name><name><surname>Klivenyi</surname><given-names>P.</given-names></name><name><surname>Yang</surname><given-names>L.</given-names></name><name><surname>Klein</surname><given-names>A. M.</given-names></name><name><surname>Mueller</surname><given-names>G.</given-names></name><name><surname>Kaddurah-Daouk</surname><given-names>R.</given-names></name><name><surname>Beal</surname><given-names>M. F.</given-names></name></person-group> (<year>1999</year>). <article-title>Creatine and cyclocreatine attenuate MPTP neurotoxicity</article-title>. <source>Exp. Neurol.</source> <volume>157</volume>, <fpage>142</fpage>&#x02013;<lpage>149</lpage><pub-id pub-id-type="doi">10.1006/exnr.1999.7045</pub-id><pub-id pub-id-type="pmid">10222117</pub-id></mixed-citation></ref><ref id="B170"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mayo</surname><given-names>J. C.</given-names></name><name><surname>Sainz</surname><given-names>R. M.</given-names></name><name><surname>Antolin</surname><given-names>I.</given-names></name><name><surname>Rodriguez</surname><given-names>C.</given-names></name></person-group> (<year>1999</year>). <article-title>Ultrastructural confirmation of neuronal protection by melatonin against the neurotoxin 6-hydroxydopamine cell damage</article-title>. <source>Brain Res.</source> <volume>818</volume>, <fpage>221</fpage>&#x02013;<lpage>227</lpage><pub-id pub-id-type="doi">10.1016/S0006-8993(98)01262-1</pub-id><pub-id pub-id-type="pmid">10082807</pub-id></mixed-citation></ref><ref id="B171"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mayo</surname><given-names>J. C.</given-names></name><name><surname>Sainz</surname><given-names>R. M.</given-names></name><name><surname>Tan</surname><given-names>D. X.</given-names></name><name><surname>Antolin</surname><given-names>I.</given-names></name><name><surname>Rodriguez</surname><given-names>C.</given-names></name><name><surname>Reiter</surname><given-names>R. J.</given-names></name></person-group> (<year>2005</year>). <article-title>Melatonin and Parkinson&#x02019;s disease</article-title>. <source>Endocrine</source> <volume>27</volume>, <fpage>169</fpage>&#x02013;<lpage>178</lpage><pub-id pub-id-type="doi">10.1385/ENDO:27:2:169</pub-id><pub-id pub-id-type="pmid">16217130</pub-id></mixed-citation></ref><ref id="B172"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mayo</surname><given-names>J. C.</given-names></name><name><surname>Sainz</surname><given-names>R. M.</given-names></name><name><surname>Uria</surname><given-names>H.</given-names></name><name><surname>Antolin</surname><given-names>I.</given-names></name><name><surname>Esteban</surname><given-names>M. M.</given-names></name><name><surname>Rodriguez</surname><given-names>C.</given-names></name></person-group> (<year>1998</year>). <article-title>Melatonin prevents apoptosis induced by 6-hydroxydopamine in neuronal cells: implications for Parkinson&#x02019;s disease</article-title>. <source>J. Pineal Res.</source> <volume>24</volume>, <fpage>179</fpage>&#x02013;<lpage>192</lpage><pub-id pub-id-type="doi">10.1111/j.1600-079X.1998.tb00531.x</pub-id><pub-id pub-id-type="pmid">9551855</pub-id></mixed-citation></ref><ref id="B173"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>McClean</surname><given-names>P. L.</given-names></name><name><surname>Parthsarathy</surname><given-names>V.</given-names></name><name><surname>Faivre</surname><given-names>E.</given-names></name><name><surname>Holscher</surname><given-names>C.</given-names></name></person-group> (<year>2010</year>). <article-title>The novel GLP-1 analogue liraglutide has neuroprotective properties in a mouse model of Alzheimer&#x02019;s disease</article-title>. <source>Regul. Pept.</source> <volume>164</volume>, <fpage>40</fpage><pub-id pub-id-type="doi">10.1016/j.regpep.2010.07.101</pub-id></mixed-citation></ref><ref id="B174"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>McClean</surname><given-names>P. L.</given-names></name><name><surname>Parthsarathy</surname><given-names>V.</given-names></name><name><surname>Faivre</surname><given-names>E.</given-names></name><name><surname>Holscher</surname><given-names>C.</given-names></name></person-group> (<year>2011</year>). <article-title>The diabetes drug liraglutide prevents degenerative processes in a mouse model of Alzheimer&#x02019;s disease</article-title>. <source>J. Neurosci.</source> <volume>31</volume>, <fpage>6587</fpage>&#x02013;<lpage>6594</lpage><pub-id pub-id-type="doi">10.1523/JNEUROSCI.0529-11.2011</pub-id><pub-id pub-id-type="pmid">21525299</pub-id></mixed-citation></ref><ref id="B175"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Merrill</surname><given-names>A. H.</given-names><suffix>Jr.</suffix></name><name><surname>Lambeth</surname><given-names>J. D.</given-names></name><name><surname>Edmondson</surname><given-names>D. E.</given-names></name><name><surname>McCormick</surname><given-names>D. B.</given-names></name></person-group> (<year>1981</year>). <article-title>Formation and mode of action of flavoproteins</article-title>. <source>Annu. Rev. Nutr.</source> <volume>1</volume>, <fpage>281</fpage>&#x02013;<lpage>317</lpage><pub-id pub-id-type="doi">10.1146/annurev.nu.01.070181.001433</pub-id><pub-id pub-id-type="pmid">6764718</pub-id></mixed-citation></ref><ref id="B176"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Meshul</surname><given-names>C. K.</given-names></name><name><surname>Kamel</surname><given-names>D.</given-names></name><name><surname>Moore</surname><given-names>C.</given-names></name><name><surname>Kay</surname><given-names>T. S.</given-names></name><name><surname>Krentz</surname><given-names>L.</given-names></name></person-group> (<year>2002</year>). <article-title>Nicotine alters striatal glutamate function and decreases the apomorphine-induced contralateral rotations in 6-OHDA-lesioned rats</article-title>. <source>Exp. Neurol.</source> <volume>175</volume>, <fpage>257</fpage>&#x02013;<lpage>274</lpage><pub-id pub-id-type="doi">10.1006/exnr.2002.7900</pub-id><pub-id pub-id-type="pmid">12009777</pub-id></mixed-citation></ref><ref id="B177"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Michel</surname><given-names>P. P.</given-names></name><name><surname>Hirsch</surname><given-names>E. C.</given-names></name><name><surname>Agid</surname><given-names>Y.</given-names></name></person-group> (<year>2002</year>). <article-title>Parkinson&#x02019;s disease: cell death mechanisms</article-title>. <source>Rev. Neurol. (Paris)</source> <volume>158</volume>, <fpage>24</fpage>&#x02013;<lpage>32</lpage><pub-id pub-id-type="pmid">12690312</pub-id></mixed-citation></ref><ref id="B178"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Miller</surname><given-names>J. W.</given-names></name><name><surname>Selhub</surname><given-names>J.</given-names></name><name><surname>Joseph</surname><given-names>J. A.</given-names></name></person-group> (<year>1996</year>). <article-title>Oxidative damage caused by free radicals produced during catecholamine autoxidation: protective effects of O-methylation and melatonin</article-title>. <source>Free Radic. Biol. Med.</source> <volume>21</volume>, <fpage>241</fpage>&#x02013;<lpage>249</lpage><pub-id pub-id-type="doi">10.1016/0891-5849(96)00033-0</pub-id><pub-id pub-id-type="pmid">8818640</pub-id></mixed-citation></ref><ref id="B179"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Molina</surname><given-names>J. A.</given-names></name><name><surname>de Bustos</surname><given-names>F.</given-names></name><name><surname>Jimenez-Jimenez</surname><given-names>F. J.</given-names></name><name><surname>Benito-Leon</surname><given-names>J.</given-names></name><name><surname>Orti-Pareja</surname><given-names>M.</given-names></name><name><surname>Gasalla</surname><given-names>T.</given-names></name><name><surname>Tallon-Barranco</surname><given-names>A.</given-names></name><name><surname>Navarro</surname><given-names>J. A.</given-names></name><name><surname>Arenas</surname><given-names>J.</given-names></name><name><surname>Enriquez-de-Salamanca</surname><given-names>R.</given-names></name></person-group> (<year>1997</year>). <article-title>Cerebrospinal fluid levels of alpha-tocopherol (vitamin E) in Parkinson&#x02019;s disease</article-title>. <source>J. Neural Transm.</source> <volume>104</volume>, <fpage>1287</fpage>&#x02013;<lpage>1293</lpage><pub-id pub-id-type="doi">10.1007/BF01294729</pub-id><pub-id pub-id-type="pmid">9503274</pub-id></mixed-citation></ref><ref id="B180"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Morens</surname><given-names>D. M.</given-names></name><name><surname>Grandinetti</surname><given-names>A.</given-names></name><name><surname>Waslien</surname><given-names>C. I.</given-names></name><name><surname>Park</surname><given-names>C. B.</given-names></name><name><surname>Ross</surname><given-names>G. W.</given-names></name><name><surname>White</surname><given-names>L. R.</given-names></name></person-group> (<year>1996</year>). <article-title>Case-control study of idiopathic Parkinson&#x02019;s disease and dietary vitamin E intake</article-title>. <source>Neurology</source> <volume>46</volume>, <fpage>1270</fpage>&#x02013;<lpage>1274</lpage><pub-id pub-id-type="pmid">8628465</pub-id></mixed-citation></ref><ref id="B181"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Morioka</surname><given-names>N.</given-names></name><name><surname>Kumagai</surname><given-names>K.</given-names></name><name><surname>Morita</surname><given-names>K.</given-names></name><name><surname>Kitayama</surname><given-names>S.</given-names></name><name><surname>Dohi</surname><given-names>T.</given-names></name></person-group> (<year>2004</year>). <article-title>Nonsteroidal anti-inflammatory drugs potentiate 1-methyl-4-phenylpyridinium (MPP+)-induced cell death by promoting the intracellular accumulation of MPP+ in PC12 cells</article-title>. <source>J. Pharmacol. Exp. Ther.</source> <volume>310</volume>, <fpage>800</fpage>&#x02013;<lpage>807</lpage><pub-id pub-id-type="doi">10.1124/jpet.104.065300</pub-id><pub-id pub-id-type="pmid">15131242</pub-id></mixed-citation></ref><ref id="B182"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Murakami</surname><given-names>K.</given-names></name><name><surname>Miyake</surname><given-names>Y.</given-names></name><name><surname>Sasaki</surname><given-names>S.</given-names></name><name><surname>Tanaka</surname><given-names>K.</given-names></name><name><surname>Fukushima</surname><given-names>W.</given-names></name><name><surname>Kiyohara</surname><given-names>C.</given-names></name><name><surname>Tsuboi</surname><given-names>Y.</given-names></name><name><surname>Yamada</surname><given-names>T.</given-names></name><name><surname>Oeda</surname><given-names>T.</given-names></name><name><surname>Miki</surname><given-names>T.</given-names></name><name><surname>Kawamura</surname><given-names>N.</given-names></name><name><surname>Sakae</surname><given-names>N.</given-names></name><name><surname>Fukuyama</surname><given-names>H.</given-names></name><name><surname>Hirota</surname><given-names>Y.</given-names></name><name><surname>Nagai</surname><given-names>M.</given-names></name></person-group> (<year>2010</year>). <article-title>Dietary intake of folate, vitamin B6, vitamin B12 and riboflavin and risk of Parkinson&#x02019;s disease: a case-control study in Japan</article-title>. <source>Br. J. Nutr.</source> <volume>104</volume>, <fpage>757</fpage>&#x02013;<lpage>764</lpage><pub-id pub-id-type="doi">10.1017/S0007114510001005</pub-id><pub-id pub-id-type="pmid">20338075</pub-id></mixed-citation></ref><ref id="B183"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Murer</surname><given-names>M. G.</given-names></name><name><surname>Yan</surname><given-names>Q.</given-names></name><name><surname>Raisman-Vozari</surname><given-names>R.</given-names></name></person-group> (<year>2001</year>). <article-title>Brain-derived neurotrophic factor in the control human brain, and in Alzheimer&#x02019;s disease and Parkinson&#x02019;s disease</article-title>. <source>Prog. Neurobiol.</source> <volume>63</volume>, <fpage>71</fpage>&#x02013;<lpage>124</lpage><pub-id pub-id-type="doi">10.1016/S0301-0082(00)00014-9</pub-id><pub-id pub-id-type="pmid">11040419</pub-id></mixed-citation></ref><ref id="B184"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nakaso</surname><given-names>K.</given-names></name><name><surname>Ito</surname><given-names>S.</given-names></name><name><surname>Nakashima</surname><given-names>K.</given-names></name></person-group> (<year>2008</year>). <article-title>Caffeine activates the PI3K/Akt pathway and prevents apoptotic cell death in a Parkinson&#x02019;s disease model of SH-SY5Y cells</article-title>. <source>Neurosci. Lett.</source> <volume>432</volume>, <fpage>146</fpage>&#x02013;<lpage>150</lpage><pub-id pub-id-type="doi">10.1016/j.neulet.2007.12.034</pub-id><pub-id pub-id-type="pmid">18201823</pub-id></mixed-citation></ref><ref id="B185"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Naveilhan</surname><given-names>P.</given-names></name><name><surname>Neveu</surname><given-names>I.</given-names></name><name><surname>Wion</surname><given-names>D.</given-names></name><name><surname>Brachet</surname><given-names>P.</given-names></name></person-group> (<year>1996</year>). <article-title>1,25-Dihydroxyvitamin D3, an inducer of glial cell line-derived neurotrophic factor</article-title>. <source>Neuroreport</source> <volume>7</volume>, <fpage>2171</fpage>&#x02013;<lpage>2175</lpage><pub-id pub-id-type="doi">10.1097/00001756-199609020-00023</pub-id><pub-id pub-id-type="pmid">8930983</pub-id></mixed-citation></ref><ref id="B186"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>NET-PD</surname><given-names>N.</given-names></name></person-group> (<year>2006</year>). <article-title>A randomized, double-blind, futility clinical trial of creatine and minocycline in early Parkinson disease</article-title>. <source>Neurology</source> <volume>66</volume>, <fpage>664</fpage>&#x02013;<lpage>671</lpage><pub-id pub-id-type="doi">10.1212/01.wnl.0000201252.57661.e1</pub-id><pub-id pub-id-type="pmid">16481597</pub-id></mixed-citation></ref><ref id="B187"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Obata</surname><given-names>T.</given-names></name></person-group> (<year>2003</year>). <article-title>Phytic acid suppresses 1-methyl-4-phenylpyridinium ion-induced hydroxyl radical generation in rat striatum</article-title>. <source>Brain Res.</source> <volume>978</volume>, <fpage>241</fpage>&#x02013;<lpage>244</lpage><pub-id pub-id-type="doi">10.1016/S0006-8993(03)02830-0</pub-id><pub-id pub-id-type="pmid">12834920</pub-id></mixed-citation></ref><ref id="B188"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Odunze</surname><given-names>I. N.</given-names></name><name><surname>Klaidman</surname><given-names>L. K.</given-names></name><name><surname>Adams</surname><given-names>J. D.</given-names><suffix>Jr.</suffix></name></person-group> (<year>1990</year>). <article-title>MPTP toxicity in the mouse brain and vitamin E</article-title>. <source>Neurosci. Lett.</source> <volume>108</volume>, <fpage>346</fpage>&#x02013;<lpage>349</lpage><pub-id pub-id-type="doi">10.1016/0304-3940(90)90665-V</pub-id><pub-id pub-id-type="pmid">2304652</pub-id></mixed-citation></ref><ref id="B189"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Offen</surname><given-names>D.</given-names></name><name><surname>Ziv</surname><given-names>I.</given-names></name><name><surname>Sternin</surname><given-names>H.</given-names></name><name><surname>Melamed</surname><given-names>E.</given-names></name><name><surname>Hochman</surname><given-names>A.</given-names></name></person-group> (<year>1996</year>). <article-title>Prevention of dopamine-induced cell death by thiol antioxidants: possible implications for treatment of Parkinson&#x02019;s disease</article-title>. <source>Exp. Neurol.</source> <volume>141</volume>, <fpage>32</fpage>&#x02013;<lpage>39</lpage><pub-id pub-id-type="doi">10.1006/exnr.1996.0136</pub-id><pub-id pub-id-type="pmid">8797665</pub-id></mixed-citation></ref><ref id="B190"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Olanow</surname><given-names>C. W.</given-names></name><name><surname>Rascol</surname><given-names>O.</given-names></name><name><surname>Hauser</surname><given-names>R.</given-names></name><name><surname>Feigin</surname><given-names>P. D.</given-names></name><name><surname>Jankovic</surname><given-names>J.</given-names></name><name><surname>Lang</surname><given-names>A.</given-names></name><name><surname>Langston</surname><given-names>W.</given-names></name><name><surname>Melamed</surname><given-names>E.</given-names></name><name><surname>Poewe</surname><given-names>W.</given-names></name><name><surname>Stocchi</surname><given-names>F.</given-names></name><name><surname>Tolosa</surname><given-names>E.</given-names></name></person-group> (<year>2009</year>). <article-title>A double-blind, delayed-start trial of rasagiline in Parkinson&#x02019;s disease</article-title>. <source>N. Engl. J. Med.</source> <volume>361</volume>, <fpage>1268</fpage>&#x02013;<lpage>1278</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa0809335</pub-id><pub-id pub-id-type="pmid">19776408</pub-id></mixed-citation></ref><ref id="B191"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ozsoy</surname><given-names>O.</given-names></name><name><surname>Seval-Celik</surname><given-names>Y.</given-names></name><name><surname>Hacioglu</surname><given-names>G.</given-names></name><name><surname>Yargicoglu</surname><given-names>P.</given-names></name><name><surname>Demir</surname><given-names>R.</given-names></name><name><surname>Agar</surname><given-names>A.</given-names></name><name><surname>Aslan</surname><given-names>M.</given-names></name></person-group> (<year>2011</year>). <article-title>The influence and the mechanism of docosahexaenoic acid on a mouse model of Parkinson&#x02019;s disease</article-title>. <source>Neurochem. Int.</source> <volume>59</volume>, <fpage>664</fpage>&#x02013;<lpage>670</lpage><pub-id pub-id-type="doi">10.1016/j.neuint.2011.06.012</pub-id><pub-id pub-id-type="pmid">21736911</pub-id></mixed-citation></ref><ref id="B192"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Palacios</surname><given-names>N.</given-names></name><name><surname>Weisskopf</surname><given-names>M.</given-names></name><name><surname>Simon</surname><given-names>K.</given-names></name><name><surname>Gao</surname><given-names>X.</given-names></name><name><surname>Schwarzschild</surname><given-names>M.</given-names></name><name><surname>Ascherio</surname><given-names>A.</given-names></name></person-group> (<year>2010</year>). <article-title>Polymorphisms of caffeine metabolism and estrogen receptor genes and risk of Parkinson&#x02019;s disease in men and women</article-title>. <source>Parkinsonism Relat. Disord.</source> <volume>16</volume>, <fpage>370</fpage>&#x02013;<lpage>375</lpage><pub-id pub-id-type="doi">10.1016/j.parkreldis.2010.02.012</pub-id><pub-id pub-id-type="pmid">20304699</pub-id></mixed-citation></ref><ref id="B193"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Paraskevas</surname><given-names>G. P.</given-names></name><name><surname>Kapaki</surname><given-names>E.</given-names></name><name><surname>Petropoulou</surname><given-names>O.</given-names></name><name><surname>Anagnostouli</surname><given-names>M.</given-names></name><name><surname>Vagenas</surname><given-names>V.</given-names></name><name><surname>Papageorgiou</surname><given-names>C.</given-names></name></person-group> (<year>2003</year>). <article-title>Plasma levels of antioxidant vitamins C and E are decreased in vascular parkinsonism</article-title>. <source>J. Neurol. Sci.</source> <volume>215</volume>, <fpage>51</fpage>&#x02013;<lpage>55</lpage><pub-id pub-id-type="doi">10.1016/S0022-510X(03)00184-9</pub-id><pub-id pub-id-type="pmid">14568128</pub-id></mixed-citation></ref><ref id="B194"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pearce</surname><given-names>R. K.</given-names></name><name><surname>Owen</surname><given-names>A.</given-names></name><name><surname>Daniel</surname><given-names>S.</given-names></name><name><surname>Jenner</surname><given-names>P.</given-names></name><name><surname>Marsden</surname><given-names>C. D.</given-names></name></person-group> (<year>1997</year>). <article-title>Alterations in the distribution of glutathione in the substantia nigra in Parkinson&#x02019;s disease</article-title>. <source>J. Neural Transm.</source> <volume>104</volume>, <fpage>661</fpage>&#x02013;<lpage>677</lpage><pub-id pub-id-type="doi">10.1007/BF01291884</pub-id><pub-id pub-id-type="pmid">9444566</pub-id></mixed-citation></ref><ref id="B195"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Perlmutter</surname><given-names>J. S.</given-names></name></person-group> (<year>1988</year>). <article-title>New insights into the pathophysiology of Parkinson&#x02019;s disease: the challenge of positron emission tomography</article-title>. <source>Trends Neurosci.</source> <volume>11</volume>, <fpage>203</fpage>&#x02013;<lpage>208</lpage><pub-id pub-id-type="doi">10.1016/0166-2236(88)90123-3</pub-id><pub-id pub-id-type="pmid">2471321</pub-id></mixed-citation></ref><ref id="B196"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Perry</surname><given-names>T.</given-names></name><name><surname>Greig</surname><given-names>N. H.</given-names></name></person-group> (<year>2005</year>). <article-title>Enhancing central nervous system endogenous GLP-1 receptor pathways for intervention in Alzheimer&#x02019;s disease</article-title>. <source>Curr. Alzheimer Res.</source> <volume>2</volume>, <fpage>377</fpage>&#x02013;<lpage>385</lpage><pub-id pub-id-type="doi">10.2174/1567205054367892</pub-id><pub-id pub-id-type="pmid">15974903</pub-id></mixed-citation></ref><ref id="B197"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Perry</surname><given-names>T.</given-names></name><name><surname>Holloway</surname><given-names>H. W.</given-names></name><name><surname>Weerasuriya</surname><given-names>A.</given-names></name><name><surname>Mouton</surname><given-names>P. R.</given-names></name><name><surname>Duffy</surname><given-names>K.</given-names></name><name><surname>Mattison</surname><given-names>J. A.</given-names></name><name><surname>Greig</surname><given-names>N. H.</given-names></name></person-group> (<year>2007</year>). <article-title>Evidence of GLP-1-mediated neuroprotection in an animal model of pyridoxine-induced peripheral sensory neuropathy</article-title>. <source>Exp. Neurol.</source> <volume>203</volume>, <fpage>293</fpage>&#x02013;<lpage>301</lpage><pub-id pub-id-type="doi">10.1016/j.expneurol.2006.09.028</pub-id><pub-id pub-id-type="pmid">17125767</pub-id></mixed-citation></ref><ref id="B198"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Perry</surname><given-names>T.</given-names></name><name><surname>Lahiri</surname><given-names>D. K.</given-names></name><name><surname>Chen</surname><given-names>D.</given-names></name><name><surname>Zhou</surname><given-names>J.</given-names></name><name><surname>Shaw</surname><given-names>K. T.</given-names></name><name><surname>Egan</surname><given-names>J. M.</given-names></name><name><surname>Greig</surname><given-names>N. H.</given-names></name></person-group> (<year>2002</year>). <article-title>A novel neurotrophic property of glucagon-like peptide 1: a promoter of nerve growth factor-mediated differentiation in PC12 cells</article-title>. <source>J. Pharmacol. Exp. Ther.</source> <volume>300</volume>, <fpage>958</fpage>&#x02013;<lpage>966</lpage><pub-id pub-id-type="doi">10.1124/jpet.300.3.958</pub-id><pub-id pub-id-type="pmid">11861804</pub-id></mixed-citation></ref><ref id="B199"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Perry</surname><given-names>T. L.</given-names></name><name><surname>Godin</surname><given-names>D. V.</given-names></name><name><surname>Hansen</surname><given-names>S.</given-names></name></person-group> (<year>1982</year>). <article-title>Parkinson&#x02019;s disease: a disorder due to nigral glutathione deficiency?</article-title> <source>Neurosci. Lett.</source> <volume>33</volume>, <fpage>305</fpage>&#x02013;<lpage>310</lpage><pub-id pub-id-type="doi">10.1016/0304-3940(82)90390-1</pub-id><pub-id pub-id-type="pmid">7162692</pub-id></mixed-citation></ref><ref id="B200"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Perry</surname><given-names>T. L.</given-names></name><name><surname>Yong</surname><given-names>V. W.</given-names></name><name><surname>Clavier</surname><given-names>R. M.</given-names></name><name><surname>Jones</surname><given-names>K.</given-names></name><name><surname>Wright</surname><given-names>J. M.</given-names></name><name><surname>Foulks</surname><given-names>J. G.</given-names></name><name><surname>Wall</surname><given-names>R. A.</given-names></name></person-group> (<year>1985</year>). <article-title>Partial protection from the dopaminergic neurotoxin N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine by four different antioxidants in the mouse</article-title>. <source>Neurosci. Lett.</source> <volume>60</volume>, <fpage>109</fpage>&#x02013;<lpage>114</lpage><pub-id pub-id-type="doi">10.1016/0304-3940(85)90229-0</pub-id><pub-id pub-id-type="pmid">3877260</pub-id></mixed-citation></ref><ref id="B201"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Perry</surname><given-names>T. L.</given-names></name><name><surname>Yong</surname><given-names>V. W.</given-names></name><name><surname>Hansen</surname><given-names>S.</given-names></name><name><surname>Jones</surname><given-names>K.</given-names></name><name><surname>Bergeron</surname><given-names>C.</given-names></name><name><surname>Foulks</surname><given-names>J. G.</given-names></name><name><surname>Wright</surname><given-names>J. M.</given-names></name></person-group> (<year>1987</year>). <article-title>Alpha-tocopherol and beta-carotene do not protect marmosets against the dopaminergic neurotoxicity of N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine</article-title>. <source>J. Neurol. Sci.</source> <volume>81</volume>, <fpage>321</fpage>&#x02013;<lpage>331</lpage><pub-id pub-id-type="doi">10.1016/0022-510X(87)90106-7</pub-id><pub-id pub-id-type="pmid">3121800</pub-id></mixed-citation></ref><ref id="B202"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pileblad</surname><given-names>E.</given-names></name><name><surname>Magnusson</surname><given-names>T.</given-names></name><name><surname>Fornstedt</surname><given-names>B.</given-names></name></person-group> (<year>1989</year>). <article-title>Reduction of brain glutathione by L-buthionine sulfoximine potentiates the dopamine-depleting action of 6-hydroxydopamine in rat striatum</article-title>. <source>J. Neurochem.</source> <volume>52</volume>, <fpage>978</fpage>&#x02013;<lpage>980</lpage><pub-id pub-id-type="doi">10.1111/j.1471-4159.1989.tb02550.x</pub-id><pub-id pub-id-type="pmid">2493072</pub-id></mixed-citation></ref><ref id="B203"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pizzi</surname><given-names>M.</given-names></name><name><surname>Ribola</surname><given-names>M.</given-names></name><name><surname>Valerio</surname><given-names>A.</given-names></name><name><surname>Memo</surname><given-names>M.</given-names></name><name><surname>Spano</surname><given-names>P.</given-names></name></person-group> (<year>1991</year>). <article-title>Various Ca2+ entry blockers prevent glutamate-induced neurotoxicity</article-title>. <source>Eur. J. Pharmacol.</source> <volume>209</volume>, <fpage>169</fpage>&#x02013;<lpage>173</lpage><pub-id pub-id-type="doi">10.1016/0014-2999(91)90166-N</pub-id><pub-id pub-id-type="pmid">1724654</pub-id></mixed-citation></ref><ref id="B204"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Powers</surname><given-names>H. J.</given-names></name></person-group> (<year>1987</year>). <article-title>A study of maternofetal iron transfer in the riboflavin-deficient rat</article-title>. <source>J. Nutr.</source> <volume>117</volume>, <fpage>852</fpage>&#x02013;<lpage>856</lpage><pub-id pub-id-type="pmid">3585538</pub-id></mixed-citation></ref><ref id="B205"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Powers</surname><given-names>H. J.</given-names></name></person-group> (<year>2003</year>). <article-title>Riboflavin (vitamin B-2) and health</article-title>. <source>Am. J. Clin. Nutr.</source> <volume>77</volume>, <fpage>1352</fpage>&#x02013;<lpage>1360</lpage><pub-id pub-id-type="pmid">12791609</pub-id></mixed-citation></ref><ref id="B206"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Powers</surname><given-names>H. J.</given-names></name><name><surname>Bates</surname><given-names>C. J.</given-names></name><name><surname>Duerden</surname><given-names>J. M.</given-names></name></person-group> (<year>1983</year>). <article-title>Effects of riboflavin deficiency in rats on some aspects of iron metabolism</article-title>. <source>Int. J. Vitam. Nutr. Res.</source> <volume>53</volume>, <fpage>371</fpage>&#x02013;<lpage>376</lpage><pub-id pub-id-type="pmid">6668137</pub-id></mixed-citation></ref><ref id="B207"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Prediger</surname><given-names>R. D.</given-names></name></person-group> (<year>2010</year>). <article-title>Effects of caffeine in Parkinson&#x02019;s disease: from neuroprotection to the management of motor and non-motor symptoms</article-title>. <source>J. Alzheimers Dis.</source> <volume>20</volume>(<issue>Suppl. 1</issue>), <fpage>S205</fpage>&#x02013;<lpage>S220</lpage><pub-id pub-id-type="pmid">20182024</pub-id></mixed-citation></ref><ref id="B208"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Quick</surname><given-names>M.</given-names></name></person-group> (<year>2004</year>). <article-title>Smoking, nicotine and Parkinson&#x02019;s disease</article-title>. <source>Trends Neurosci.</source> <volume>27</volume>, <fpage>561</fpage>&#x02013;<lpage>568</lpage><pub-id pub-id-type="doi">10.1016/j.tins.2004.06.008</pub-id><pub-id pub-id-type="pmid">15331239</pub-id></mixed-citation></ref><ref id="B209"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Quik</surname><given-names>M.</given-names></name><name><surname>Jeyarasasingam</surname><given-names>G.</given-names></name></person-group> (<year>2000</year>). <article-title>Nicotinic receptors and Parkinson&#x02019;s disease</article-title>. <source>Eur. J. Pharmacol.</source> <volume>393</volume>, <fpage>223</fpage>&#x02013;<lpage>230</lpage><pub-id pub-id-type="doi">10.1016/S0014-2999(99)00888-2</pub-id><pub-id pub-id-type="pmid">10771017</pub-id></mixed-citation></ref><ref id="B210"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Quik</surname><given-names>M.</given-names></name><name><surname>Parameswaran</surname><given-names>N.</given-names></name><name><surname>McCallum</surname><given-names>S. E.</given-names></name><name><surname>Bordia</surname><given-names>T.</given-names></name><name><surname>Bao</surname><given-names>S.</given-names></name><name><surname>McCormack</surname><given-names>A.</given-names></name><name><surname>Kim</surname><given-names>A.</given-names></name><name><surname>Tyndale</surname><given-names>R. F.</given-names></name><name><surname>Langston</surname><given-names>J. W.</given-names></name><name><surname>Di Monte</surname><given-names>D. A.</given-names></name></person-group> (<year>2006</year>). <article-title>Chronic oral nicotine treatment protects against striatal degeneration in MPTP-treated primates</article-title>. <source>J. Neurochem.</source> <volume>98</volume>, <fpage>1866</fpage>&#x02013;<lpage>1875</lpage><pub-id pub-id-type="doi">10.1111/j.1471-4159.2006.04078.x</pub-id><pub-id pub-id-type="pmid">16882311</pub-id></mixed-citation></ref><ref id="B211"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Quintero</surname><given-names>E. M.</given-names></name><name><surname>Willis</surname><given-names>L.</given-names></name><name><surname>Singleton</surname><given-names>R.</given-names></name><name><surname>Harris</surname><given-names>N.</given-names></name><name><surname>Huang</surname><given-names>P.</given-names></name><name><surname>Bhat</surname><given-names>N.</given-names></name><name><surname>Granholm</surname><given-names>A. C.</given-names></name></person-group> (<year>2006</year>). <article-title>Behavioral and morphological effects of minocycline in the 6-hydroxydopamine rat model of Parkinson&#x02019;s disease</article-title>. <source>Brain Res.</source> <volume>1093</volume>, <fpage>198</fpage>&#x02013;<lpage>207</lpage><pub-id pub-id-type="doi">10.1016/j.brainres.2006.03.104</pub-id><pub-id pub-id-type="pmid">16712819</pub-id></mixed-citation></ref><ref id="B212"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Radad</surname><given-names>K.</given-names></name><name><surname>Moldzio</surname><given-names>R.</given-names></name><name><surname>Rausch</surname><given-names>W. D.</given-names></name></person-group> (<year>2010</year>). <article-title>Minocycline protects dopaminergic neurons against long-term rotenone toxicity</article-title>. <source>Can. J. Neurol. Sci.</source> <volume>37</volume>, <fpage>81</fpage>&#x02013;<lpage>85</lpage><pub-id pub-id-type="pmid">20169778</pub-id></mixed-citation></ref><ref id="B213"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rascol</surname><given-names>O.</given-names></name><name><surname>Fitzer-Attas</surname><given-names>C. J.</given-names></name><name><surname>Hauser</surname><given-names>R.</given-names></name><name><surname>Jankovic</surname><given-names>J.</given-names></name><name><surname>Lang</surname><given-names>A.</given-names></name><name><surname>Langston</surname><given-names>J. W.</given-names></name><name><surname>Melamed</surname><given-names>E.</given-names></name><name><surname>Poewe</surname><given-names>W.</given-names></name><name><surname>Stocchi</surname><given-names>F.</given-names></name><name><surname>Tolosa</surname><given-names>E.</given-names></name><name><surname>Eyal</surname><given-names>E.</given-names></name><name><surname>Weiss</surname><given-names>Y. M.</given-names></name><name><surname>Olanow</surname><given-names>C. W.</given-names></name></person-group> (<year>2011</year>). <article-title>A double-blind, delayed-start trial of rasagiline in Parkinson&#x02019;s disease (the ADAGIO study): prespecified and post-hoc analyses of the need for additional therapies, changes in UPDRS scores, and non-motor outcomes</article-title>. <source>Lancet Neurol.</source> <volume>10</volume>, <fpage>415</fpage>&#x02013;<lpage>423</lpage><pub-id pub-id-type="doi">10.1016/S1474-4422(11)70073-4</pub-id><pub-id pub-id-type="pmid">21482191</pub-id></mixed-citation></ref><ref id="B214"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ravina</surname><given-names>B. M.</given-names></name><name><surname>Fagan</surname><given-names>S. C.</given-names></name><name><surname>Hart</surname><given-names>R. G.</given-names></name><name><surname>Hovinga</surname><given-names>C. A.</given-names></name><name><surname>Murphy</surname><given-names>D. D.</given-names></name><name><surname>Dawson</surname><given-names>T. M.</given-names></name><name><surname>Marler</surname><given-names>J. R.</given-names></name></person-group> (<year>2003</year>). <article-title>Neuroprotective agents for clinical trials in Parkinson&#x02019;s disease: a systematic assessment</article-title>. <source>Neurology</source> <volume>60</volume>, <fpage>1234</fpage>&#x02013;<lpage>1240</lpage><pub-id pub-id-type="pmid">12707423</pub-id></mixed-citation></ref><ref id="B215"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Reiter</surname><given-names>R. J.</given-names></name><name><surname>Carneiro</surname><given-names>R. C.</given-names></name><name><surname>Oh</surname><given-names>C. S.</given-names></name></person-group> (<year>1997</year>). <article-title>Melatonin in relation to cellular antioxidative defense mechanisms</article-title>. <source>Horm. Metab. Res.</source> <volume>29</volume>, <fpage>363</fpage>&#x02013;<lpage>372</lpage><pub-id pub-id-type="doi">10.1055/s-2007-979057</pub-id><pub-id pub-id-type="pmid">9288572</pub-id></mixed-citation></ref><ref id="B216"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ren</surname><given-names>Y. R.</given-names></name><name><surname>Nishida</surname><given-names>Y.</given-names></name><name><surname>Yoshimi</surname><given-names>K.</given-names></name><name><surname>Yasuda</surname><given-names>T.</given-names></name><name><surname>Jishage</surname><given-names>K.</given-names></name><name><surname>Uchihara</surname><given-names>T.</given-names></name><name><surname>Yokota</surname><given-names>T.</given-names></name><name><surname>Mizuno</surname><given-names>Y.</given-names></name><name><surname>Mochizuki</surname><given-names>H.</given-names></name></person-group> (<year>2006</year>). <article-title>Genetic vitamin E deficiency does not affect MPTP susceptibility in the mouse brain</article-title>. <source>J. Neurochem.</source> <volume>98</volume>, <fpage>1810</fpage>&#x02013;<lpage>1816</lpage><pub-id pub-id-type="doi">10.1111/j.1471-4159.2006.04046.x</pub-id><pub-id pub-id-type="pmid">16787402</pub-id></mixed-citation></ref><ref id="B217"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ricciarelli</surname><given-names>R.</given-names></name><name><surname>Argellati</surname><given-names>F.</given-names></name><name><surname>Pronzato</surname><given-names>M. A.</given-names></name><name><surname>Domenicotti</surname><given-names>C.</given-names></name></person-group> (<year>2007</year>). <article-title>Vitamin E and neurodegenerative diseases</article-title>. <source>Mol. Aspects Med.</source> <volume>28</volume>, <fpage>591</fpage>&#x02013;<lpage>606</lpage><pub-id pub-id-type="doi">10.1016/j.mam.2007.01.004</pub-id><pub-id pub-id-type="pmid">17306357</pub-id></mixed-citation></ref><ref id="B218"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Riederer</surname><given-names>P.</given-names></name><name><surname>Sofic</surname><given-names>E.</given-names></name><name><surname>Rausch</surname><given-names>W. D.</given-names></name><name><surname>Schmidt</surname><given-names>B.</given-names></name><name><surname>Reynolds</surname><given-names>G. P.</given-names></name><name><surname>Jellinger</surname><given-names>K.</given-names></name><name><surname>Youdim</surname><given-names>M. B.</given-names></name></person-group> (<year>1989</year>). <article-title>Transition metals, ferritin, glutathione, and ascorbic acid in parkinsonian brains</article-title>. <source>J. Neurochem.</source> <volume>52</volume>, <fpage>515</fpage>&#x02013;<lpage>520</lpage><pub-id pub-id-type="doi">10.1111/j.1471-4159.1989.tb09150.x</pub-id><pub-id pub-id-type="pmid">2911028</pub-id></mixed-citation></ref><ref id="B219"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rocchitta</surname><given-names>G.</given-names></name><name><surname>Migheli</surname><given-names>R.</given-names></name><name><surname>Esposito</surname><given-names>G.</given-names></name><name><surname>Marchetti</surname><given-names>B.</given-names></name><name><surname>Desole</surname><given-names>M. S.</given-names></name><name><surname>Miele</surname><given-names>E.</given-names></name><name><surname>Serra</surname><given-names>P. A.</given-names></name></person-group> (<year>2006</year>). <article-title>Endogenous melatonin protects L-DOPA from autoxidation in the striatal extracellular compartment of the freely moving rat: potential implication for long-term L-DOPA therapy in Parkinson&#x02019;s disease</article-title>. <source>J. Pineal Res.</source> <volume>40</volume>, <fpage>204</fpage>&#x02013;<lpage>213</lpage><pub-id pub-id-type="doi">10.1111/j.1600-079X.2005.00299.x</pub-id><pub-id pub-id-type="pmid">16499555</pub-id></mixed-citation></ref><ref id="B220"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Roghani</surname><given-names>M.</given-names></name><name><surname>Behzadi</surname><given-names>G.</given-names></name></person-group> (<year>2001</year>). <article-title>Neuroprotective effect of vitamin E on the early model of Parkinson&#x02019;s disease in rat: behavioral and histochemical evidence</article-title>. <source>Brain Res.</source> <volume>892</volume>, <fpage>211</fpage>&#x02013;<lpage>217</lpage><pub-id pub-id-type="doi">10.1016/S0006-8993(00)03296-0</pub-id><pub-id pub-id-type="pmid">11172767</pub-id></mixed-citation></ref><ref id="B221"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ross</surname><given-names>G. W.</given-names></name><name><surname>Abbott</surname><given-names>R. D.</given-names></name><name><surname>Petrovitch</surname><given-names>H.</given-names></name><name><surname>Morens</surname><given-names>D. M.</given-names></name><name><surname>Grandinetti</surname><given-names>A.</given-names></name><name><surname>Tung</surname><given-names>K. H.</given-names></name><name><surname>Tanner</surname><given-names>C. M.</given-names></name><name><surname>Masaki</surname><given-names>K. H.</given-names></name><name><surname>Blanchette</surname><given-names>P. L.</given-names></name><name><surname>Curb</surname><given-names>J. D.</given-names></name><name><surname>Popper</surname><given-names>J. S.</given-names></name><name><surname>White</surname><given-names>L. R.</given-names></name></person-group> (<year>2000</year>). <article-title>Association of coffee and caffeine intake with the risk of Parkinson disease</article-title>. <source>JAMA</source> <volume>283</volume>, <fpage>2674</fpage>&#x02013;<lpage>2679</lpage><pub-id pub-id-type="doi">10.1001/jama.283.20.2674</pub-id><pub-id pub-id-type="pmid">10819950</pub-id></mixed-citation></ref><ref id="B222"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ryan</surname><given-names>M. E.</given-names></name><name><surname>Ashley</surname><given-names>R. A.</given-names></name></person-group> (<year>1998</year>). <article-title>How do tetracyclines work?</article-title> <source>Adv. Dent. Res.</source> <volume>12</volume>, <fpage>149</fpage>&#x02013;<lpage>151</lpage><pub-id pub-id-type="doi">10.1177/08959374980120011201</pub-id><pub-id pub-id-type="pmid">9972140</pub-id></mixed-citation></ref><ref id="B223"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ryan</surname><given-names>M. E.</given-names></name><name><surname>Ramamurthy</surname><given-names>N. S.</given-names></name><name><surname>Golub</surname><given-names>L. M.</given-names></name></person-group> (<year>1998</year>). <article-title>Tetracyclines inhibit protein glycation in experimental diabetes</article-title>. <source>Adv. Dent. Res.</source> <volume>12</volume>, <fpage>152</fpage>&#x02013;<lpage>158</lpage><pub-id pub-id-type="doi">10.1177/08959374980120011201</pub-id><pub-id pub-id-type="pmid">9972141</pub-id></mixed-citation></ref><ref id="B224"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Saaksjarvi</surname><given-names>K.</given-names></name><name><surname>Knekt</surname><given-names>P.</given-names></name><name><surname>Rissanen</surname><given-names>H.</given-names></name><name><surname>Laaksonen</surname><given-names>M. A.</given-names></name><name><surname>Reunanen</surname><given-names>A.</given-names></name><name><surname>Mannisto</surname><given-names>S.</given-names></name></person-group> (<year>2008</year>). <article-title>Prospective study of coffee consumption and risk of Parkinson&#x02019;s disease</article-title>. <source>Eur. J. Clin. Nutr.</source> <volume>62</volume>, <fpage>908</fpage>&#x02013;<lpage>915</lpage><pub-id pub-id-type="doi">10.1038/sj.ejcn.1602788</pub-id><pub-id pub-id-type="pmid">17522612</pub-id></mixed-citation></ref><ref id="B225"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sagi</surname><given-names>Y.</given-names></name><name><surname>Weinreb</surname><given-names>O.</given-names></name><name><surname>Weinstock</surname><given-names>M.</given-names></name><name><surname>Youdim</surname><given-names>M. B.</given-names></name></person-group> (<year>2001</year>). <article-title>Neuroprotective and neurorescue properties of rasagiline and TV3326 in MPTP model of Parkinson&#x02019;s disease</article-title>. <source>Neural Plast.</source> <volume>8</volume>, <fpage>197</fpage>&#x02013;<lpage>198</lpage></mixed-citation></ref><ref id="B226"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Saini</surname><given-names>T.</given-names></name><name><surname>Bagchi</surname><given-names>M.</given-names></name><name><surname>Bagchi</surname><given-names>D.</given-names></name><name><surname>Jaeger</surname><given-names>S.</given-names></name><name><surname>Hosoyama</surname><given-names>S.</given-names></name><name><surname>Stohs</surname><given-names>S. J.</given-names></name></person-group> (<year>1998</year>). <article-title>Protective ability of acetylsalicylic acid (aspirin) to scavenge radiation induced free radicals in J774A.1 macrophage cells</article-title>. <source>Res Commun. Mol. Pathol. Pharmacol.</source> <volume>101</volume>, <fpage>259</fpage>&#x02013;<lpage>268</lpage><pub-id pub-id-type="pmid">9874284</pub-id></mixed-citation></ref><ref id="B227"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sairam</surname><given-names>K.</given-names></name><name><surname>Saravanan</surname><given-names>K. S.</given-names></name><name><surname>Banerjee</surname><given-names>R.</given-names></name><name><surname>Mohanakumar</surname><given-names>K. P.</given-names></name></person-group> (<year>2003</year>). <article-title>Non-steroidal anti-inflammatory drug sodium salicylate, but not diclofenac or celecoxib, protects against 1-methyl-4-phenyl pyridinium-induced dopaminergic neurotoxicity in rats</article-title>. <source>Brain Res.</source> <volume>966</volume>, <fpage>245</fpage>&#x02013;<lpage>252</lpage><pub-id pub-id-type="doi">10.1016/S0006-8993(02)04174-4</pub-id><pub-id pub-id-type="pmid">12618347</pub-id></mixed-citation></ref><ref id="B228"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sakamoto</surname><given-names>T.</given-names></name><name><surname>Cansev</surname><given-names>M.</given-names></name><name><surname>Wurtman</surname><given-names>R. J.</given-names></name></person-group> (<year>2007</year>). <article-title>Oral supplementation with docosahexaenoic acid and uridine-5&#x02032;-monophosphate increases dendritic spine density in adult gerbil hippocampus</article-title>. <source>Brain Res.</source> <volume>1182</volume>, <fpage>50</fpage>&#x02013;<lpage>59</lpage><pub-id pub-id-type="doi">10.1016/j.brainres.2007.08.089</pub-id><pub-id pub-id-type="pmid">17950710</pub-id></mixed-citation></ref><ref id="B229"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Salem</surname><given-names>N.</given-names><suffix>Jr.</suffix></name><name><surname>Litman</surname><given-names>B.</given-names></name><name><surname>Kim</surname><given-names>H. Y.</given-names></name><name><surname>Gawrisch</surname><given-names>K.</given-names></name></person-group> (<year>2001</year>). <article-title>Mechanisms of action of docosahexaenoic acid in the nervous system</article-title>. <source>Lipids</source> <volume>36</volume>, <fpage>945</fpage>&#x02013;<lpage>959</lpage><pub-id pub-id-type="doi">10.1007/s11745-001-0805-6</pub-id><pub-id pub-id-type="pmid">11724467</pub-id></mixed-citation></ref><ref id="B230"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Samadi</surname><given-names>P.</given-names></name><name><surname>Gregoire</surname><given-names>L.</given-names></name><name><surname>Rouillard</surname><given-names>C.</given-names></name><name><surname>Bedard</surname><given-names>P. J.</given-names></name><name><surname>Di Paolo</surname><given-names>T.</given-names></name><name><surname>Levesque</surname><given-names>D.</given-names></name></person-group> (<year>2006</year>). <article-title>Docosahexaenoic acid reduces levodopa-induced dyskinesias in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine monkeys</article-title>. <source>Ann. Neurol.</source> <volume>59</volume>, <fpage>282</fpage>&#x02013;<lpage>288</lpage><pub-id pub-id-type="doi">10.1002/ana.20738</pub-id><pub-id pub-id-type="pmid">16437566</pub-id></mixed-citation></ref><ref id="B231"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Samii</surname><given-names>A.</given-names></name><name><surname>Etminan</surname><given-names>M.</given-names></name><name><surname>Wiens</surname><given-names>M. O.</given-names></name><name><surname>Jafari</surname><given-names>S.</given-names></name></person-group> (<year>2009</year>). <article-title>NSAID use and the risk of Parkinson&#x02019;s disease: systematic review and meta-analysis of observational studies</article-title>. <source>Drugs Aging</source> <volume>26</volume>, <fpage>769</fpage>&#x02013;<lpage>779</lpage><pub-id pub-id-type="doi">10.2165/11316780-000000000-00000</pub-id><pub-id pub-id-type="pmid">19728750</pub-id></mixed-citation></ref><ref id="B232"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sandyk</surname><given-names>R.</given-names></name></person-group> (<year>1990</year>). <article-title>Mechanisms of action of ECT in Parkinson&#x02019;s disease: possible role of pineal melatonin</article-title>. <source>Int. J. Neurosci.</source> <volume>50</volume>, <fpage>83</fpage>&#x02013;<lpage>94</lpage><pub-id pub-id-type="doi">10.3109/00207459008987174</pub-id><pub-id pub-id-type="pmid">2269603</pub-id></mixed-citation></ref><ref id="B233"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sato</surname><given-names>Y.</given-names></name><name><surname>Kikuyama</surname><given-names>M.</given-names></name><name><surname>Oizumi</surname><given-names>K.</given-names></name></person-group> (<year>1997</year>). <article-title>High prevalence of vitamin D deficiency and reduced bone mass in Parkinson&#x02019;s disease</article-title>. <source>Neurology</source> <volume>49</volume>, <fpage>1273</fpage>&#x02013;<lpage>1278</lpage><pub-id pub-id-type="pmid">9371907</pub-id></mixed-citation></ref><ref id="B234"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sautter</surname><given-names>J.</given-names></name><name><surname>Kupsch</surname><given-names>A.</given-names></name><name><surname>Earl</surname><given-names>C. D.</given-names></name><name><surname>Oertel</surname><given-names>W. H.</given-names></name></person-group> (<year>1997</year>). <article-title>Degeneration of pre-labelled nigral neurons induced by intrastriatal 6-hydroxydopamine in the rat: behavioural and biochemical changes and pretreatment with the calcium-entry blocker nimodipine</article-title>. <source>Exp. Brain Res.</source> <volume>117</volume>, <fpage>111</fpage>&#x02013;<lpage>119</lpage><pub-id pub-id-type="doi">10.1007/s002210050204</pub-id><pub-id pub-id-type="pmid">9386009</pub-id></mixed-citation></ref><ref id="B235"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Scheider</surname><given-names>W. L.</given-names></name><name><surname>Hershey</surname><given-names>L. A.</given-names></name><name><surname>Vena</surname><given-names>J. E.</given-names></name><name><surname>Holmlund</surname><given-names>T.</given-names></name><name><surname>Marshall</surname><given-names>J. R.</given-names></name><name><surname>Freudenheim</surname><given-names>J. L.</given-names></name></person-group> (<year>1997</year>). <article-title>Dietary antioxidants and other dietary factors in the etiology of Parkinson&#x02019;s disease</article-title>. <source>Mov. Disord.</source> <volume>12</volume>, <fpage>190</fpage>&#x02013;<lpage>196</lpage><pub-id pub-id-type="doi">10.1002/mds.870120209</pub-id><pub-id pub-id-type="pmid">9087977</pub-id></mixed-citation></ref><ref id="B236"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Scherzer</surname><given-names>C. R.</given-names></name><name><surname>Eklund</surname><given-names>A. C.</given-names></name><name><surname>Morse</surname><given-names>L. J.</given-names></name><name><surname>Liao</surname><given-names>Z.</given-names></name><name><surname>Locascio</surname><given-names>J. J.</given-names></name><name><surname>Fefer</surname><given-names>D.</given-names></name><name><surname>Schwarzschild</surname><given-names>M. A.</given-names></name><name><surname>Schlossmacher</surname><given-names>M. G.</given-names></name><name><surname>Hauser</surname><given-names>M. A.</given-names></name><name><surname>Vance</surname><given-names>J. M.</given-names></name><name><surname>Sudarsky</surname><given-names>L. R.</given-names></name><name><surname>Standaert</surname><given-names>D. G.</given-names></name><name><surname>Growdon</surname><given-names>J. H.</given-names></name><name><surname>Jensen</surname><given-names>R. V.</given-names></name><name><surname>Gullans</surname><given-names>S. R.</given-names></name></person-group> (<year>2007</year>). <article-title>Molecular markers of early Parkinson&#x02019;s disease based on gene expression in blood</article-title>. <source>Proc. Natl. Acad. Sci. U.S.A.</source> <volume>104</volume>, <fpage>955</fpage>&#x02013;<lpage>960</lpage><pub-id pub-id-type="doi">10.1073/pnas.0610204104</pub-id><pub-id pub-id-type="pmid">17215369</pub-id></mixed-citation></ref><ref id="B237"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schlesinger</surname><given-names>I.</given-names></name><name><surname>Schlesinger</surname><given-names>N.</given-names></name></person-group> (<year>2008</year>). <article-title>Uric acid in Parkinson&#x02019;s disease</article-title>. <source>Mov. Disord.</source> <volume>23</volume>, <fpage>1653</fpage>&#x02013;<lpage>1657</lpage><pub-id pub-id-type="doi">10.1002/mds.22139</pub-id><pub-id pub-id-type="pmid">18618666</pub-id></mixed-citation></ref><ref id="B238"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schulz</surname><given-names>J. B.</given-names></name><name><surname>Lindenau</surname><given-names>J.</given-names></name><name><surname>Seyfried</surname><given-names>J.</given-names></name><name><surname>Dichgans</surname><given-names>J.</given-names></name></person-group> (<year>2000</year>). <article-title>Glutathione, oxidative stress and neurodegeneration</article-title>. <source>Eur. J. Biochem.</source> <volume>267</volume>, <fpage>4904</fpage>&#x02013;<lpage>4911</lpage><pub-id pub-id-type="doi">10.1046/j.1432-1327.2000.01595.x</pub-id><pub-id pub-id-type="pmid">10931172</pub-id></mixed-citation></ref><ref id="B239"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schwarzschild</surname><given-names>M. A.</given-names></name><name><surname>Schwid</surname><given-names>S. R.</given-names></name><name><surname>Marek</surname><given-names>K.</given-names></name><name><surname>Watts</surname><given-names>A.</given-names></name><name><surname>Lang</surname><given-names>A. E.</given-names></name><name><surname>Oakes</surname><given-names>D.</given-names></name><name><surname>Shoulson</surname><given-names>I.</given-names></name><name><surname>Ascherio</surname><given-names>A.</given-names></name><name><surname>Hyson</surname><given-names>C.</given-names></name><name><surname>Gorbold</surname><given-names>E.</given-names></name><name><surname>Rudolph</surname><given-names>A.</given-names></name><name><surname>Kieburtz</surname><given-names>K.</given-names></name><name><surname>Fahn</surname><given-names>S.</given-names></name><name><surname>Gauger</surname><given-names>L.</given-names></name><name><surname>Goetz</surname><given-names>C.</given-names></name><name><surname>Seibyl</surname><given-names>J.</given-names></name><name><surname>Forrest</surname><given-names>M.</given-names></name><name><surname>Ondrasik</surname><given-names>J.</given-names></name></person-group> (<year>2008</year>). <article-title>Serum urate as a predictor of clinical and radiographic progression in Parkinson disease</article-title>. <source>Arch. Neurol.</source> <volume>65</volume>, <fpage>716</fpage>&#x02013;<lpage>723</lpage><pub-id pub-id-type="doi">10.1001/archneur.2008.65.6.nct70003</pub-id><pub-id pub-id-type="pmid">18413464</pub-id></mixed-citation></ref><ref id="B240"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Seaton</surname><given-names>T. A.</given-names></name><name><surname>Jenner</surname><given-names>P.</given-names></name><name><surname>Marsden</surname><given-names>C. D.</given-names></name></person-group> (<year>1996</year>). <article-title>Thioctic acid does not restore glutathione levels or protect against the potentiation of 6-hydroxydopamine toxicity induced by glutathione depletion in rat brain</article-title>. <source>J. Neural Transm.</source> <volume>103</volume>, <fpage>315</fpage>&#x02013;<lpage>329</lpage><pub-id pub-id-type="doi">10.1007/BF01271243</pub-id><pub-id pub-id-type="pmid">8739843</pub-id></mixed-citation></ref><ref id="B241"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shamsuddin</surname><given-names>A. M.</given-names></name><name><surname>Vucenik</surname><given-names>I.</given-names></name><name><surname>Cole</surname><given-names>K. E.</given-names></name></person-group> (<year>1997</year>). <article-title>IP6: a novel anti-cancer agent</article-title>. <source>Life Sci.</source> <volume>61</volume>, <fpage>343</fpage>&#x02013;<lpage>354</lpage><pub-id pub-id-type="doi">10.1016/S0024-3205(97)00092-1</pub-id><pub-id pub-id-type="pmid">9244360</pub-id></mixed-citation></ref><ref id="B242"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sharma</surname><given-names>S.</given-names></name><name><surname>Kheradpezhou</surname><given-names>M.</given-names></name><name><surname>Shavali</surname><given-names>S.</given-names></name><name><surname>El Refaey</surname><given-names>H.</given-names></name><name><surname>Eken</surname><given-names>J.</given-names></name><name><surname>Hagen</surname><given-names>C.</given-names></name><name><surname>Ebadi</surname><given-names>M.</given-names></name></person-group> (<year>2004</year>). <article-title>Neuroprotective actions of coenzyme Q10 in Parkinson&#x02019;s disease</article-title>. <source>Meth. Enzymol.</source> <volume>382</volume>, <fpage>488</fpage>&#x02013;<lpage>509</lpage><pub-id pub-id-type="doi">10.1016/S0076-6879(04)82027-5</pub-id><pub-id pub-id-type="pmid">15047119</pub-id></mixed-citation></ref><ref id="B243"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shults</surname><given-names>C. W.</given-names></name></person-group> (<year>2003</year>). <article-title>Coenzyme Q10 in neurodegenerative diseases</article-title>. <source>Curr. Med. Chem.</source> <volume>10</volume>, <fpage>1917</fpage>&#x02013;<lpage>1921</lpage><pub-id pub-id-type="doi">10.2174/0929867033456882</pub-id><pub-id pub-id-type="pmid">12871093</pub-id></mixed-citation></ref><ref id="B244"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shults</surname><given-names>C. W.</given-names></name><name><surname>Flint Beal</surname><given-names>M.</given-names></name><name><surname>Song</surname><given-names>D.</given-names></name><name><surname>Fontaine</surname><given-names>D.</given-names></name></person-group> (<year>2004</year>). <article-title>Pilot trial of high dosages of coenzyme Q10 in patients with Parkinson&#x02019;s disease</article-title>. <source>Exp. Neurol.</source> <volume>188</volume>, <fpage>491</fpage>&#x02013;<lpage>494</lpage><pub-id pub-id-type="doi">10.1016/j.expneurol.2004.05.003</pub-id><pub-id pub-id-type="pmid">15246848</pub-id></mixed-citation></ref><ref id="B245"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shults</surname><given-names>C. W.</given-names></name><name><surname>Haas</surname><given-names>R. H.</given-names></name><name><surname>Beal</surname><given-names>M. F.</given-names></name></person-group> (<year>1999</year>). <article-title>A possible role of coenzyme Q10 in the etiology and treatment of Parkinson&#x02019;s disease</article-title>. <source>Biofactors</source> <volume>9</volume>, <fpage>267</fpage>&#x02013;<lpage>272</lpage><pub-id pub-id-type="doi">10.1002/biof.5520090223</pub-id><pub-id pub-id-type="pmid">10416040</pub-id></mixed-citation></ref><ref id="B246"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shults</surname><given-names>C. W.</given-names></name><name><surname>Haas</surname><given-names>R. H.</given-names></name><name><surname>Passov</surname><given-names>D.</given-names></name><name><surname>Beal</surname><given-names>M. F.</given-names></name></person-group> (<year>1997</year>). <article-title>Coenzyme Q10 levels correlate with the activities of complexes I and II/III in mitochondria from parkinsonian and nonparkinsonian subjects</article-title>. <source>Ann. Neurol.</source> <volume>42</volume>, <fpage>261</fpage>&#x02013;<lpage>264</lpage><pub-id pub-id-type="doi">10.1002/ana.410420221</pub-id><pub-id pub-id-type="pmid">9266740</pub-id></mixed-citation></ref><ref id="B247"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shults</surname><given-names>C. W.</given-names></name><name><surname>Oakes</surname><given-names>D.</given-names></name><name><surname>Kieburtz</surname><given-names>K.</given-names></name><name><surname>Beal</surname><given-names>M. F.</given-names></name><name><surname>Haas</surname><given-names>R.</given-names></name><name><surname>Plumb</surname><given-names>S.</given-names></name><name><surname>Juncos</surname><given-names>J. L.</given-names></name><name><surname>Nutt</surname><given-names>J.</given-names></name><name><surname>Shoulson</surname><given-names>I.</given-names></name><name><surname>Carter</surname><given-names>J.</given-names></name><name><surname>Kompoliti</surname><given-names>K.</given-names></name><name><surname>Perlmutter</surname><given-names>J. S.</given-names></name><name><surname>Reich</surname><given-names>S.</given-names></name><name><surname>Stern</surname><given-names>M.</given-names></name><name><surname>Watts</surname><given-names>R. L.</given-names></name><name><surname>Kurlan</surname><given-names>R.</given-names></name><name><surname>Molho</surname><given-names>E.</given-names></name><name><surname>Harrison</surname><given-names>M.</given-names></name><name><surname>Lew</surname><given-names>M.</given-names></name></person-group> (<year>2002</year>). <article-title>Effects of coenzyme Q10 in early Parkinson disease: evidence of slowing of the functional decline</article-title>. <source>Arch. Neurol.</source> <volume>59</volume>, <fpage>1541</fpage>&#x02013;<lpage>1550</lpage><pub-id pub-id-type="doi">10.1001/archneur.59.10.1541</pub-id><pub-id pub-id-type="pmid">12374491</pub-id></mixed-citation></ref><ref id="B248"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sian</surname><given-names>J.</given-names></name><name><surname>Dexter</surname><given-names>D. T.</given-names></name><name><surname>Lees</surname><given-names>A. J.</given-names></name><name><surname>Daniel</surname><given-names>S.</given-names></name><name><surname>Agid</surname><given-names>Y.</given-names></name><name><surname>Javoy-Agid</surname><given-names>F.</given-names></name><name><surname>Jenner</surname><given-names>P.</given-names></name><name><surname>Marsden</surname><given-names>C. D.</given-names></name></person-group> (<year>1994</year>). <article-title>Alterations in glutathione levels in Parkinson&#x02019;s disease and other neurodegenerative disorders affecting basal ganglia</article-title>. <source>Ann. Neurol.</source> <volume>36</volume>, <fpage>348</fpage>&#x02013;<lpage>355</lpage><pub-id pub-id-type="doi">10.1002/ana.410360305</pub-id><pub-id pub-id-type="pmid">8080242</pub-id></mixed-citation></ref><ref id="B249"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Simon</surname><given-names>K. C.</given-names></name><name><surname>Chen</surname><given-names>H.</given-names></name><name><surname>Gao</surname><given-names>X.</given-names></name><name><surname>Schwarzschild</surname><given-names>M. A.</given-names></name><name><surname>Ascherio</surname><given-names>A.</given-names></name></person-group> (<year>2009</year>). <article-title>Reproductive factors, exogenous estrogen use, and risk of Parkinson&#x02019;s disease</article-title>. <source>Mov. Disord.</source> <volume>24</volume>, <fpage>1359</fpage>&#x02013;<lpage>1365</lpage><pub-id pub-id-type="doi">10.1002/mds.22619</pub-id><pub-id pub-id-type="pmid">19424986</pub-id></mixed-citation></ref><ref id="B250"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Simuni</surname><given-names>T.</given-names></name><name><surname>Borushko</surname><given-names>E.</given-names></name><name><surname>Avram</surname><given-names>M. J.</given-names></name><name><surname>Miskevics</surname><given-names>S.</given-names></name><name><surname>Martel</surname><given-names>A.</given-names></name><name><surname>Zadikoff</surname><given-names>C.</given-names></name><name><surname>Videnovic</surname><given-names>A.</given-names></name><name><surname>Weaver</surname><given-names>F. M.</given-names></name><name><surname>Williams</surname><given-names>K.</given-names></name><name><surname>Surmeier</surname><given-names>D. J.</given-names></name></person-group> (<year>2010</year>). <article-title>Tolerability of isradipine in early Parkinson&#x02019;s disease: a pilot dose escalation study</article-title>. <source>Mov. Disord.</source> <volume>25</volume>, <fpage>2863</fpage>&#x02013;<lpage>2866</lpage><pub-id pub-id-type="doi">10.1002/mds.23308</pub-id><pub-id pub-id-type="pmid">20818667</pub-id></mixed-citation></ref><ref id="B251"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Singh</surname><given-names>S.</given-names></name><name><surname>Singh</surname><given-names>K.</given-names></name><name><surname>Patel</surname><given-names>S.</given-names></name><name><surname>Patel</surname><given-names>D. K.</given-names></name><name><surname>Singh</surname><given-names>C.</given-names></name><name><surname>Nath</surname><given-names>C.</given-names></name><name><surname>Singh</surname><given-names>M. P.</given-names></name></person-group> (<year>2008</year>). <article-title>Nicotine and caffeine-mediated modulation in the expression of toxicant responsive genes and vesicular monoamine transporter-2 in 1-methyl 4-phenyl-1,2,3,6-tetrahydropyridine-induced Parkinson&#x02019;s disease phenotype in mouse</article-title>. <source>Brain Res.</source> <volume>1207</volume>, <fpage>193</fpage>&#x02013;<lpage>206</lpage><pub-id pub-id-type="doi">10.1016/j.brainres.2008.02.023</pub-id><pub-id pub-id-type="pmid">18374908</pub-id></mixed-citation></ref><ref id="B252"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sirivech</surname><given-names>S.</given-names></name><name><surname>Driskell</surname><given-names>J.</given-names></name><name><surname>Frieden</surname><given-names>E.</given-names></name></person-group> (<year>1977</year>). <article-title>NADH-FMN oxidoreductase activity and iron content of organs from riboflavin and iron-deficient rats</article-title>. <source>J. Nutr.</source> <volume>107</volume>, <fpage>739</fpage>&#x02013;<lpage>745</lpage><pub-id pub-id-type="pmid">859041</pub-id></mixed-citation></ref><ref id="B253"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Smith</surname><given-names>M. P.</given-names></name><name><surname>Fletcher-Turner</surname><given-names>A.</given-names></name><name><surname>Yurek</surname><given-names>D. M.</given-names></name><name><surname>Cass</surname><given-names>W. A.</given-names></name></person-group> (<year>2006</year>). <article-title>Calcitriol protection against dopamine loss induced by intracerebroventricular administration of 6-hydroxydopamine</article-title>. <source>Neurochem. Res.</source> <volume>31</volume>, <fpage>533</fpage>&#x02013;<lpage>539</lpage><pub-id pub-id-type="doi">10.1007/s11064-006-9048-4</pub-id><pub-id pub-id-type="pmid">16758362</pub-id></mixed-citation></ref><ref id="B254"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sohmiya</surname><given-names>M.</given-names></name><name><surname>Tanaka</surname><given-names>M.</given-names></name><name><surname>Tak</surname><given-names>N. W.</given-names></name><name><surname>Yanagisawa</surname><given-names>M.</given-names></name><name><surname>Tanino</surname><given-names>Y.</given-names></name><name><surname>Suzuki</surname><given-names>Y.</given-names></name><name><surname>Okamoto</surname><given-names>K.</given-names></name><name><surname>Yamamoto</surname><given-names>Y.</given-names></name></person-group> (<year>2004</year>). <article-title>Redox status of plasma coenzyme Q10 indicates elevated systemic oxidative stress in Parkinson&#x02019;s disease</article-title>. <source>J. Neurol. Sci.</source> <volume>223</volume>, <fpage>161</fpage>&#x02013;<lpage>166</lpage><pub-id pub-id-type="doi">10.1016/j.jns.2004.05.007</pub-id><pub-id pub-id-type="pmid">15337618</pub-id></mixed-citation></ref><ref id="B255"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Speiser</surname><given-names>Z.</given-names></name><name><surname>Mayk</surname><given-names>A.</given-names></name><name><surname>Eliash</surname><given-names>S.</given-names></name><name><surname>Cohen</surname><given-names>S.</given-names></name></person-group> (<year>1999</year>). <article-title>Studies with rasagiline, a MAO-B inhibitor, in experimental focal ischemia in the rat</article-title>. <source>J. Neural Transm.</source> <volume>106</volume>, <fpage>593</fpage>&#x02013;<lpage>606</lpage><pub-id pub-id-type="doi">10.1007/s007020050182</pub-id><pub-id pub-id-type="pmid">10907720</pub-id></mixed-citation></ref><ref id="B256"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sriram</surname><given-names>K.</given-names></name><name><surname>Miller</surname><given-names>D. B.</given-names></name><name><surname>O&#x02019;Callaghan</surname><given-names>J. P.</given-names></name></person-group> (<year>2006</year>). <article-title>Minocycline attenuates microglial activation but fails to mitigate striatal dopaminergic neurotoxicity: role of tumor necrosis factor-alpha</article-title>. <source>J. Neurochem.</source> <volume>96</volume>, <fpage>706</fpage>&#x02013;<lpage>718</lpage><pub-id pub-id-type="doi">10.1111/j.1471-4159.2005.03566.x</pub-id><pub-id pub-id-type="pmid">16405514</pub-id></mixed-citation></ref><ref id="B257"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Takeuchi</surname><given-names>H.</given-names></name><name><surname>Yanagida</surname><given-names>T.</given-names></name><name><surname>Inden</surname><given-names>M.</given-names></name><name><surname>Takata</surname><given-names>K.</given-names></name><name><surname>Kitamura</surname><given-names>Y.</given-names></name><name><surname>Yamakawa</surname><given-names>K.</given-names></name><name><surname>Sawada</surname><given-names>H.</given-names></name><name><surname>Izumi</surname><given-names>Y.</given-names></name><name><surname>Yamamoto</surname><given-names>N.</given-names></name><name><surname>Kihara</surname><given-names>T.</given-names></name><name><surname>Uemura</surname><given-names>K.</given-names></name><name><surname>Inoue</surname><given-names>H.</given-names></name><name><surname>Taniguchi</surname><given-names>T.</given-names></name><name><surname>Akaike</surname><given-names>A.</given-names></name><name><surname>Takahashi</surname><given-names>R.</given-names></name><name><surname>Shimohama</surname><given-names>S.</given-names></name></person-group> (<year>2009</year>). <article-title>Nicotinic receptor stimulation protects nigral dopaminergic neurons in rotenone-induced Parkinson&#x02019;s disease models</article-title>. <source>J. Neurosci. Res.</source> <volume>87</volume>, <fpage>576</fpage>&#x02013;<lpage>585</lpage><pub-id pub-id-type="doi">10.1002/jnr.21869</pub-id><pub-id pub-id-type="pmid">18803299</pub-id></mixed-citation></ref><ref id="B258"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tan</surname><given-names>E. K.</given-names></name><name><surname>Tan</surname><given-names>C.</given-names></name><name><surname>Fook-Chong</surname><given-names>S. M.</given-names></name><name><surname>Lum</surname><given-names>S. Y.</given-names></name><name><surname>Chai</surname><given-names>A.</given-names></name><name><surname>Chung</surname><given-names>H.</given-names></name><name><surname>Shen</surname><given-names>H.</given-names></name><name><surname>Zhao</surname><given-names>Y.</given-names></name><name><surname>Teoh</surname><given-names>M. L.</given-names></name><name><surname>Yih</surname><given-names>Y.</given-names></name><name><surname>Pavanni</surname><given-names>R.</given-names></name><name><surname>Chandran</surname><given-names>V. R.</given-names></name><name><surname>Wong</surname><given-names>M. C.</given-names></name></person-group> (<year>2003</year>). <article-title>Dose-dependent protective effect of coffee, tea, and smoking in Parkinson&#x02019;s disease: a study in ethnic Chinese</article-title>. <source>J. Neurol. Sci.</source> <volume>216</volume>, <fpage>163</fpage>&#x02013;<lpage>167</lpage><pub-id pub-id-type="doi">10.1016/j.jns.2003.07.006</pub-id><pub-id pub-id-type="pmid">14607318</pub-id></mixed-citation></ref><ref id="B259"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tapias</surname><given-names>V.</given-names></name><name><surname>Cannon</surname><given-names>J. R.</given-names></name><name><surname>Greenamyre</surname><given-names>J. T.</given-names></name></person-group> (<year>2010</year>). <article-title>Melatonin treatment potentiates neurodegeneration in a rat rotenone Parkinson&#x02019;s disease model</article-title>. <source>J. Neurosci. Res.</source> <volume>88</volume>, <fpage>420</fpage>&#x02013;<lpage>427</lpage><pub-id pub-id-type="doi">10.1002/jnr.22201</pub-id><pub-id pub-id-type="pmid">19681169</pub-id></mixed-citation></ref><ref id="B260"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tappel</surname><given-names>A.</given-names></name></person-group> (<year>1962</year>). <article-title>Vitamin E as the biological lipid antioxidant</article-title>. <source>Vitam. Horm.</source> <volume>20</volume>, <fpage>493</fpage>&#x02013;<lpage>509</lpage><pub-id pub-id-type="doi">10.1016/S0083-6729(08)60732-3</pub-id></mixed-citation></ref><ref id="B261"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tarnopolsky</surname><given-names>M. A.</given-names></name><name><surname>Beal</surname><given-names>M. F.</given-names></name></person-group> (<year>2001</year>). <article-title>Potential for creatine and other therapies targeting cellular energy dysfunction in neurological disorders</article-title>. <source>Ann. Neurol.</source> <volume>49</volume>, <fpage>561</fpage>&#x02013;<lpage>574</lpage><pub-id pub-id-type="doi">10.1002/ana.1028</pub-id><pub-id pub-id-type="pmid">11357946</pub-id></mixed-citation></ref><ref id="B262"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tatton</surname><given-names>W.</given-names></name><name><surname>Chalmers-Redman</surname><given-names>R.</given-names></name><name><surname>Tatton</surname><given-names>N.</given-names></name></person-group> (<year>2003</year>). <article-title>Neuroprotection by deprenyl and other propargylamines: glyceraldehyde-3-phosphate dehydrogenase rather than monoamine oxidase B</article-title>. <source>J. Neural Transm.</source> <volume>110</volume>, <fpage>509</fpage>&#x02013;<lpage>515</lpage><pub-id pub-id-type="doi">10.1007/s00702-002-0827-z</pub-id><pub-id pub-id-type="pmid">12721812</pub-id></mixed-citation></ref><ref id="B263"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tikka</surname><given-names>T.</given-names></name><name><surname>Fiebich</surname><given-names>B. L.</given-names></name><name><surname>Goldsteins</surname><given-names>G.</given-names></name><name><surname>Keinanen</surname><given-names>R.</given-names></name><name><surname>Koistinaho</surname><given-names>J.</given-names></name></person-group> (<year>2001</year>). <article-title>Minocycline, a tetracycline derivative, is neuroprotective against excitotoxicity by inhibiting activation and proliferation of microglia</article-title>. <source>J. Neurosci.</source> <volume>21</volume>, <fpage>2580</fpage>&#x02013;<lpage>2588</lpage><pub-id pub-id-type="pmid">11306611</pub-id></mixed-citation></ref><ref id="B264"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tohgi</surname><given-names>H.</given-names></name><name><surname>Abe</surname><given-names>T.</given-names></name><name><surname>Takahashi</surname><given-names>S.</given-names></name><name><surname>Kikuchi</surname><given-names>T.</given-names></name></person-group> (<year>1993</year>). <article-title>The urate and xanthine concentrations in the cerebrospinal fluid in patients with vascular dementia of the Binswanger type, Alzheimer type dementia, and Parkinson&#x02019;s disease</article-title>. <source>J. Neural Transm. Park. Dis. Dement. Sect.</source> <volume>6</volume>, <fpage>119</fpage>&#x02013;<lpage>126</lpage><pub-id pub-id-type="doi">10.1007/BF02261005</pub-id><pub-id pub-id-type="pmid">8117408</pub-id></mixed-citation></ref><ref id="B265"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ton</surname><given-names>T. G.</given-names></name><name><surname>Heckbert</surname><given-names>S. R.</given-names></name><name><surname>Longstreth</surname><given-names>W. T.</given-names><suffix>Jr.</suffix></name><name><surname>Rossing</surname><given-names>M. A.</given-names></name><name><surname>Kukull</surname><given-names>W. A.</given-names></name><name><surname>Franklin</surname><given-names>G. M.</given-names></name><name><surname>Swanson</surname><given-names>P. D.</given-names></name><name><surname>Smith-Weller</surname><given-names>T.</given-names></name><name><surname>Checkoway</surname><given-names>H.</given-names></name></person-group> (<year>2006</year>). <article-title>Nonsteroidal anti-inflammatory drugs and risk of Parkinson&#x02019;s disease</article-title>. <source>Mov. Disord.</source> <volume>21</volume>, <fpage>964</fpage>&#x02013;<lpage>969</lpage><pub-id pub-id-type="doi">10.1002/mds.20856</pub-id><pub-id pub-id-type="pmid">16550541</pub-id></mixed-citation></ref><ref id="B266"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Toulorge</surname><given-names>D.</given-names></name><name><surname>Guerreiro</surname><given-names>S.</given-names></name><name><surname>Hild</surname><given-names>A.</given-names></name><name><surname>Maskos</surname><given-names>U.</given-names></name><name><surname>Hirsch</surname><given-names>E. C.</given-names></name><name><surname>Michel</surname><given-names>P. P.</given-names></name></person-group> (<year>2011</year>). <article-title>Neuroprotection of midbrain dopamine neurons by nicotine is gated by cytoplasmic Ca2+</article-title>. <source>FASEB J.</source> <volume>25</volume>, <fpage>2563</fpage>&#x02013;<lpage>2573</lpage><pub-id pub-id-type="doi">10.1096/fj.11-182824</pub-id><pub-id pub-id-type="pmid">21507900</pub-id></mixed-citation></ref><ref id="B267"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Traber</surname><given-names>M. G.</given-names></name><name><surname>Sies</surname><given-names>H.</given-names></name></person-group> (<year>1996</year>). <article-title>Vitamin E in humans: demand and delivery</article-title>. <source>Annu. Rev. Nutr.</source> <volume>16</volume>, <fpage>321</fpage>&#x02013;<lpage>347</lpage><pub-id pub-id-type="doi">10.1146/annurev.nu.16.070196.001541</pub-id><pub-id pub-id-type="pmid">8839930</pub-id></mixed-citation></ref><ref id="B268"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Trinh</surname><given-names>K.</given-names></name><name><surname>Andrews</surname><given-names>L.</given-names></name><name><surname>Krause</surname><given-names>J.</given-names></name><name><surname>Hanak</surname><given-names>T.</given-names></name><name><surname>Lee</surname><given-names>D.</given-names></name><name><surname>Gelb</surname><given-names>M.</given-names></name><name><surname>Pallanck</surname><given-names>L.</given-names></name></person-group> (<year>2010</year>). <article-title>Decaffeinated coffee and nicotine-free tobacco provide neuroprotection in <italic>Drosophila</italic> models of Parkinson&#x02019;s disease through an NRF2-dependent mechanism</article-title>. <source>J. Neurosci.</source> <volume>30</volume>, <fpage>5525</fpage>&#x02013;<lpage>5532</lpage><pub-id pub-id-type="doi">10.1523/JNEUROSCI.4777-09.2010</pub-id><pub-id pub-id-type="pmid">20410106</pub-id></mixed-citation></ref><ref id="B269"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>van den Pol</surname><given-names>A. N.</given-names></name></person-group> (<year>1986</year>). <article-title>Tyrosine hydroxylase immunoreactive neurons throughout the hypothalamus receive glutamate decarboxylase immunoreactive synapses: a double pre-embedding immunocytochemical study with particulate silver and HRP</article-title>. <source>J. Neurosci.</source> <volume>6</volume>, <fpage>877</fpage>&#x02013;<lpage>891</lpage><pub-id pub-id-type="pmid">2870143</pub-id></mixed-citation></ref><ref id="B270"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wahner</surname><given-names>A. D.</given-names></name><name><surname>Bronstein</surname><given-names>J. M.</given-names></name><name><surname>Bordelon</surname><given-names>Y. M.</given-names></name><name><surname>Ritz</surname><given-names>B.</given-names></name></person-group> (<year>2007</year>). <article-title>Nonsteroidal anti-inflammatory drugs may protect against Parkinson disease</article-title>. <source>Neurology</source> <volume>69</volume>, <fpage>1836</fpage>&#x02013;<lpage>1842</lpage><pub-id pub-id-type="doi">10.1212/01.wnl.0000279519.99344.ad</pub-id><pub-id pub-id-type="pmid">17984451</pub-id></mixed-citation></ref><ref id="B271"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>J. Y.</given-names></name><name><surname>Wu</surname><given-names>J. N.</given-names></name><name><surname>Cherng</surname><given-names>T. L.</given-names></name><name><surname>Hoffer</surname><given-names>B. J.</given-names></name><name><surname>Chen</surname><given-names>H. H.</given-names></name><name><surname>Borlongan</surname><given-names>C. V.</given-names></name><name><surname>Wang</surname><given-names>Y.</given-names></name></person-group> (<year>2001</year>). <article-title>Vitamin D(3) attenuates 6-hydroxydopamine-induced neurotoxicity in rats</article-title>. <source>Brain Res.</source> <volume>904</volume>, <fpage>67</fpage>&#x02013;<lpage>75</lpage><pub-id pub-id-type="doi">10.1016/S0006-8993(01)02450-7</pub-id><pub-id pub-id-type="pmid">11516412</pub-id></mixed-citation></ref><ref id="B272"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>X.</given-names></name><name><surname>Zhao</surname><given-names>X.</given-names></name><name><surname>Mao</surname><given-names>Z. Y.</given-names></name><name><surname>Wang</surname><given-names>X. M.</given-names></name><name><surname>Liu</surname><given-names>Z. L.</given-names></name></person-group> (<year>2003</year>). <article-title>Neuroprotective effect of docosahexaenoic acid on glutamate-induced cytotoxicity in rat hippocampal cultures</article-title>. <source>Neuroreport</source> <volume>14</volume>, <fpage>2457</fpage>&#x02013;<lpage>2461</lpage><pub-id pub-id-type="doi">10.1097/00001756-200305060-00008</pub-id><pub-id pub-id-type="pmid">14663210</pub-id></mixed-citation></ref><ref id="B273"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Weinreb</surname><given-names>O.</given-names></name><name><surname>Bar-Am</surname><given-names>O.</given-names></name><name><surname>Amit</surname><given-names>T.</given-names></name><name><surname>Chillag-Talmor</surname><given-names>O.</given-names></name><name><surname>Youdim</surname><given-names>M. B.</given-names></name></person-group> (<year>2004</year>). <article-title>Neuroprotection via pro-survival protein kinase C isoforms associated with Bcl-2 family members</article-title>. <source>FASEB J.</source> <volume>18</volume>, <fpage>1471</fpage>&#x02013;<lpage>1473</lpage><pub-id pub-id-type="pmid">15247150</pub-id></mixed-citation></ref><ref id="B274"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wu</surname><given-names>A.</given-names></name><name><surname>Ying</surname><given-names>Z.</given-names></name><name><surname>Gomez-Pinilla</surname><given-names>F.</given-names></name></person-group> (<year>2004</year>). <article-title>Dietary omega-3 fatty acids normalize BDNF levels, reduce oxidative damage, and counteract learning disability after traumatic brain injury in rats</article-title>. <source>J. Neurotrauma</source> <volume>21</volume>, <fpage>1457</fpage>&#x02013;<lpage>1467</lpage><pub-id pub-id-type="doi">10.1089/neu.2004.21.1457</pub-id><pub-id pub-id-type="pmid">15672635</pub-id></mixed-citation></ref><ref id="B275"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wu</surname><given-names>D. C.</given-names></name><name><surname>Jackson-Lewis</surname><given-names>V.</given-names></name><name><surname>Vila</surname><given-names>M.</given-names></name><name><surname>Tieu</surname><given-names>K.</given-names></name><name><surname>Teismann</surname><given-names>P.</given-names></name><name><surname>Vadseth</surname><given-names>C.</given-names></name><name><surname>Choi</surname><given-names>D. K.</given-names></name><name><surname>Ischiropoulos</surname><given-names>H.</given-names></name><name><surname>Przedborski</surname><given-names>S.</given-names></name></person-group> (<year>2002</year>). <article-title>Blockade of microglial activation is neuroprotective in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine mouse model of Parkinson disease</article-title>. <source>J. Neurosci.</source> <volume>22</volume>, <fpage>1763</fpage>&#x02013;<lpage>1771</lpage><pub-id pub-id-type="pmid">11880505</pub-id></mixed-citation></ref><ref id="B276"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wullner</surname><given-names>U.</given-names></name><name><surname>Loschmann</surname><given-names>P. A.</given-names></name><name><surname>Schulz</surname><given-names>J. B.</given-names></name><name><surname>Schmid</surname><given-names>A.</given-names></name><name><surname>Dringen</surname><given-names>R.</given-names></name><name><surname>Eblen</surname><given-names>F.</given-names></name><name><surname>Turski</surname><given-names>L.</given-names></name><name><surname>Klockgether</surname><given-names>T.</given-names></name></person-group> (<year>1996</year>). <article-title>Glutathione depletion potentiates MPTP and MPP+ toxicity in nigral dopaminergic neurones</article-title>. <source>Neuroreport</source> <volume>7</volume>, <fpage>921</fpage>&#x02013;<lpage>923</lpage><pub-id pub-id-type="doi">10.1097/00001756-199603220-00018</pub-id><pub-id pub-id-type="pmid">8724674</pub-id></mixed-citation></ref><ref id="B277"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wurtman</surname><given-names>R. J.</given-names></name><name><surname>Ulus</surname><given-names>I. H.</given-names></name><name><surname>Cansev</surname><given-names>M.</given-names></name><name><surname>Watkins</surname><given-names>C. J.</given-names></name><name><surname>Wang</surname><given-names>L.</given-names></name><name><surname>Marzloff</surname><given-names>G.</given-names></name></person-group> (<year>2006</year>). <article-title>Synaptic proteins and phospholipids are increased in gerbil brain by administering uridine plus docosahexaenoic acid orally</article-title>. <source>Brain Res.</source> <volume>1088</volume>, <fpage>83</fpage>&#x02013;<lpage>92</lpage><pub-id pub-id-type="doi">10.1016/j.brainres.2006.03.019</pub-id><pub-id pub-id-type="pmid">16631143</pub-id></mixed-citation></ref><ref id="B278"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Xu</surname><given-names>C. J.</given-names></name><name><surname>Klunk</surname><given-names>W. E.</given-names></name><name><surname>Kanfer</surname><given-names>J. N.</given-names></name><name><surname>Xiong</surname><given-names>Q.</given-names></name><name><surname>Miller</surname><given-names>G.</given-names></name><name><surname>Pettegrew</surname><given-names>J. W.</given-names></name></person-group> (<year>1996</year>). <article-title>Phosphocreatine-dependent glutamate uptake by synaptic vesicles. A comparison with atp-dependent glutamate uptake</article-title>. <source>J. Biol. Chem.</source> <volume>271</volume>, <fpage>13435</fpage>&#x02013;<lpage>13440</lpage><pub-id pub-id-type="doi">10.1074/jbc.271.31.18520</pub-id><pub-id pub-id-type="pmid">8662761</pub-id></mixed-citation></ref><ref id="B279"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Xu</surname><given-names>K.</given-names></name><name><surname>Xu</surname><given-names>Y.</given-names></name><name><surname>Brown-Jermyn</surname><given-names>D.</given-names></name><name><surname>Chen</surname><given-names>J. F.</given-names></name><name><surname>Ascherio</surname><given-names>A.</given-names></name><name><surname>Dluzen</surname><given-names>D. E.</given-names></name><name><surname>Schwarzschild</surname><given-names>M. A.</given-names></name></person-group> (<year>2006</year>). <article-title>Estrogen prevents neuroprotection by caffeine in the mouse 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine model of Parkinson&#x02019;s disease</article-title>. <source>J. Neurosci.</source> <volume>26</volume>, <fpage>535</fpage>&#x02013;<lpage>541</lpage><pub-id pub-id-type="doi">10.1523/JNEUROSCI.5476-05.2006</pub-id><pub-id pub-id-type="pmid">16407551</pub-id></mixed-citation></ref><ref id="B280"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Xu</surname><given-names>K.</given-names></name><name><surname>Xu</surname><given-names>Y. H.</given-names></name><name><surname>Chen</surname><given-names>J. F.</given-names></name><name><surname>Schwarzschild</surname><given-names>M. A.</given-names></name></person-group> (<year>2002</year>). <article-title>Caffeine&#x02019;s neuroprotection against 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine toxicity shows no tolerance to chronic caffeine administration in mice</article-title>. <source>Neurosci. Lett.</source> <volume>322</volume>, <fpage>13</fpage>&#x02013;<lpage>16</lpage><pub-id pub-id-type="doi">10.1016/S0304-3940(02)00071-X</pub-id><pub-id pub-id-type="pmid">11958832</pub-id></mixed-citation></ref><ref id="B281"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Xu</surname><given-names>K.</given-names></name><name><surname>Xu</surname><given-names>Y. H.</given-names></name><name><surname>Chen</surname><given-names>J. F.</given-names></name><name><surname>Schwarzschild</surname><given-names>M. A.</given-names></name></person-group> (<year>2010</year>). <article-title>Neuroprotection by caffeine: time course and role of its metabolites in the MPTP model of Parkinson&#x02019;s disease</article-title>. <source>Neuroscience</source> <volume>167</volume>, <fpage>475</fpage>&#x02013;<lpage>481</lpage><pub-id pub-id-type="doi">10.1016/j.neuroscience.2010.01.048</pub-id><pub-id pub-id-type="pmid">20167258</pub-id></mixed-citation></ref><ref id="B282"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Xu</surname><given-names>Q.</given-names></name><name><surname>Kanthasamy</surname><given-names>A. G.</given-names></name><name><surname>Reddy</surname><given-names>M. B.</given-names></name></person-group> (<year>2008</year>). <article-title>Neuroprotective effect of the natural iron chelator, phytic acid in a cell culture model of Parkinson&#x02019;s disease</article-title>. <source>Toxicology</source> <volume>245</volume>, <fpage>101</fpage>&#x02013;<lpage>108</lpage><pub-id pub-id-type="doi">10.1016/j.tox.2007.12.017</pub-id><pub-id pub-id-type="pmid">18255213</pub-id></mixed-citation></ref><ref id="B283"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Xu</surname><given-names>Q.</given-names></name><name><surname>Kanthasamy</surname><given-names>A. G.</given-names></name><name><surname>Reddy</surname><given-names>M. B.</given-names></name></person-group> (<year>2011</year>). <article-title>Phytic acid protects against 6-hydroxydopamine-induced dopaminergic neuron apoptosis in normal and iron excess conditions in a cell culture model</article-title>. <source>Parkinsons Dis.</source> <volume>2011</volume>, <fpage>431068</fpage><pub-id pub-id-type="pmid">21331377</pub-id></mixed-citation></ref><ref id="B284"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yang</surname><given-names>L.</given-names></name><name><surname>Calingasan</surname><given-names>N. Y.</given-names></name><name><surname>Wille</surname><given-names>E. J.</given-names></name><name><surname>Cormier</surname><given-names>K.</given-names></name><name><surname>Smith</surname><given-names>K.</given-names></name><name><surname>Ferrante</surname><given-names>R. J.</given-names></name><name><surname>Beal</surname><given-names>M. F.</given-names></name></person-group> (<year>2009</year>). <article-title>Combination therapy with coenzyme Q10 and creatine produces additive neuroprotective effects in models of Parkinson&#x02019;s and Huntington&#x02019;s diseases</article-title>. <source>J. Neurochem.</source> <volume>109</volume>, <fpage>1427</fpage>&#x02013;<lpage>1439</lpage><pub-id pub-id-type="doi">10.1111/j.1471-4159.2009.06074.x</pub-id><pub-id pub-id-type="pmid">19476553</pub-id></mixed-citation></ref><ref id="B285"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yang</surname><given-names>L.</given-names></name><name><surname>Sugama</surname><given-names>S.</given-names></name><name><surname>Chirichigno</surname><given-names>J. W.</given-names></name><name><surname>Gregorio</surname><given-names>J.</given-names></name><name><surname>Lorenzl</surname><given-names>S.</given-names></name><name><surname>Shin</surname><given-names>D. H.</given-names></name><name><surname>Browne</surname><given-names>S. E.</given-names></name><name><surname>Shimizu</surname><given-names>Y.</given-names></name><name><surname>Joh</surname><given-names>T. H.</given-names></name><name><surname>Beal</surname><given-names>M. F.</given-names></name><name><surname>Albers</surname><given-names>D. S.</given-names></name></person-group> (<year>2003</year>). <article-title>Minocycline enhances MPTP toxicity to dopaminergic neurons</article-title>. <source>J. Neurosci. Res.</source> <volume>74</volume>, <fpage>278</fpage>&#x02013;<lpage>285</lpage><pub-id pub-id-type="doi">10.1002/jnr.10818</pub-id><pub-id pub-id-type="pmid">14515357</pub-id></mixed-citation></ref><ref id="B286"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yavin</surname><given-names>E.</given-names></name><name><surname>Brand</surname><given-names>A.</given-names></name><name><surname>Green</surname><given-names>P.</given-names></name></person-group> (<year>2002</year>). <article-title>Docosahexaenoic acid abundance in the brain: a biodevice to combat oxidative stress</article-title>. <source>Nutr. Neurosci.</source> <volume>5</volume>, <fpage>149</fpage>&#x02013;<lpage>157</lpage><pub-id pub-id-type="doi">10.1080/10284150290003159</pub-id><pub-id pub-id-type="pmid">12041873</pub-id></mixed-citation></ref><ref id="B287"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yogev-Falach</surname><given-names>M.</given-names></name><name><surname>Amit</surname><given-names>T.</given-names></name><name><surname>Bar-Am</surname><given-names>O.</given-names></name><name><surname>Youdim</surname><given-names>M. B.</given-names></name></person-group> (<year>2003</year>). <article-title>The importance of propargylamine moiety in the anti-Parkinson drug rasagiline and its derivatives in MAPK-dependent amyloid precursor protein processing</article-title>. <source>FASEB J.</source> <volume>17</volume>, <fpage>2325</fpage>&#x02013;<lpage>2327</lpage><pub-id pub-id-type="pmid">14525944</pub-id></mixed-citation></ref><ref id="B288"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yokota</surname><given-names>T.</given-names></name><name><surname>Igarashi</surname><given-names>K.</given-names></name><name><surname>Uchihara</surname><given-names>T.</given-names></name><name><surname>Jishage</surname><given-names>K.</given-names></name><name><surname>Tomita</surname><given-names>H.</given-names></name><name><surname>Inaba</surname><given-names>A.</given-names></name><name><surname>Li</surname><given-names>Y.</given-names></name><name><surname>Arita</surname><given-names>M.</given-names></name><name><surname>Suzuki</surname><given-names>H.</given-names></name><name><surname>Mizusawa</surname><given-names>H.</given-names></name><name><surname>Arai</surname><given-names>H.</given-names></name></person-group> (<year>2001</year>). <article-title>Delayed-onset ataxia in mice lacking alpha-tocopherol transfer protein: model for neuronal degeneration caused by chronic oxidative stress</article-title>. <source>Proc. Natl. Acad. Sci. U.S.A.</source> <volume>98</volume>, <fpage>15185</fpage>&#x02013;<lpage>15190</lpage><pub-id pub-id-type="doi">10.1073/pnas.261456098</pub-id><pub-id pub-id-type="pmid">11752462</pub-id></mixed-citation></ref><ref id="B289"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yong</surname><given-names>V. W.</given-names></name><name><surname>Perry</surname><given-names>T. L.</given-names></name><name><surname>Krisman</surname><given-names>A. A.</given-names></name></person-group> (<year>1986</year>). <article-title>Depletion of glutathione in brainstem of mice caused by N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine is prevented by antioxidant pretreatment</article-title>. <source>Neurosci. Lett.</source> <volume>63</volume>, <fpage>56</fpage>&#x02013;<lpage>60</lpage><pub-id pub-id-type="doi">10.1016/0304-3940(86)90012-1</pub-id><pub-id pub-id-type="pmid">3485266</pub-id></mixed-citation></ref><ref id="B290"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Youdim</surname><given-names>M. B.</given-names></name><name><surname>Amit</surname><given-names>T.</given-names></name><name><surname>Falach-Yogev</surname><given-names>M.</given-names></name><name><surname>Bar Am</surname><given-names>O.</given-names></name><name><surname>Maruyama</surname><given-names>W.</given-names></name><name><surname>Naoi</surname><given-names>M.</given-names></name></person-group> (<year>2003</year>). <article-title>The essentiality of Bcl-2, PKC and proteasome-ubiquitin complex activations in the neuroprotective-antiapoptotic action of the anti-Parkinson drug, rasagiline</article-title>. <source>Biochem. Pharmacol.</source> <volume>66</volume>, <fpage>1635</fpage>&#x02013;<lpage>1641</lpage><pub-id pub-id-type="doi">10.1016/S0006-2952(03)00535-5</pub-id><pub-id pub-id-type="pmid">14555244</pub-id></mixed-citation></ref><ref id="B291"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Youdim</surname><given-names>M. B.</given-names></name><name><surname>Gross</surname><given-names>A.</given-names></name><name><surname>Finberg</surname><given-names>J. P.</given-names></name></person-group> (<year>2001a</year>). <article-title>Rasagiline [N-propargyl-1R(+)-aminoindan], a selective and potent inhibitor of mitochondrial monoamine oxidase B</article-title>. <source>Br. J. Pharmacol.</source> <volume>132</volume>, <fpage>500</fpage>&#x02013;<lpage>506</lpage><pub-id pub-id-type="doi">10.1038/sj.bjp.0703826</pub-id><pub-id pub-id-type="pmid">11159700</pub-id></mixed-citation></ref><ref id="B292"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Youdim</surname><given-names>M. B.</given-names></name><name><surname>Wadia</surname><given-names>A.</given-names></name><name><surname>Tatton</surname><given-names>W.</given-names></name><name><surname>Weinstock</surname><given-names>M.</given-names></name></person-group> (<year>2001b</year>). <article-title>The anti-Parkinson drug rasagiline and its cholinesterase inhibitor derivatives exert neuroprotection unrelated to MAO inhibition in cell culture and in vivo</article-title>. <source>Ann. N. Y. Acad. Sci.</source> <volume>939</volume>, <fpage>450</fpage>&#x02013;<lpage>458</lpage><pub-id pub-id-type="doi">10.1111/j.1749-6632.2001.tb03656.x</pub-id><pub-id pub-id-type="pmid">11462801</pub-id></mixed-citation></ref><ref id="B293"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Youdim</surname><given-names>M. B.</given-names></name><name><surname>Weinstock</surname><given-names>M.</given-names></name></person-group> (<year>2001</year>). <article-title>Molecular basis of neuroprotective activities of rasagiline and the anti-Alzheimer drug TV3326 [(N-propargyl-(3R)aminoindan-5-YL)-ethyl methyl carbamate]</article-title>. <source>Cell. Mol. Neurobiol.</source> <volume>21</volume>, <fpage>555</fpage>&#x02013;<lpage>573</lpage><pub-id pub-id-type="doi">10.1023/A:1015131516649</pub-id><pub-id pub-id-type="pmid">12043833</pub-id></mixed-citation></ref><ref id="B294"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yrjanheikki</surname><given-names>J.</given-names></name><name><surname>Keinanen</surname><given-names>R.</given-names></name><name><surname>Pellikka</surname><given-names>M.</given-names></name><name><surname>Hokfelt</surname><given-names>T.</given-names></name><name><surname>Koistinaho</surname><given-names>J.</given-names></name></person-group> (<year>1998</year>). <article-title>Tetracyclines inhibit microglial activation and are neuroprotective in global brain ischemia</article-title>. <source>Proc. Natl. Acad. Sci. U.S.A.</source> <volume>95</volume>, <fpage>15769</fpage>&#x02013;<lpage>15774</lpage><pub-id pub-id-type="doi">10.1073/pnas.95.26.15769</pub-id><pub-id pub-id-type="pmid">9861045</pub-id></mixed-citation></ref><ref id="B295"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yu</surname><given-names>Z. F.</given-names></name><name><surname>Bruce-Keller</surname><given-names>A. J.</given-names></name><name><surname>Goodman</surname><given-names>Y.</given-names></name><name><surname>Mattson</surname><given-names>M. P.</given-names></name></person-group> (<year>1998</year>). <article-title>Uric acid protects neurons against excitotoxic and metabolic insults in cell culture, and against focal ischemic brain injury in vivo</article-title>. <source>J. Neurosci. Res.</source> <volume>53</volume>, <fpage>613</fpage>&#x02013;<lpage>625</lpage><pub-id pub-id-type="doi">10.1002/(SICI)1097-4547(19980901)53:5&#x0003c;613::AID-JNR11&#x0003e;3.0.CO;2-1</pub-id><pub-id pub-id-type="pmid">9726432</pub-id></mixed-citation></ref><ref id="B296"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>S. M.</given-names></name><name><surname>Hernan</surname><given-names>M. A.</given-names></name><name><surname>Chen</surname><given-names>H.</given-names></name><name><surname>Spiegelman</surname><given-names>D.</given-names></name><name><surname>Willett</surname><given-names>W. C.</given-names></name><name><surname>Ascherio</surname><given-names>A.</given-names></name></person-group> (<year>2002</year>). <article-title>Intakes of vitamins E and C, carotenoids, vitamin supplements, and PD risk</article-title>. <source>Neurology</source> <volume>59</volume>, <fpage>1161</fpage>&#x02013;<lpage>1169</lpage><pub-id pub-id-type="pmid">12391343</pub-id></mixed-citation></ref><ref id="B297"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhao</surname><given-names>C.</given-names></name><name><surname>Ling</surname><given-names>Z.</given-names></name><name><surname>Newman</surname><given-names>M. B.</given-names></name><name><surname>Bhatia</surname><given-names>A.</given-names></name><name><surname>Carvey</surname><given-names>P. M.</given-names></name></person-group> (<year>2007</year>). <article-title>TNF-alpha knockout and minocycline treatment attenuates blood-brain barrier leakage in MPTP-treated mice</article-title>. <source>Neurobiol. Dis.</source> <volume>26</volume>, <fpage>36</fpage>&#x02013;<lpage>46</lpage><pub-id pub-id-type="doi">10.1016/j.nbd.2006.11.012</pub-id><pub-id pub-id-type="pmid">17234424</pub-id></mixed-citation></ref><ref id="B298"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhou</surname><given-names>W.</given-names></name><name><surname>Bercury</surname><given-names>K.</given-names></name><name><surname>Cummiskey</surname><given-names>J.</given-names></name><name><surname>Luong</surname><given-names>N.</given-names></name><name><surname>Lebin</surname><given-names>J.</given-names></name><name><surname>Freed</surname><given-names>C. R.</given-names></name></person-group> (<year>2011</year>). <article-title>Phenylbutyrate up-regulates the DJ-1 protein and protects neurons in cell culture and in animal models of Parkinson disease</article-title>. <source>J. Biol. Chem.</source> <volume>286</volume>, <fpage>14941</fpage>&#x02013;<lpage>14951</lpage><pub-id pub-id-type="doi">10.1074/jbc.M111.267161</pub-id><pub-id pub-id-type="pmid">21372141</pub-id></mixed-citation></ref></ref-list></back></article>